Difference between revisions of "Staging page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
−
{{#lst:Section editor transclusions|peds-neuro}}
+
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Breast_cancer|main breast cancer page]] for current regimens.
−
''Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the [[Neuroblastoma_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
−
|-
 
−
|<b>Neuroblastoma</b>
 
 
|-
 
|-
 
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 +
|}
 +
{{TOC limit|limit=3}}
 +
=Neoadjuvant therapy=
 +
==CVAP {{#subobject:4a01b8|Regimen=1}}==
 +
CVAP: '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin),  '''<u>P</u>'''rednisolone
 +
<br>VACP: '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rednisolone
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:7b4b85|Variant=1}}===
 +
{| class="wikitable" style="width: 40%; text-align:center;"
 +
!style="width: 25%"|Study
 +
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.2002.20.6.1456 Smith et al. 2002]
 +
| style="background-color:#91cf61" |Non-randomized portion of RCT
 +
|-
 +
|[https://doi.org/10.1200/JCO.2004.05.207 Thomas et al. 2004b]
 +
| style="background-color:#91cf61" |Non-randomized portion of RCT
 
|-
 
|-
−
|ICD-O-3 code: 123.456
 
 
|}
 
|}
−
''Neuroblastoma is a rare cancer but is the most common malignancy of infancy.''
+
<div class="toccolours" style="background-color:#b3e2cd">
−
{{TOC limit|limit=4}}
+
====Chemotherapy====
−
=High Risk=
+
*[[Cyclophosphamide (Cytoxan)]]
−
==COG ANBL0931==
+
*[[Vincristine (Oncovin)]]
−
'''Patients were only eligible if they had previously completed therapy including intensive induction chemotherapy followed by ASCT and radiotherapy'''
+
*[[Doxorubicin (Adriamycin)]]
−
===Post-Consolidation, Study Therapy===
+
====Endocrine therapy====
−
====Immunotherapy, Course 1====
+
*[[Prednisolone (Millipred)]]
−
*[[Sargramostim (Leukine)]] 250 μg/m<sup>2</sup> SubQ (strongly recommended) or IV over 2 hours once daily on days 0 through 13
+
</div>
−
**Hold [[Sargramostim (Leukine)]] if the total white cell count is > 50,000/µL and resume once the total white cell count is < 20,000/µL and then resume at 50% dose for the remainder of that course
+
<div class="toccolours" style="background-color:#cbd5e7">
−
====Chemotherapy, Course 1====
+
====Subsequent treatment====
−
*[[Dinutuximab (Unituxin)]] 25 mg/m<sup>2</sup> IV over 10 to 20 hours once daily on days 3 through 6
+
*[[Surgery#Breast_cancer_surgery|Surgery]]
−
**Begin [[Dinutuximab (Unituxin)]] infusion 1 hour after completion of [[Sargramostim (Leukine)]] infusion each day
 
−
**Max Infusion Time = 20 hours even if the total dose has not been administered
 
−
*[[Isotretinoin (Accutane)]] by the following weight-based criteria:
 
−
** > 12 kg: 80 mg/m<sup>2</sup> (rounded up to nearest 10 mg) PO BID on days 11 through 24
 
−
** ≤ 12 kg: 2.67 mg/kg (rounded up to nearest 10 mg) PO BID on days 11 through 24
 
−
'''25 Day Course'''
 
−
====Immunotherapy, Course 2 and 4====
 
−
*[[Aldesleukin (Proleukin)]] 3,000,000 IU/m<sup>2</sup> IV continuous infusion over 96 hours (4 days) on day 0
 
−
*[[Aldesleukin (Proleukin)]] 4,500,000 IU/m<sup>2</sup> IV continuous infusion over 96 hours (4 days) on day 7
 
−
====Chemotherapy, Course 2 and 4====
 
−
*[[Dinutuximab (Unituxin)]] 25 mg/m<sup>2</sup> IV over 10 to 20 hours once daily on days 7 through 10
 
−
**Max Infusion Time = 20 hours even if the total dose has not been administered
 
−
*[[Isotretinoin (Accutane)]] by the following weight-based criteria:
 
−
** > 12 kg: 80 mg/m<sup>2</sup> (rounded up to nearest 10 mg) PO BID on days 14 through 27
 
−
** ≤ 12 kg: 2.67 mg/kg (rounded up to nearest 10 mg) PO BID on days 14 through 27
 
−
'''32 Day Course'''
 
−
====Immunotherapy, Courses 3 and 5====
 
−
*[[Sargramostim (Leukine)]] 250 μg/m<sup>2</sup> SubQ (strongly recommended) or IV over 2 hours once daily on days 0 through 13
 
−
**Hold [[Sargramostim (Leukine)]] if the total white cell count is > 50,000/µL and resume once the total white cell count is < 20,000/µL and then resume at 50% dose for the remainder of that course
 
−
====Chemotherapy, Courses 3 and 5====
 
−
*[[Dinutuximab (Unituxin)]] 25 mg/m<sup>2</sup> IV over 10 to 20 hours once daily on days 3 through 6
 
−
**Begin [[Dinutuximab (Unituxin)]] infusion 1 hour after completion of [[Sargramostim (Leukine)]] infusion each day
 
−
**Max Infusion Time = 20 hours even if the total dose has not been administered
 
−
*[[Isotretinoin (Accutane)]] by the following weight-based criteria:
 
−
** > 12 kg: 80 mg/m<sup>2</sup> (rounded up to nearest 10 mg) PO BID on days 10 through 23
 
−
** ≤ 12 kg: 2.67 mg/kg (rounded up to nearest 10 mg) PO BID on days 10 through 23
 
−
'''24 Day Cycle'''
 
−
====Chemotherapy, Course 6====
 
−
*[[Isotretinoin (Accutane)]] by the following weight-based criteria:
 
−
** > 12 kg: 80 mg/m<sup>2</sup> (rounded up to nearest 10 mg) PO BID on days 14 through 27
 
−
** ≤ 12 kg: 2.67 mg/kg (rounded up to nearest 10 mg) PO BID on days 14 through 27
 
−
'''28 Day Cycle'''
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''COG ANBL0931:''' Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL; A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol. 2018 Jun 18;9:1355 [https://doi.org/10.3389/fimmu.2018.01355 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29967609/ link to PubMed] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016521/ link to PMC article]   NCT01041638
+
# Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002 Mar 15;20(6):1456-66. [https://doi.org/10.1200/JCO.2002.20.6.1456 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11896092 PubMed]
−
==COG ANBL0532 Regimen B==
+
# Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004 Jun 15;22(12):2294-302. [https://doi.org/10.1200/JCO.2004.05.207 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15197190 PubMed]
 +
=Adjuvant therapy, sequential protocols=
 +
==FAC-MV {{#subobject:eb48eb|Regimen=1}}==
 +
FAC-MV: '''<u>F</u>'''luorouracil, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, followed by '''<u>M</u>'''ethotrexate & '''<u>V</u>'''inblastine
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Induction,===
+
===Protocol {{#subobject:883648|Variant=1}}===
−
====Chemotherapy, Cycle 1 (CPM + TOPO)====
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
*[[Cyclophosphamide (Cytoxan)]] by the following weight-based criteria:
+
!style="width: 20%"|Study
−
**≤ 12 kg: 13.3 mg/kg iV over 30 to 60 minutes once daily on days 1 through 5
+
!style="width: 20%"|Years of enrollment
−
**> 12 kg: 400 mg/m<sup>2</sup> IV over 30 to 60 minutes once daily on days 1 through 5
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
*[[Topotecan (Hycamtin)]] 1.2 mg/m<sup>2</sup> IV over 30 minutes once daily on days 1 through 5
+
!style="width: 20%"|Comparator
−
'''21 Day Cycle'''
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
====Chemotherapy, Cycle 2 (CPM + TOPO)====
+
|-
−
*[[Cyclophosphamide (Cytoxan)]] by the following weight-based criteria:
+
|[https://doi.org/10.1002/cncr.11396 Assikis et al. 2003]
−
**≤ 12 kg: 13.3 mg/kg iV over 30 to 60 minutes once daily on days 1 through 5
+
|1986-1994
−
**> 12 kg: 400 mg/m<sup>2</sup> IV over 30 to 60 minutes once daily on days 1 through 5
+
|style="background-color:#1a9851"|Phase 3 (E-switch-ooc)
−
*[[Topotecan (Hycamtin)]] 1.2 mg/m<sup>2</sup> IV over 30 minutes once daily on days 1 through 5
+
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_2|Tamoxifen]]
−
'''21 Day Cycle'''
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
−
====Supportive Therapy, Cycle 2====
+
|-
−
*[[Filgrastim (Neupogen)]] 5 μg/kg SubQ or IV once daily on Day 6 beginning 24 hours after completion of chemotherapy and continuing until ANC > 1000/μL
+
|}
−
*[[Filgrastim (Neupogen)]] 10 μg/kg SubQ or IV once daily beginning once ANC > 1000/μL and continuing until PBSC harvest is complete
+
<div class="toccolours" style="background-color:#cbd5e8">
−
*PBSC harvest on day 14
+
====Preceding treatment====
−
'''21 Day Cycle'''
+
*[[Surgery#Breast_cancer_surgery|Surgery]]
−
====Chemotherapy, Cycle 3 (CDDP + ETOP)====
+
</div>
−
*[[Cisplatin (Platinol)]] by the following weight-based criteria:
+
<div class="toccolours" style="background-color:#b3e2cd">
−
**≤ 12 kg: 1.66 mg/kg IV over 1 hour once daily on days 1 through 4
+
====Chemotherapy, FAC portion====
−
**> 12 kg: 50 mg/m<sup>2</sup> IV over 1 hour once daily on days 1 through 4
+
*[[Fluorouracil (5-FU)]]
−
*[[Etoposide (Vepesid)]] by the following weight-based criteria:
+
*[[Doxorubicin (Adriamycin)]]
−
**≤ 12 kg: 6.67 mg/kg IV over 1 hour once daily on days 1 through 3
+
*[[Cyclophosphamide (Cytoxan)]]
−
**> 12 kg: 200 mg/m<sup>2</sup> IV over 1 hour once daily on days 1 through 3
+
====Chemotherapy, MV portion====
−
====Chemotherapy, Cycle 4 (CPM + DOXO + VCR)====
+
*[[Methotrexate (MTX)]] 75 mg/m<sup>2</sup> IV once on day 1
−
*[[Cyclophosphamide (Cytoxan)]] by the following weight-based criteria:
+
*[[Vinblastine (Velban)]] 1.7 mg/m<sup>2</sup>/day continuous infusion over 120 hours, started on day 1 (total dose per cycle: 8.5 mg/m<sup>2</sup>)
−
**≤ 12 kg: 70 mg/kg iV over 6 hours once daily on days 1 through 2
+
====Supportive therapy====
−
**> 12 kg: 2100 mg/m<sup>2</sup> IV over 6 hours once daily on days 1 through 2
+
*[[Folinic acid (Leucovorin)]] rescue
−
*[[Vincristine (Oncovin)]] by the following criteria:
+
'''21- to 28-day cycle for 4 cycles'''
−
**< 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before [[Doxorubicin (Adriamycin)]]  on days 1 through 3
+
</div></div>
−
**≥ 12 months and > 12 kg: 0.097 mg/m<sup>2</sup> or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before [[Doxorubicin (Adriamycin)]] on days 1 through 3
+
===References===
−
**≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before [[Doxorubicin (Adriamycin)]] on days 1 through 3
+
# Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 1;97(11):2716-23. [https://doi.org/10.1002/cncr.11396 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/12767083 PubMed]
−
*[[Doxorubicin (Adriamycin)]] by the following weight-based criteria:
+
=Adjuvant therapy=
−
**≤ 12 kg: 0.83 mg/kg iV over 24 hours once daily on days 1 through 3
+
==ACT {{#subobject:4a01b8|Regimen=1}}==
−
**> 12 kg: 25 mg/m<sup>2</sup> IV over 24 hours once daily on days 1 through 3
+
ACT: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''amoxifen
−
'''21 Day Cycle'''
+
<div class="toccolours" style="background-color:#eeeeee">
−
====Supportive Therapy, Cycle 4 (CPM + DOXO + VCR)====
+
===Regimen variant #1, 40/500/20 {{#subobject:7b46yg|Variant=1}}===
−
*[[Mesna (Mesnex)]] by the following weight-based criteria:
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
**≤ 12 kg: 14 mg/kg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 4 and 8 hours after  each[[Cyclophosphamide (Cytoxan)]] infusion
+
!style="width: 20%"|Study
−
**> 12 kg: 420 mg/m<sup>2</sup> IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 4 and 8 hours after  each[[Cyclophosphamide (Cytoxan)]] infusion
+
!style="width: 20%"|Years of enrollment
−
'''21 Day Cycle'''
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
====Chemotherapy, Cycle 5 (CDDP + ETOP)====
+
!style="width: 20%"|Comparator
−
*[[Cisplatin (Platinol)]] by the following weight-based criteria:
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
**≤ 12 kg: 1.66 mg/kg IV over 1 hour once daily on days 1 through 4
+
|-
−
**> 12 kg: 50 mg/m<sup>2</sup> IV over 1 hour once daily on days 1 through 4
+
|[https://doi.org/10.1007/s10147-013-0657-z Shien et al. 2014 (JCOG9401)]
−
*[[Etoposide (Vepesid)]] by the following weight-based criteria:
+
|1994-1999
−
**≤ 12 kg: 6.67 mg/kg IV over 1 hour once daily on days 1 through 3
+
|style="background-color:#1a9851" |Phase 3 (E-esc)
−
**> 12 kg: 200 mg/m<sup>2</sup> IV over 1 hour once daily on days 1 through 3
+
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_2|Tamoxifen]]
−
'''21 Day Cycle'''
+
| style="background-color:#91cf60" |Seems to have superior RFS
−
====Chemotherapy, Cycle 6 (CPM + DOXO + VCR)====
+
|-
−
*[[Cyclophosphamide (Cytoxan)]] by the following weight-based criteria:
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143604/ Shien et al. 2014 (JCOG9404)]
−
**≤ 12 kg: 70 mg/kg iV over 6 hours once daily on days 1 through 2
+
|1994-1999
−
**> 12 kg: 2100 mg/m<sup>2</sup> IV over 6 hours once daily on days 1 through 2
+
|style="background-color:#1a9851" |Phase 3 (E-de-esc)
−
*[[Vincristine (Oncovin)]] by the following criteria:
+
|[[#TUFT_88|TUFT]]
−
**< 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before [[Doxorubicin (Adriamycin)]] on days 1 through 3
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
−
**≥ 12 months and > 12 kg: 0.097 mg/m<sup>2</sup> or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before [[Doxorubicin (Adriamycin)]] on days 1 through 3
+
|-
−
**≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before [[Doxorubicin (Adriamycin)]] on days 1 through 3
+
|}
−
*[[Doxorubicin (Adriamycin)]] by the following weight-based criteria:
+
<div class="toccolours" style="background-color:#cbd5e8">
−
**≤ 12 kg: 0.83 mg/kg iV over 24 hours once daily on days 1 through 3
+
====Preceding treatment====
−
**> 12 kg: 25 mg/m<sup>2</sup> IV over 24 hours once daily on days 1 through 3
+
*[[Surgery#Breast_cancer_surgery|Surgery]]
−
'''21 Day Cycle'''
+
</div>
−
====Supportive Therapy, Cycle 6 (CPM + DOXO + VCR)====
+
<div class="toccolours" style="background-color:#b3e2cd">
−
*[[Mesna (Mesnex)]] by the following weight-based criteria:
+
====Chemotherapy====
−
**≤ 12 kg: 14 mg/kg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 4 and 8 hours after  each[[Cyclophosphamide (Cytoxan)]] infusion
+
*[[Doxorubicin (Adriamycin)]] as follows:
−
**> 12 kg: 420 mg/m<sup>2</sup> IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 4 and 8 hours after  each[[Cyclophosphamide (Cytoxan)]] infusion
+
**Cycles 1 to 6: 40 mg/m<sup>2</sup> IV once on day 1
−
'''21 Day Cycle'''
+
*[[Cyclophosphamide (Cytoxan)]] as follows:
 +
**Cycles 1 to 6: 500 mg/m<sup>2</sup> IV once on day 1
 +
====Endocrine therapy====
 +
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day
 +
'''28-day cycle for 6 cycles, then continuous for a total of 2 years'''
 
</div></div><br>
 
</div></div><br>
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Consolidation,===
+
===Regimen variant #2, 60/600/20 {{#subobject:7b4b85|Variant=1}}===
−
====Chemotherapy, Tandem HSCT #1 (Thiotepa and Cyclophosphamide)====
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
*[[Thiotepa (Thioplex)]] by the following weight-based criteria:
+
!style="width: 20%"|Study
−
**≤ 12 kg: 10 mg/kg IV over 2 hours once daily on days -7, -6, -5
+
!style="width: 20%"|Years of enrollment
−
**> 12 kg: 300 mg/m<sup>2</sup> IV over 2 hours once daily on days -7, -6, -5
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
*[[Cyclophosphamide (Cytoxan)]] by the following weight-based criteria:
+
!style="width: 20%"|Comparator
−
**≤ 12 kg: 50mg/kg IV over 1 hour once daily on days -5, -4, -3, -2
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
**> 12 kg: 1500 mg/m<sup>2</sup> IV over 1 hour once daily on days -5, -4, -3, -2
+
|-
−
*PBSC on day 0
+
|rowspan=2|[https://doi.org/10.1200/JCO.1990.8.6.1005 Fisher et al. 1990 (NSABP B-16)]
−
'''50 Day Cycle'''
+
|rowspan=2|1985-1988
−
====Supportive therapy, Tandem HSCT #1 (Thiotepa and Cyclophosphamide)====
+
|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
−
*[[Mesna (Mesnex)]] by the following weight-based criteria:
+
|1. [[#PFT|PFT]]
−
**≤ 12 kg: 10 mg/kg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 4 and 8 hours after  each[[Cyclophosphamide (Cytoxan)]] infusion
+
| style="background-color:#d3d3d3" |Not reported
−
**> 12 kg: 300 mg/m<sup>2</sup> IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 4 and 8 hours after  each[[Cyclophosphamide (Cytoxan)]] infusion
+
|-
−
*[[Filgrastim (Neupogen)]] 5 μg/kg SubQ or IV once daily starting on day 0 and continuing until post-nadir ANC > 2000/μL for 3 consecutive days
+
|2. [[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_2|Tamoxifen]]
−
'''50 Day Cycle'''
+
| style="background-color:#91cf60" |Seems to have superior OS
−
====Chemotherapy, Tandem HSCT #2 (CEM)====
+
|-
−
*[[Melphalan (Alkeran)]] by the following criteria:
+
|}
−
** ≤ 12 kg and GFR ≥ 100 mL/min: 2 mg/kg IV over 15 to 30 minutes once daily on days -7, -6, -5
+
<div class="toccolours" style="background-color:#cbd5e8">
−
** > 12 kg and GFR ≥ 100 mL/min: 60 mg/m<sup>2</sup> IV over 15 to 30 minutes once daily on days -7, -6, -5
+
====Preceding treatment====
−
** ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 2 mg/kg IV over 15 to 30 minutes once daily on days -7, -6, -5
+
*[[Surgery#Breast_cancer_surgery|Surgery]]
−
** > 12 kg and GFR between 100 mL/min and 60 mL/min: 60 mg/m<sup>2</sup> IV over 15 to 30 minutes once daily on days -7, -6, -5
+
</div>
−
*[[Etoposide (Vepesid)]] by the following criteria:
+
<div class="toccolours" style="background-color:#b3e2cd">
−
** ≤ 12 kg and GFR ≥ 100 mL/min: 12 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
+
====Chemotherapy====
−
** > 12 kg and GFR ≥ 100 mL/min: 300 mg/m<sup>2</sup> IV over 24 hours once daily on days -7, -6, -5, -4
+
*[[Doxorubicin (Adriamycin)]] as follows:
−
** ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 6.7 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
+
**Cycles 1 to 4: 60 mg/m<sup>2</sup> IV once on day 1
−
** > 12 kg and GFR between 100 mL/min and 60 mL/min: 200 mg/m<sup>2</sup> IV over 24 hours once daily on days -7, -6, -5, -4
+
*[[Cyclophosphamide (Cytoxan)]] as follows:
−
*[[Carboplatin (Paraplatin)]] by the following criteria:
+
**Cycles 1 to 4: 600 mg/m<sup>2</sup> IV once on day 1
−
** ≤ 12 kg and GFR ≥ 100 mL/min: 12 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
+
====Endocrine therapy====
−
** > 12 kg and GFR ≥ 100 mL/min: 375 mg/m<sup>2</sup> IV over 24 hours once daily on days -7, -6, -5, -4
+
*[[Tamoxifen (Nolvadex)]] 10 mg PO twice per day
−
** ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 4.1 AUC using Calvert Formula (Max Dose = 300 mg/m<sup>2</sup>) IV over 24 hours once daily on days -7, -6, -5, -4
+
'''21-day cycle for 4 cycles, then continuous for a total of 5 years'''
−
** > 12 kg and GFR between 100 mL/min and 60 mL/min: Use the lowest of either 4.1 AUC using Calvert Formula or 10 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
+
</div></div>
−
*PBSC on day 0
+
===References===
−
'''36 Day Cycle'''
+
# '''NSABP B-16:''' Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Myers DB, Hoehn JL. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990 Jun;8(6):1005-18. [https://doi.org/10.1200/JCO.1990.8.6.1005 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2189950 PubMed]
−
====Supportive Therapy, Tandem HSCT #2 (CEM)====
+
## '''Pooled update:''' Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. [https://doi.org/10.1200/JCO.2004.01.042 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15452182 PubMed]
−
*[[Filgrastim (Neupogen)]] 5 μg/kg SubQ or IV once daily starting on day 0 and continuing until post-nadir ANC > 2000/μL for 3 consecutive days
+
# '''JCOG9401:''' Shien T, Iwata H, Aogi K, Fukutomi T, Inoue K, Kinoshita T, Takahashi M, Matsui A, Shibata T, Fukuda H. Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401). Int J Clin Oncol. 2014 Dec;19(6):982-8. Epub 2014 Jan 7. [https://doi.org/10.1007/s10147-013-0657-z link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/24395447 PubMed]
−
'''36 Day Cycle'''
+
# '''JCOG9404:''' Shien T, Iwata H, Fukutomi T, Inoue K, Aogi K, Kinoshita T, Ando J, Takashima S, Nakamura K, Shibata T, Fukuda H. Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404. Cancer Chemother Pharmacol. 2014 Sep;74(3):603-9. Epub 2014 Jul 24. [https://doi.org/10.1007/s00280-014-2545-2 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143604/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25055938 PubMed]
−
</div></div><br>
+
==AVCF {{#subobject:4a0878|Regimen=1}}==
 +
AVCF: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''incristine, '''<u>C</u>'''yclophosphamide, '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:7b4c73|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.1996.14.4.1136 Misset et al. 1996 (OncoFrance)]
 +
|1978-1981
 +
| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
 +
|[[Breast_cancer#CMF|CMF]]
 +
| style="background-color:#1a9850" |Superior OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Doxorubicin (Adriamycin)]]
 +
*[[Vincristine (Oncovin)]]
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Fluorouracil (5-FU)]]
 +
</div></div>
 +
===References===
 +
# '''OncoFrance:''' Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol. 1996 Apr;14(4):1136-45. [https://doi.org/10.1200/JCO.1996.14.4.1136 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8648368 PubMed]
 +
==AVCMF {{#subobject:4a3928|Regimen=1}}==
 +
AVCMF: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:7bcju3|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.karger.com/Article/PDF/69831 Ploner et al. 2003 (ABCSG 3)]
 +
|1984-NR
 +
| style="background-color:#1a9851" |Randomized (E-RT-esc)
 +
|[[Breast_cancer,_triple_negative#CMF|CMF]]
 +
| style="background-color:#ffffbf" |Did not meet endpoints of DFS/OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Doxorubicin (Adriamycin)]]
 +
*[[Vinblastine (Velban)]]
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
</div></div>
 +
===References===
 +
# '''ABCSG 3:''' Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; ABCSG. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie. 2003 Apr;26(2):115-9. [https://doi.org/10.1159/000069831 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12771518 PubMed]
 +
==CAMFP {{#subobject:4a01b8|Regimen=1}}==
 +
CAMFP: '''<u>C</u>'''yclophosphamide,  '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:7b4b85|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1056/NEJM199605233342102 Recht et al. 1996]
 +
|1984-1992
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[Complex_multipart_regimens#Recht_et_al._1996|See link]]
 +
|[[Complex_multipart_regimens#Recht_et_al._1996|See link]]
 +
|-
 +
|}
 +
''Note: this was a trial examining sequencing of chemotherapy and radiotherapy; see text for efficacy details.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Lumpectomy|Lumpectomy]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
 +
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV once on day 3
 +
*[[Methotrexate (MTX)]] 200 mg/m<sup>2</sup> IV once per day on days 1 & 15
 +
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5
 +
====Supportive therapy====
 +
*[[Folinic acid (Leucovorin)]] 10 mg/m<sup>2</sup> PO four times per day on days 2 to 4, 16 to 18
 +
'''21-day cycle for 4 cycles'''
 +
</div></div>
 +
===References===
 +
# Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996 May 23;334(21):1356-61. [https://doi.org/10.1056/NEJM199605233342102 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8614420 PubMed]
 +
==CEF/CMF {{#subobject:682333|Regimen=1}}==
 +
CEF/CMF: '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil alternating with '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Protocol {{#subobject:3d1971|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202939/ Bedognetti et al. 2011]
 +
|1985-1992
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#CEFT.2FCMFT_99|CEFT/CMFT]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy, CEF portion====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Epirubicin (Ellence)]]
 +
*[[Fluorouracil (5-FU)]]
 +
====Chemotherapy, CMF portion====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
</div></div>
 +
===References===
 +
# Bedognetti D, Sertoli MR, Pronzato P, Del Mastro L, Venturini M, Taveggia P, Zanardi E, Siffredi G, Pastorino S, Queirolo P, Gardin G, Wang E, Monzeglio C, Boccardo F, Bruzzi P. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst. 2011 Oct 19;103(20):1529-39. Epub 2011 Sep 15. [https://academic.oup.com/jnci/article/103/20/1529/905862 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202939/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21921285 PubMed]
 +
==CFP {{#subobject:b514cd|Regimen=1}}==
 +
CFP: '''<u>C</u>'''yclophosphamide, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:3b8f7d|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(78)90678-5 Ahmann et al. 1978]
 +
|NR
 +
|style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[#Melphalan_monotherapy|Melphalan]]
 +
| style="background-color:#91cf60" |Seems to have superior OS
 +
|-
 +
|rowspan=2|[https://jamanetwork.com/journals/jama/article-abstract/370748 Caprini et al. 1980]
 +
|rowspan=2|1975-1979
 +
|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|1. [[#Melphalan_monotherapy|Melphalan]]
 +
| style="background-color:#91cf60" |Seems to have superior DFS
 +
|-
 +
|2. [[#CFP_.26_BCG_99|CFP & BCG]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of DFS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Fluorouracil (5-FU)]]
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]]
 +
</div></div>
 +
===References===
 +
# Ahmann DL, Scanlon PW, Bisel HF, Edmonson JH, Frytak S, Payne WS, O'Fallon JR, Hahn RG, Ingle JN, O'Connell MJ, Rubin J. Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. Lancet. 1978 Apr 29;1(8070):893-6. [https://doi.org/10.1016/S0140-6736(78)90678-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/76842 PubMed]
 +
# Caprini JA, Oviedo MA, Cunningham MP, Cohen E, Trueheart RS, Khandekar JD, Scanlon EF. Adjuvant chemotherapy for stage II and III breast carcinoma. JAMA. 1980 Jul 18;244(3):243-6. [https://jamanetwork.com/journals/jama/article-abstract/370748 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6991733 PubMed]
 +
==CFP & Oophorectomy {{#subobject:ba429d|Regimen=1}}==
 +
CFP & Oophorectomy: '''<u>C</u>'''yclophosphamide, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone & Bilateral Oophorectomy
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:26519a|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1056/NEJM197708182970704 Ahmann et al. 1977]
 +
|NR
 +
| style="background-color:#1a9851" |Randomized (E-esc)
 +
|[[#Oophorectomy|Oophorectomy]]
 +
| style="background-color:#91cf60" |Seems to have superior PFS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]], 3 weeks prior
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]] 150 mg/m<sup>2</sup> IV once per day on days 1 to 5
 +
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup> IV once per day on days 1 to 5
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]] 30 mg PO once per day on days 1 to 7
 +
*[[Endocrine_ablation_surgery#Bilateral_oophorectomy|Bilateral oophorectomy]]
 +
'''35-day cycles'''
 +
</div></div>
 +
===References===
 +
# Ahmann DL, O'Connell MJ, Hahn RG, Bisel HF, Lee RA, Edmonson JH. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med. 1977 Aug 18;297(7):356-60. [https://doi.org/10.1056/NEJM197708182970704 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/876327 PubMed]
 +
==CMFL {{#subobject:1abd14|Regimen=1}}==
 +
CMFL: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid)
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:3dbcd1|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1056/NEJM198902233200804 Goldhirsch et al. 1989 (LCBS V)]
 +
|1981-1985
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer_-_null_regimens#Observation|No further treatment]]
 +
| style="background-color:#91cf60" |Seems to have superior DFS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Mastectomy|Mastectomy]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
*[[Folinic acid (Leucovorin)]]
 +
'''8-day course'''
 +
</div></div>
 +
===References===
 +
# '''LCBS V:''' Goldhirsch A, Gelber RD; Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 1989 Feb 23;320(8):491-6. [https://doi.org/10.1056/NEJM198902233200804 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2644533 PubMed]
 +
==CMFP {{#subobject:527931|Regimen=1}}==
 +
CMFP: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Maintenance, 6 Cycles===
+
===Regimen {{#subobject:3feec0|Variant=1}}===
−
====Chemotherapy,====
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
*[[Isotretinoin (Accutane)]] by the following weight-based criteria:
+
!style="width: 20%"|Study
−
**≤ 12 kg: 5.33 mg/kg (Round dose to nearest 10 mg) PO twice daily on days 1 through 14
+
!style="width: 20%"|Years of enrollment
−
**> 12 kg: 160 mg/m<sup>2</sup> (Round dose to nearest 10 mg) PO twice daily on days 1 through 14
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
'''28 Day Cycle'''
+
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19900115)65:2%3C200::AID-CNCR2820650203%3E3.0.CO;2-Q Tormey et al. 1990 (ECOG E5177)]
 +
|1978-1982
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|1. [[Breast_cancer#CMF|CMF]]<br>2. [[#CMFPT|CMFPT]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoints of TTR/OS
 +
|-
 +
|[https://doi.org/10.1056/NEJM198809153191104 Goldhirsch et al. 1988 (IBCSG V)]
 +
|1981-1985
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#CMFL|CMFL]] x 1
 +
| style="background-color:#91cf60" |Seems to have superior OS
 +
|-
 +
|[https://doi.org/10.1056/NEJM198902233200803 Mansour et al. 1989 (INT-0011)]
 +
|1981-1988
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer_-_null_regimens#Observation|No further treatment]]
 +
| style="background-color:#1a9850" |Superior DFS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Modified_radical_mastectomy|Modified radical mastectomy]] or [[Surgery#Mastectomy|total mastectomy]] with [[Surgery#Axillary_lymph_node_dissection|low axillary-node dissection]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]]
 +
'''28-day cycle for 6 to 12 cycles'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#'''COG ANBL0532:'''Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul;48(7):947-52. [https://doi.org/10.1038/bmt.2012.276 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638062/pdf/nihms426908.pdf link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23334272/ PubMed]
+
# '''IBCSG V:''' Goldhirsch A; Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med. 1988 Sep 15;319(11):677-83. [https://doi.org/10.1056/NEJM198809153191104 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2901037 PubMed]
−
==COG ANBL 0032 Regimen B==
+
# '''ECOG E1180:''' Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an intergroup study. N Engl J Med. 1989 Feb 23;320(8):485-90. [https://doi.org/10.1056/NEJM198902233200803 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2915651 PubMed]
−
===Post Consolidation, Study Phase===
+
## '''Update:''' Mansour EG, Eudey L, Tormey DC, Shatila AH, Osborne CK, Gilchrist KW, Cooper MR, Falkson G. Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992;(11):97-104. [https://pubmed.ncbi.nlm.nih.gov/1627437 PubMed]
−
====Immunotherapy, Course 1====
+
# '''ECOG E5177:''' Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. Cancer. 1990 Jan 15;65(2):200-6. [https://doi.org/10.1002/1097-0142(19900115)65:2%3C200::AID-CNCR2820650203%3E3.0.CO;2-Q link to original article] [https://pubmed.ncbi.nlm.nih.gov/2403834 PubMed]
−
*[[Sargramostim (Leukine)]] 250 μg/m<sup>2</sup> SubQ (strongly recommended) or IV over 2 hours once daily on days 0 through 13
+
==CMFPT {{#subobject:204d9d|Regimen=1}}==
−
**Hold [[Sargramostim (Leukine)]] if the total white cell count is > 50,000/µL and resume once the total white cell count is < 20,000/µL and then resume at 50% dose for the remainder of that course
+
CMFPT: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone, '''<u>T</u>'''amoxifen
−
====Chemotherapy, Course 1====
+
<div class="toccolours" style="background-color:#eeeeee">
−
*[[Dinutuximab (Unituxin)]] 25 mg/m<sup>2</sup> IV over 10 to 20 hours on days 3 through 6
+
===Regimen {{#subobject:3a762a|Variant=1}}===
−
**Begin [[Dinutuximab (Unituxin)]] at a rate of 0.88 mg/m<sup>2</sup>/hr x 0.5 hrs, then increase to 1.75 mg/m<sup>2</hr for the remainder of the dose if tolerated
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
**Begin [[Dinutuximab (Unituxin)]] infusion 1 hour after completion of [[Sargramostim (Leukine)]] infusion each day
+
!style="width: 20%"|Study
−
**Max Infusion Time = 20 hours even if the total dose has not been administered
+
!style="width: 20%"|Years of enrollment
−
*[[Isotretinoin (Accutane)]] by the following weight based criteria:
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
**> 12 kg: 80 mg/m<sup>2</sup> (Round to nearest 10 mg) PO BID on days 11 through 24
+
!style="width: 20%"|Comparator
−
** ≤ 12 kg: 2.67 mg/kg (Round to nearest 10 mg) PO BID on days 11 through 24
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
'''25-Day Cycle'''
+
|-
−
====Immunotherapy, Course 2 and 4====
+
|rowspan = 2|[https://doi.org/10.1016/S0140-6736(84)92445-0 Goldhirsch et al. 1984 (LBCS III)]
−
*[[Aldesleukin (Proleukin)]] 3,000,000 IU/m<sup>2</sup> IV continuous infusion over 96 hours (4 days) on day 0
+
|rowspan=2|1978-1981
−
*[[Aldesleukin (Proleukin)]] 4,500,000 IU/m<sup>2</sup> IV continuous infusion over 96 hours (4 days) on day 7
+
|rowspan = 2 style="background-color:#1a9851" |Phase 3 (E-esc)
−
====Chemotherapy, Course 2 and 4====
+
|1. [[Breast_cancer_-_null_regimens#Observation|Observation]]
−
*[[Dinutuximab (Unituxin)]] 25 mg/m<sup>2</sup> IV over 10 to 20 hours on days 3 through 6
+
| style="background-color:#1a9850" |Superior DFS
−
**Begin [[Dinutuximab (Unituxin)]] at a rate of 0.88 mg/m<sup>2</sup>/hr x 0.5 hrs, then increase to 1.75 mg/m<sup>2</hr for the remainder of the dose if tolerated
+
|-
−
**Begin [[Dinutuximab (Unituxin)]] infusion 1 hour after completion of [[Sargramostim (Leukine)]] infusion each day
+
|2. [[#PT|PT]]
−
**Max Infusion Time = 20 hours even if the total dose has not been administered
+
| style="background-color:#91cf60" |Seems to have superior DFS
−
*[[Isotretinoin (Accutane)]] by the following weight based criteria:
+
|-
−
**> 12 kg: 80 mg/m<sup>2</sup> (Round to nearest 10 mg) PO BID on days 11 through 24
+
|[https://doi.org/10.1002/1097-0142(19900115)65:2%3C200::AID-CNCR2820650203%3E3.0.CO;2-Q Tormey et al. 1990 (ECOG E5177)]
−
** ≤ 12 kg: 2.67 mg/kg (Round to nearest 10 mg) PO BID on days 11 through 24
+
|1978-1982
−
'''32 Day Cycle'''
+
| style="background-color:#1a9851" |Phase 3 (E-esc)
−
====Immunotherapy, Courses 3 and 5====
+
|1. [[Breast_cancer#CMF|CMF]]<br>2. [[#CMFP|CMFP]]
−
*[[Sargramostim (Leukine)]] 250 μg/m<sup>2</sup> SubQ (strongly recommended) or IV over 2 hours once daily on days 0 through 13
+
| style="background-color:#ffffbf" |Did not meet primary endpoints of TTR/OS
−
**Hold [[Sargramostim (Leukine)]] if the total white cell count is > 50,000/µL and resume once the total white cell count is < 20,000/µL and then resume at 50% dose for the remainder of that course
+
|-
−
====Chemotherapy, Courses 3 and 5====
+
|[https://doi.org/10.1056/NEJM198809153191104 Goldhirsch et al. 1988 (IBCSG V)]
−
*[[Dinutuximab (Unituxin)]] 25 mg/m<sup>2</sup> IV over 10 to 20 hours once daily on days 3 through 6
+
|1981-1985
−
**Begin [[Dinutuximab (Unituxin)]] infusion 1 hour after completion of [[Sargramostim (Leukine)]] infusion each day
+
| style="background-color:#1a9851" |Phase 3 (C)
−
**Max Infusion Time = 20 hours even if the total dose has not been administered
+
|[[#CMFL|CMFL]] x 1
−
*[[Isotretinoin (Accutane)]] by the following weight based criteria:
+
| style="background-color:#91cf60" |Seems to have superior OS
−
**> 12 kg: 80 mg/m<sup>2</sup> (Round to nearest 10 mg) PO BID on days 11 through 24
+
|-
−
** ≤ 12 kg: 2.67 mg/kg (Round to nearest 10 mg) PO BID on days 11 through 24
+
|[https://doi.org/10.1200/JCO.1990.8.4.599 Falkson et al. 1990]
−
'''24 Day Cycle'''
+
|1982-NR
−
====Chemotherapy, Course 6====
+
| style="background-color:#1a9851" |Phase 3 (C)
−
*[[Isotretinoin (Accutane)]] by the following weight based criteria:
+
|[[#CMFPT|CMFPT]] x 4
−
**> 12 kg: 80 mg/m<sup>2</sup> (Round to nearest 10 mg) PO BID on days 11 through 24
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of DFS
−
** ≤ 12 kg: 2.67 mg/kg (Round to nearest 10 mg) PO BID on days 11 through 24
+
|-
−
'''28 Day Cycle'''
+
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Modified_radical_mastectomy|Modified radical mastectomy]] or [[Surgery#Mastectomy|total mastectomy]] with [[Surgery#Axillary_lymph_node_dissection|low axillary-node dissection]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]]
 +
*[[Tamoxifen (Nolvadex)]]
 +
'''28-day cycle for 6 to 12 cycles'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#'''COG ANBL0032:'''Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, SMith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld R, Gillies SD, Cohn SL, Maris JM, Sondel PM. Anti-GD2 Antibody with GM-CSF, IL2, and Isotretinoin for Neuroblastoma. N Engl J Med. 2010 Sep;363(14):1324-34. [https://doi.org/10.1056/nejmoa0911123 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20879881/ PubMed]
+
# '''LBCS III/IV:''' Goldhirsch A; Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet. 1984 Jun 9;1(8389):1256-60. [https://doi.org/10.1016/S0140-6736(84)92445-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6144974 PubMed]
−
==COG ANBL17P1==
+
# '''IBCSG V:''' Goldhirsch A; Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med. 1988 Sep 15;319(11):677-83. [https://doi.org/10.1056/NEJM198809153191104 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2901037 PubMed]
 +
# '''ECOG E5177:''' Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. Cancer. 1990 Jan 15;65(2):200-6. [https://doi.org/10.1002/1097-0142(19900115)65:2%3C200::AID-CNCR2820650203%3E3.0.CO;2-Q link to original article] [https://pubmed.ncbi.nlm.nih.gov/2403834 PubMed]
 +
# Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC, Falkson G; [[Study_Groups#ECOG|ECOG]]. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol. 1990 Apr;8(4):599-607. Erratum in: J Clin Oncol 1990 Sep;8(9):1603. [https://doi.org/10.1200/JCO.1990.8.4.599 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2179477 PubMed]
 +
==CMFVP {{#subobject:ae7a82|Regimen=1}}==
 +
CMFVP: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Induction===
+
===Regimen {{#subobject:538cb7|Variant=1}}===
−
====Chemotherapy, Cycle 1 (TOPO/CPM)====
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
*[[Cyclophosphamide (Cytoxan)]] by the following BSA-based criteria:
+
!style="width: 20%"|Study
−
**0.25 to 0.29 m<sup>2</sup>: 68 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
!style="width: 20%"|Years of enrollment
−
**0.3 to 0.34 m<sup>2</sup>: 100 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
**0.35 to 0.39 m<sup>2</sup>: 124 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
!style="width: 20%"|Comparator
−
**0.4 to 0.44 m<sup>2</sup>: 148 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
**0.45 to 0.49 m<sup>2</sup>: 180 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|-
−
**0.5 to 0.54 m<sup>2</sup>: 200 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|[https://doi.org/10.1002/1097-0142(19820801)50:3%3C423::AID-CNCR2820500307%3E3.0.CO;2-O Glucksberg et al. 1982 (SWOG S7436)]
−
**0.55 to 0.59 m<sup>2</sup>: 220 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|1975-1978
−
**≥ 0.6 m<sup>2</sup>: 400 mg/m<sup>2</sup> IV over 15 to 30 minutes once daily on days 1 through 5
+
|style="background-color:#1a9851" |Randomized (E-esc)
−
*[[Topotecan (Hycamtin)]] by the following BSA-based criteria:
+
|[[#Melphalan_monotherapy|Melphalan]]
−
**0.25 to 0.29 m<sup>2</sup>: 0.32 mg IV over 30 minutes once daily on days 1 through 5
+
| style="background-color:#1a9850" |Superior OS
−
**0.3 to 0.34 m<sup>2</sup>: 0.38 mg IV over 30 minutes once daily on days 1 through 5
+
|-
−
**0.35 to 0.39 m<sup>2</sup>: 0.44 mg IV over 30 minutes once daily on days 1 through 5
+
|rowspan=2|[https://doi.org/10.1200/JCO.1983.1.2.138 Tormey et al. 1983a]
−
**0.4 to 0.44 m<sup>2</sup>: 0.5 mg IV over 30 minutes once daily on days 1 through 5
+
|rowspan=2|1975-1980
−
**0.45 to 0.49 m<sup>2</sup>: 0.56 mg IV over 30 minutes once daily on days 1 through 5
+
|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
−
**0.5 to 0.54 m<sup>2</sup>: 0.62 mg IV over 30 minutes once daily on days 1 through 5
+
|[[Breast_cancer#CMF|CMF]]
−
**0.55 to 0.59 m<sup>2</sup>: 0.68 mg IV over 30 minutes once daily on days 1 through 5
+
| style="background-color:#1a9850" |Superior DFS
−
**≥ 0.6 m<sup>2</sup>: 1.2 mg/m<sup>2</sup> IV over 30 minutes once daily on days 1 through 5
+
|-
−
'''21-Day Cycle'''
+
|[[#CMF-MER_77|CMF-MER]]
−
====Supportive Therapy, Cycle 1 (TOPO/CPM)====
+
| style="background-color:#d3d3d3" |Not reported
−
*[[Filgrastim (Neupogen)]] 5 μg/kg SubQ or IV once daily on Day 6 beginning 24 to 48 hours after completion of chemotherapy and continuing until ANC > 2000/μL
+
|-
−
'''21-Day Cycle'''
+
|[https://doi.org/10.1200/JCO.1993.11.9.1710 Rivkin et al. 1993 (SWOG S7827<sub>ER-</sub>)]
−
====Chemotherapy, Cycle 2 (TOPO/CPM)====
+
|1979-1984
−
*[[Cyclophosphamide (Cytoxan)]] by the following BSA-based criteria:
+
|style="background-color:#1a9851" |Phase 3 (C)
−
**0.25 to 0.29 m<sup>2</sup>: 68 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|[[#CMFVP|CMFVP]] x 2 y
−
**0.3 to 0.34 m<sup>2</sup>: 100 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
| style="background-color:#ffffbf" |Did not meet primary endpoints of DFS/OS
−
**0.35 to 0.39 m<sup>2</sup>: 124 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|-
−
**0.4 to 0.44 m<sup>2</sup>: 148 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|[https://doi.org/10.1200/JCO.1996.14.1.46 Rivkin et al. 1996 (SWOG S7821)]
−
**0.45 to 0.49 m<sup>2</sup>: 180 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|1979-1989
−
**0.5 to 0.54 m<sup>2</sup>: 200 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|style="background-color:#1a9851" |Randomized (C)
−
**0.55 to 0.59 m<sup>2</sup>: 220 mg IV over 15 to 30 minutes once daily on days 1 through 5
+
|[[#CMFVP_.26_Oophorectomy_99|CMFVP & Oophorectomy]]
−
**≥ 0.6 m<sup>2</sup>: 400 mg/m<sup>2</sup> IV over 15 to 30 minutes once daily on days 1 through 5
+
| style="background-color:#ffffbf" |Did not meet primary endpoints of DFS/OS
−
*[[Topotecan (Hycamtin)]] by the following BSA-based criteria:
+
|-
−
**0.25 to 0.29 m<sup>2</sup>: 0.32 mg IV over 30 minutes once daily on days 1 through 5
+
|[https://doi.org/10.1200/JCO.1996.14.5.1589 Perloff et al. 1996 (CALGB 8082)]
−
**0.3 to 0.34 m<sup>2</sup>: 0.38 mg IV over 30 minutes once daily on days 1 through 5
+
|1980-1984
−
**0.35 to 0.39 m<sup>2</sup>: 0.44 mg IV over 30 minutes once daily on days 1 through 5
+
| style="background-color:#91cf61" |Non-randomized portion of RCT
−
**0.4 to 0.44 m<sup>2</sup>: 0.5 mg IV over 30 minutes once daily on days 1 through 5
+
| style="background-color:#d3d3d3" |
−
**0.45 to 0.49 m<sup>2</sup>: 0.56 mg IV over 30 minutes once daily on days 1 through 5
+
| style="background-color:#d3d3d3" |
−
**0.5 to 0.54 m<sup>2</sup>: 0.62 mg IV over 30 minutes once daily on days 1 through 5
+
|-
−
**0.55 to 0.59 m<sup>2</sup>: 0.68 mg IV over 30 minutes once daily on days 1 through 5
+
|[https://doi.org/10.1200/JCO.1995.13.4.831 Budd et al. 1995 (SWOG S8313)]
−
**≥ 0.6 m<sup>2</sup>: 1.2 mg/m<sup>2</sup> IV over 30 minutes once daily on days 1 through 5
+
|1984-1990
−
*PBSC Harvest on Day 15 of Cycle 2
+
|style="background-color:#1a9851" |Phase 3 (C)
−
'''21-Day Cycle'''
+
|[[#FAC-M_99|FAC-M]]
−
====Supportive Therapy, Cycle 2 (TOPO/CPM)====
+
| style="background-color:#d9ef8b" |Might have superior DFS
−
*[[Filgrastim (Neupogen)]] 5 μg/kg SubQ or IV once daily on Day 6 beginning 24 to 48 hours after completion of chemotherapy and continuing until ANC > 2000/μL
+
|-
−
'''21-Day Cycle'''
+
|}
−
====Chemotherapy, Cycle 3 (CDDP/ETOP/DIN)====
+
<div class="toccolours" style="background-color:#cbd5e8">
−
*[[Cisplatin (Platinol)]] by the following BSA-based criteria:
+
====Preceding treatment====
−
**0.25 to 0.29 m<sup>2</sup>: 10 mg IV over 1 hour once daily on days 1 through 3
+
*[[Surgery#Breast_cancer_surgery|Surgery]]
−
**0.3 to 0.34 m<sup>2</sup>: 14 mg IV over 1 hour once daily on days 1 through 3
+
</div>
−
**0.35 to 0.39 m<sup>2</sup>: 18 mg IV over 1 hour once daily on days 1 through 3
+
<div class="toccolours" style="background-color:#b3e2cd">
−
**0.4 to 0.44 m<sup>2</sup>: 22 mg IV over 1 hour once daily on days 1 through 3
+
====Chemotherapy====
−
**0.45 to 0.49 m<sup>2</sup>: 26 mg IV over 1 hour once daily on days 1 through 3
+
*[[Cyclophosphamide (Cytoxan)]]
−
**0.5 to 0.54 m<sup>2</sup>: 30 mg IV over 1 hour once daily on days 1 through 3
+
*[[Methotrexate (MTX)]]
−
**0.55 to 0.59 m<sup>2</sup>: 34 mg IV over 1 hour once daily on days 1 through 3
+
*[[Fluorouracil (5-FU)]]
−
**≥ 0.6 m<sup>2</sup>: 60 mg/m<sup>2</sup> IV over 1 hour once daily on days 1 through 3
+
*[[Vincristine (Oncovin)]]
−
*[[Etoposide (Vepesid)]] by the following BSA-based criteria:
+
====Endocrine therapy====
−
**0.25 to 0.29 m<sup>2</sup>: 34 mg IV over 2 hours once daily on days 1 through 3
+
*[[Prednisone (Sterapred)]]
−
**0.3 to 0.34 m<sup>2</sup>: 48 mg IV over 2 hours once daily on days 1 through 3
+
</div></div>
−
**0.35 to 0.39 m<sup>2</sup>: 60 mg IV over 2 hours once daily on days 1 through 3
+
===References===
−
**0.4 to 0.44 m<sup>2</sup>: 72 mg IV over 2 hours once daily on days 1 through 3
+
# '''SWOG S7436:''' Glucksberg H, Rivkin SE, Rasmussen S, Tranum B, Gad-el-Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J, Vaughn C. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer. 1982 Aug 1;50(3):423-34. [https://doi.org/10.1002/1097-0142(19820801)50:3%3C423::AID-CNCR2820500307%3E3.0.CO;2-O link to original article] [https://pubmed.ncbi.nlm.nih.gov/7046900 PubMed]
−
**0.45 to 0.49 m<sup>2</sup>: 88 mg IV over 2 hours once daily on days 1 through 3
+
## '''Update:''' Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 1;97(1):21-9. [https://doi.org/10.1002/cncr.10982 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12491501 PubMed]
−
**0.5 to 0.54 m<sup>2</sup>: 100 mg IV over 2 hours once daily on days 1 through 3
+
# Tormey DC, Weinberg VE, Holland JF, Weiss RB, Glidewell OJ, Perloff M, Falkson G, Falkson HC, Henry PH, Leone LA, Rafla S, Ginsberg SJ, Silver RT, Blom J, Carey RW, Schein PS, Lesnick GJ. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. J Clin Oncol. 1983 Feb;1(2):138-45. [https://doi.org/10.1200/JCO.1983.1.2.138 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6366133 PubMed]
−
**0.55 to 0.59 m<sup>2</sup>: 112 mg IV over 2 hours once daily on days 1 through 3
+
# '''SWOG S7827:''' Rivkin SE, Green S, Metch B, Jewell WR, Costanzi JJ, Altman SJ, Minton JP, O'Bryan RM, Osborne CK. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 1993 Sep;11(9):1710-6. [https://doi.org/10.1200/JCO.1993.11.9.1710 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8355037 PubMed]
−
**≥ 0.6 m<sup>2</sup>: 200 mg/m<sup>2</sup> IV over 2 hours once daily on days 1 through 3
+
# '''SWOG S8313:''' Budd GT, Green S, O'Bryan RM, Martino S, Abeloff MD, Rinehart JJ, Hahn R, Harris J, Tormey D, O'Sullivan J, Osborne CK. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. J Clin Oncol. 1995 Apr;13(4):831-9. [https://doi.org/10.1200/JCO.1995.13.4.831 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7707108 PubMed]
−
*[[Dinutuximab (Unituxin)]] 17.5 mg/m<sup>2</sup> IV over 10 hours (may be extended up to 20 hours) on days 2 through 5
+
# '''SWOG S7821:''' Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Osborne CK. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996 Jan;14(1):46-51. [https://doi.org/10.1200/JCO.1996.14.1.46 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8558219 PubMed]
−
'''21-Day Cycle'''
+
# '''CALGB 8082:''' Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May;14(5):1589-98. [https://doi.org/10.1200/JCO.1996.14.5.1589 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8622076 PubMed]
−
====Immunotherapy, Cycle 3 (GM-CSF)====
+
==CPB {{#subobject:0d159a|Regimen=1}}==
−
*[[Sargramostim (Leukine)]] 250 μg/m<sup>2</sup> SubQ once on Day 6 (or Day 7) beginning 24 to 48 hours after completion of [[Dinutuximab (Unituxin)]] (Day 5)
+
CPB: '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''latinol (Cisplatin), '''<u>B</u>'''CNU (Carmustine)
−
**Hold [[Sargramostim (Leukine)]] if the total white cell count is > 50,000/µL and resume once the total white cell count is < 20,000/µL and then resume at 50% dose for the remainder of that course
+
<div class="toccolours" style="background-color:#eeeeee">
−
**Hold [[Sargramostim (Leukine)]] if [[Dinutuximab (Unituxin)]] is not given
+
===Regimen {{#subobject:683965|Variant=1}}===
−
'''21-Day Cycle'''
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
====Chemotherapy, Cycle 4 (VCR/DOXO/CPM/DIN)====
+
!style="width: 20%"|Study
−
*[[Vincristine (Oncovin)]] by the following BSA-based criteria:
+
!style="width: 20%"|Years of enrollment
−
**0.25 to 0.29 m<sup>2</sup>: 0.32 mg IV push over 1 minute or IV infusion per institutional policy once on day 1
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
**0.3 to 0.34 m<sup>2</sup>: 0.46 mg IV push over 1 minute or IV infusion per institutional policy once on day 1
+
!style="width: 20%"|Comparator
−
**0.35 to 0.39 m<sup>2</sup>: 0.6 mg IV push over 1 minute or IV infusion per institutional policy once on day 1
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
**0.4 to 0.44 m<sup>2</sup>: 0.72 mg IV push over 1 minute or IV infusion per institutional policy once on day 1
+
|-
−
**0.45 to 0.49 m<sup>2</sup>: 0.88 mg IV push over 1 minute or IV infusion per institutional policy once on day 1
+
|[https://doi.org/10.1200/JCO.2005.10.202 Peters et al. 2005 (CALGB 9082)]
−
**0.5 to 0.54 m<sup>2</sup>: 1 mg IV push over 1 minute or IV infusion per institutional policy once on day 1
+
|1991-1998
−
**0.55 to 0.59 m<sup>2</sup>: 1.1 mg IV push over 1 minute or IV infusion per institutional policy once on day 1
+
| style="background-color:#1a9851" |Phase 3 (E-de-esc)
−
**≥ 0.6 m<sup>2</sup>: 2 mg/m<sup>2</sup> (Max dose = 2 mg) IV push over 1 minute or IV infusion per institutional policy once on day 1
+
|[[#High-dose_CPB.2C_then_auto_HSCT_99|HD-CPB with auto HSCT]]
−
***Administer prior to [[Dexrazoxane (Zinecard)]]
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS
−
*[[Doxorubicin (Adriamycin)]] by the following BSA-based criteria:
+
|-
−
**0.25 to 0.29 m<sup>2</sup>: 6.6 mg IV over 5 to 15 minutes on days 1, 2
+
|}
−
**0.3 to 0.34 m<sup>2</sup>: 9.2 mg IV over 5 to 15 minutes on days 1, 2
+
''Note: this trial is of important historic significance. Although neither arm was standard of care, the results established the non-value of high-dose therapy with autologous HSCT in the adjuvant treatment of breast cancer.''
−
**0.35 to 0.39 m<sup>2</sup>: 12 mg IV over 5 to 15 minutes on days 1, 2
+
<div class="toccolours" style="background-color:#cbd5e8">
−
**0.4 to 0.44 m<sup>2</sup>: 14 mg IV over 5 to 15 minutes on days 1, 2
+
====Preceding treatment====
−
**0.45 to 0.49 m<sup>2</sup>: 16 mg IV over 5 to 15 minutes on days 1, 2
+
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#FAC_2|FAC]] x 3
−
**0.5 to 0.54 m<sup>2</sup>: 18 mg IV over 5 to 15 minutes on days 1, 2
+
</div>
−
**0.55 to 0.59 m<sup>2</sup>: 20 mg IV over 5 to 15 minutes on days 1, 2
+
<div class="toccolours" style="background-color:#b3e2cd">
−
**≥ 0.6 m<sup>2</sup>: 37.5 mg/m<sup>2</sup> IV over 5 to 15 minutes on days 1, 2
+
====Chemotherapy====
−
***given immediately after [[Dexrazoxane (Zinecard)]]
+
*[[Cyclophosphamide (Cytoxan)]] 900 mg/m<sup>2</sup> IV over 60 hours once per day on days 1 to 3
−
*[[Cyclophosphamide (Cytoxan)]] by the following BSA-based criteria:
+
*[[Cisplatin (Platinol)]] 30 mg/mg<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 1 (total dose: 90 mg/m<sup>2</sup>)
−
**0.25 to 0.29 m<sup>2</sup>: 360 mg IV over 1 hour on days 1, 2
+
*[[Carmustine (BCNU)]] 90 mg/m<sup>2</sup> IV over 18 hours once on day 3
−
**0.3 to 0.34 m<sup>2</sup>: 480 mg IV over 1 hour on days 1, 2
+
</div>
−
**0.35 to 0.39 m<sup>2</sup>: 600 mg IV over 1 hour on days 1, 2
+
<div class="toccolours" style="background-color:#cbd5e7">
−
**0.4 to 0.44 m<sup>2</sup>: 720 mg IV over 1 hour on days 1, 2
+
====Subsequent treatment====
−
**0.45 to 0.49 m<sup>2</sup>: 880 mg IV over 1 hour on days 1, 2
+
*[[Breast_cancer#FAC_2|FAC]] x 1
−
**0.5 to 0.54 m<sup>2</sup>: 1000 mg IV over 1 hour on days 1, 2
+
</div></div>
−
**0.55 to 0.59 m<sup>2</sup>: 1100 mg IV over 1 hour on days 1, 2
+
===References===
−
**≥ 0.6 m<sup>2</sup>: 2000 mg/m<sup>2</sup> IV over 1 hour on days 1, 2
+
# '''CALGB 9082:''' Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 1;23(10):2191-200. Epub 2005 Mar 14. [https://doi.org/10.1200/JCO.2005.10.202 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15767638 PubMed]
−
*[[Dinutuximab (Unituxin)]] 17.5 mg/m<sup>2</sup> IV over 10 hours (may be extended up to 20 hours) on days 2 through 5
+
==CTCb, then auto HSCT {{#subobject:7a4fec|Regimen=1}}==
−
'''21-Day Cycle'''
+
CTCb: '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''hiotepa, '''<u>C</u>'''ar'''<u>b</u>'''oplatin
−
====Immunotherapy, Cycle 4 (GM-CSF)====
+
<br>STAMP-V
−
*[[Sargramostim (Leukine)]] 250 μg/m<sup>2</sup> SubQ once on Day 6 (or Day 7) beginning 24 to 48 hours after completion of [[Dinutuximab (Unituxin)]] (Day 5)
+
<div class="toccolours" style="background-color:#eeeeee">
−
**Hold [[Sargramostim (Leukine)]] if the total white cell count is > 50,000/µL and resume once the total white cell count is < 20,000/µL and then resume at 50% dose for the remainder of that course
+
===Regimen {{#subobject:9d0c8a|Variant=1}}===
−
**Hold [[Sargramostim (Leukine)]] if [[Dinutuximab (Unituxin)]] is not given
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
'''21-Day Cycle'''
+
!style="width: 20%"|Study
−
====Supportive Therapy, Cycle 4====
+
!style="width: 20%"|Years of enrollment
−
*[[Dexrazoxane (Zinecard)]] by the following BSA-based criteria:
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
**0.25 to 0.29 m<sup>2</sup>: 66 mg IV over 5 to 15 minutes on days 1, 2
+
!style="width: 20%"|Comparator
−
**0.3 to 0.34 m<sup>2</sup>: 92 mg IV over 5 to 15 minutes on days 1, 2
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
**0.35 to 0.39 m<sup>2</sup>: 120 mg IV over 5 to 15 minutes on days 1, 2
+
|-
−
**0.4 to 0.44 m<sup>2</sup>: 140 mg IV over 5 to 15 minutes on days 1, 2
+
|[https://doi.org/10.1200/jco.1990.8.7.1239 Eder et al. 1990]
−
**0.45 to 0.49 m<sup>2</sup>: 160 mg IV over 5 to 15 minutes on days 1, 2
+
|1987-1988
−
**0.5 to 0.54 m<sup>2</sup>: 180 mg IV over 5 to 15 minutes on days 1, 2
+
| style="background-color:#91cf61" |Phase 1/2
−
**0.55 to 0.59 m<sup>2</sup>: 200 mg IV over 5 to 15 minutes on days 1, 2
+
| style="background-color:#d3d3d3" |
−
**≥ 0.6 m<sup>2</sup>: 375 mg/m<sup>2</sup> IV over 5 to 15 minutes on days 1, 2
+
| style="background-color:#d3d3d3" |
−
***given immediately prior to [[Doxorubicin (Adriamycin)]]
+
|-
−
*[[Mesna (Mesnex)]] by the following weight-based criteria:
+
|[https://doi.org/10.1016/S0140-6736(98)01350-6 Rodenhuis et al. 1998]
−
**0.25 to 0.29 m<sup>2</sup>: 72 mg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 3, 6, 9, & 12 hours from the start of [[Cyclophosphamide (Cytoxan)]] infusion
+
|1991-1995
−
**0.3 to 0.34 m<sup>2</sup>: 96 mg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 3, 6, 9, & 12 hours from the start of [[Cyclophosphamide (Cytoxan)]] infusion
+
| style="background-color:#1a9851" |Randomized Phase 2 (E-esc)
−
**0.35 to 0.39 m<sup>2</sup>: 120 mg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 3, 6, 9, & 12 hours from the start of [[Cyclophosphamide (Cytoxan)]] infusion
+
|Standard adjuvant therapy
−
**0.4 to 0.44 m<sup>2</sup>: 144 mg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 3, 6, 9, & 12 hours from the start of [[Cyclophosphamide (Cytoxan)]] infusion
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
−
**0.45 to 0.49 m<sup>2</sup>: 176 mg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 3, 6, 9, & 12 hours from the start of [[Cyclophosphamide (Cytoxan)]] infusion
+
|-
−
**0.5 to 0.54 m<sup>2</sup>: 200 mg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 3, 6, 9, & 12 hours from the start of [[Cyclophosphamide (Cytoxan)]] infusion
+
|[https://doi.org/10.1056/NEJMoa022794 Rodenhuis et al. 2003 (Dutch National Study)]
−
**0.55 to 0.59 m<sup>2</sup>: 220 mg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 3, 6, 9, & 12 hours from the start of [[Cyclophosphamide (Cytoxan)]] infusion
+
|1993-1999
−
**≥ 0.6 m<sup>2</sup>: 400 mg/m<sup>2</sup> IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 3, 6, 9, & 12 hours from the start of [[Cyclophosphamide (Cytoxan)]] infusion
+
| style="background-color:#1a9851" |Phase 3 (E-esc)
−
'''21-Day Cycle'''
+
|[[Breast_cancer#FEC_2|FEC]] x 5
−
====Chemotherapy, Cycle 5 (CDDP/ETOP/DIN)====
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS<sup>1</sup>
−
*[[Cisplatin (Platinol)]] by the following BSA-based criteria:
+
|-
−
**0.25 to 0.29 m<sup>2</sup>: 10 mg IV over 1 hour once daily on days 1 through 3
+
|[https://doi.org/10.1016/s0140-6736(00)02841-5 Bergh et al. 2000 (SBG 9401)]
−
**0.3 to 0.34 m<sup>2</sup>: 14 mg IV over 1 hour once daily on days 1 through 3
+
|1994-1998
−
**0.35 to 0.39 m<sup>2</sup>: 18 mg IV over 1 hour once daily on days 1 through 3
+
| style="background-color:#1a9851" |Phase 3 (C)
−
**0.4 to 0.44 m<sup>2</sup>: 22 mg IV over 1 hour once daily on days 1 through 3
+
|[[Complex_multipart_regimens#SBG_9401|See link]]
−
**0.45 to 0.49 m<sup>2</sup>: 26 mg IV over 1 hour once daily on days 1 through 3
+
| style="background-color:#fc8d59" |[[Complex_multipart_regimens#SBG_9401|See link]]
−
**0.5 to 0.54 m<sup>2</sup>: 30 mg IV over 1 hour once daily on days 1 through 3
+
|-
−
**0.55 to 0.59 m<sup>2</sup>: 34 mg IV over 1 hour once daily on days 1 through 3
+
|}
−
**≥ 0.6 m<sup>2</sup>: 60 mg/m<sup>2</sup> IV over 1 hour once daily on days 1 through 3
+
''<sup>1</sup>Reported efficacy for the Dutch National Study is based on the 2020 update.''
−
*[[Etoposide (Vepesid)]] by the following BSA-based criteria:
+
<div class="toccolours" style="background-color:#cbd5e8">
−
**0.25 to 0.29 m<sup>2</sup>: 34 mg IV over 2 hours once daily on days 1 through 3
+
====Preceding treatment====
−
**0.3 to 0.34 m<sup>2</sup>: 48 mg IV over 2 hours once daily on days 1 through 3
+
*Rodenhuis et al. 1998: [[Breast_cancer#FEC|Neoadjuvant FEC]] x 3, then [[Surgery#Breast_cancer_surgery|surgery]], then [[Breast_cancer#FEC_2|FEC]] x 1
−
**0.35 to 0.39 m<sup>2</sup>: 60 mg IV over 2 hours once daily on days 1 through 3
+
*Dutch National Study: [[Breast_cancer#FEC_2|FEC]] x 4
−
**0.4 to 0.44 m<sup>2</sup>: 72 mg IV over 2 hours once daily on days 1 through 3
+
</div>
−
**0.45 to 0.49 m<sup>2</sup>: 88 mg IV over 2 hours once daily on days 1 through 3
+
<div class="toccolours" style="background-color:#b3e2cd">
−
**0.5 to 0.54 m<sup>2</sup>: 100 mg IV over 2 hours once daily on days 1 through 3
+
====Chemotherapy====
−
**0.55 to 0.59 m<sup>2</sup>: 112 mg IV over 2 hours once daily on days 1 through 3
+
*[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup>/day IV on days -7 to -4
−
**≥ 0.6 m<sup>2</sup>: 200 mg/m<sup>2</sup> IV over 2 hours once daily on days 1 through 3
+
*[[Thiotepa (Thioplex)]] 125 mg/m<sup>2</sup>/day IV on days -7 to -4
−
*[[Dinutuximab (Unituxin)]] 17.5 mg/m<sup>2</sup> IV over 10 hours (may be extended up to 20 hours) on days 2 through 5
+
*[[Carboplatin (Paraplatin)]] 200 mg/m<sup>2</sup>/day IV on days -7 to -4
−
'''21-Day Cycle'''
+
'''Stem cells re-infused on day 0'''
−
====Immunotherapy, Cycle 5 (GM-CSF)====
+
</div></div>
−
*[[Sargramostim (Leukine)]] 250 μg/m<sup>2</sup> SubQ once on Day 6 (or Day 7) beginning 24 to 48 hours after completion of [[Dinutuximab (Unituxin)]] (Day 5)
+
===References===
−
**Hold [[Sargramostim (Leukine)]] if the total white cell count is > 50,000/µL and resume once the total white cell count is < 20,000/µL and then resume at 50% dose for the remainder of that course
+
# Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E 3rd, Antman K. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol. 1990 Jul;8(7):1239-45. [https://doi.org/10.1200/jco.1990.8.7.1239 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2162912 PubMed]
−
**Hold [[Sargramostim (Leukine)]] if [[Dinutuximab (Unituxin)]] is not given
+
# Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998 Aug 15;352(9127):515-21. [https://doi.org/10.1016/S0140-6736(98)01350-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9716055 PubMed]
−
'''21-Day Cycle'''
+
# '''SBG 9401:''' Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N; Scandinavian Breast Group. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet. 2000 Oct 21;356(9239):1384-91. Erratum in: Lancet 2000 Dec 23-30;356(9248):2196. [https://doi.org/10.1016/s0140-6736(00)02841-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11052580 PubMed]
−
</div></div><br>
+
# '''Dutch National Study:''' Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003 Jul 3;349(1):7-16. [https://doi.org/10.1056/NEJMoa022794 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12840087 PubMed] NCT03087409
 +
## '''Update:''' Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, van Tinteren H, Peterse JL, van de Vijver MJ, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumours. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol. 2006 Apr;17(4):588-96. Epub 2006 Jan 30. [https://doi.org/10.1093/annonc/mdl001 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16446318/ PubMed]
 +
## '''Update:''' Steenbruggen TG, Steggink LC, Seynaeve CM, van der Hoeven JJM, Hooning MJ, Jager A, Konings IR, Kroep JR, Smit WM, Tjan-Heijnen VCG, van der Wall E, Bins AD, Linn SC, Schaapveld M, Jacobse JN, van Leeuwen FE, Schröder CP, van Tinteren H, de Vries EGE, Sonke GS, Gietema JA. High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Apr 1;6(4):528-534. [https://doi.org/10.1001/jamaoncol.2019.6276 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7042796/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31999296 PubMed]
 +
==Cyclophosphamide monotherapy {{#subobject:7b2fec|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Consolidation===
+
===Regimen {{#subobject:9d3c8a|Variant=1}}===
−
====Chemotherapy, Tandem HSCT #1 (Thiotepa and Cyclophosphamide)====
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
−
*[[Thiotepa (Thioplex)]] by the following weight-based criteria:
+
!style="width: 20%"|Study
−
**≤ 12 kg: 10 mg/kg IV over 2 hours once daily on days -7, -6, -5
+
!style="width: 20%"|Years of enrollment
−
**> 12 kg: 300 mg/m<sup>2</sup> IV over 2 hours once daily on days -7, -6, -5
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
*[[Cyclophosphamide (Cytoxan)]] by the following weight-based criteria:
+
!style="width: 20%"|Comparator
−
**≤ 12 kg: 50 mg/kg IV over 1 hour once daily on days -5, -4, -3, -2
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
**> 12 kg: 1500 mg/m<sup>2</sup> IV over 1 hour once daily on days -5, -4, -3, -2
 
−
*PBSC on day 0
 
−
'''50 Day Cycle'''
 
−
====Supportive Therapy, Tandem HSCT #1 (Thiotepa and Cyclophosphamide)====
 
−
*[[Mesna (Mesnex)]] by the following weight-based criteria:
 
−
**≤ 12 kg: 10 mg/kg IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 4 and 8 hours after  each[[Cyclophosphamide (Cytoxan)]] infusion
 
−
**> 12 kg: 300 mg/m<sup>2</sup> IV over 15 minutes immediately prior to each [[Cyclophosphamide (Cytoxan)]] dose and again at 4 and 8 hours after  each[[Cyclophosphamide (Cytoxan)]] infusion
 
−
*[[Filgrastim (Neupogen)]] 5 μg/kg SubQ or IV once daily starting on day 0 and continuing until post-nadir ANC > 2000/μL for 3 consecutive days
 
−
'''50 Day Cycle'''
 
−
====Chemotherapy, Tandem HSCT #2 (CEM)====
 
−
*[[Melphalan (Alkeran)]] by the following criteria:
 
−
** ≤ 12 kg: 2 mg/kg IV over 30 minutes once daily on days -7, -6, -5
 
−
** > 12 kg: 60 mg/m<sup>2</sup> IV over 30 minutes once daily on days -7, -6, -5
 
−
*[[Etoposide (Vepesid)]] by the following criteria:
 
−
** ≤ 12 kg and GFR ≥ 100 mL/min: 10 mg/kg IV continuous infusion on days -7, -6, -5, -4
 
−
** > 12 kg and GFR ≥ 100 mL/min: 300 mg/m<sup>2</sup> IV continuous infusion on days -7, -6, -5, -4
 
−
** ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 6.7 mg/kg IV continuous infusion on days -7, -6, -5, -4
 
−
** > 12 kg and GFR between 100 mL/min and 60 mL/min: 200 mg/m<sup>2</sup> IV continuous infusion on days -7, -6, -5, -4
 
−
*[[Carboplatin (Paraplatin)]] by the following criteria:
 
−
{| class="wikitable" style="width: 40%; text-align:center;"  
 
−
! style="width: 20%" |BSA (m<sup>2</sup>)
 
−
! style="width: 20%" |GFR ≤ 100 mL/min/1.73 m<sup>2</sup>
 
−
! style="width: 20%" |GFR 91-99 mL/min/1.73 m<sup>2</sup>
 
−
! style="width: 20%" |GFR 76-90 mL/min/1.73 m<sup>2</sup>
 
−
! style="width: 20%" |GFR 60-75 mL/min/1.73 m<sup>2</sup>
 
 
|-
 
|-
−
|0.25 - 0.29
+
|rowspan=3|[https://doi.org/10.1007/BF01806239 Brinker et al. 1983 (DBCG 77B)]
−
|68 mg
+
|rowspan=3|1977-1983
−
|54 mg
+
|rowspan=3 style="background-color:#1a9851" |Phase 3 (C)
−
|48 mg
+
|1. [[Breast_cancer#CMF|CMF]]
−
|40 mg
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of RFS
 
|-
 
|-
−
|0.3 - 0.34
+
|2. [[Breast_cancer_-_null_regimens#Observation|Observation]]
−
|80 mg
+
| style="background-color:#91cf60" |Seems to have superior OS<sup>1</sup>
−
|64 mg
 
−
|56 mg
 
−
|48 mg
 
 
|-
 
|-
−
|0.35 - 0.39
+
|3. [[#Levamisole_monotherapy|Levamisole]]
−
|90 mg
+
| style="background-color:#d3d3d3" |Not reported
−
|72 mg
 
−
|64 mg
 
−
|54 mg
 
 
|-
 
|-
−
|0.4 - 0.44
+
|[https://doi.org/10.1016/j.breast.2009.09.006 Killander et al. 2009]
−
|110 mg
+
|1978-1983
−
|90 mg
+
|style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
−
|74 mg
+
|1. [[#Radiation_therapy_88|RT]]<br>2. [[#Cyclophosphamide_.26_RT_88|Cyclophosphamide & RT]]
−
|66 mg
+
| style="background-color:#d3d3d3" |Not reported
 
|-
 
|-
−
|0.45 - 0.49
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3228158/ Miles et al. 2011]
−
|130 mg
+
|1998-2003
−
|100 mg
+
|style="background-color:#1a9851" |Phase 3 (C)
−
|90 mg
+
|[[#STn-KLH_vaccine_77|STn-KLH vaccine]]
−
|80 mg
+
| style="background-color:#ffffbf" |Did not meet primary endpoints of TTP/OS
 
|-
 
|-
−
|0.5 - 0.54
+
|}
−
|160 mg
+
''<sup>1</sup>Reported efficacy for DBCG 77B is based on the 2010 update.''
−
|130 mg
+
<div class="toccolours" style="background-color:#b3e2cd">
−
|110 mg
+
====Chemotherapy====
−
|100 mg
+
*[[Cyclophosphamide (Cytoxan)]]
 +
</div></div>
 +
===References===
 +
# '''DBCG 77B:''' Brincker H, Mouridsen HT, Andersen KW. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat. 1983;3(1):91-5. [https://doi.org/10.1007/BF01806239 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/6347278 PubMed]
 +
## '''Update:''' Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Andersson M, Kamby C, Knoop AS; Danish Breast Cancer Cooperative Group. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Cancer. 2010 May 1;116(9):2081-9. [https://doi.org/10.1002/cncr.24969 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20186830 PubMed]
 +
#Killander F, Anderson H, Rydén S, Möller T, Hafström LO, Malmström P. Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer - a randomized trial from the South Sweden Breast Cancer Group. Breast. 2009 Oct;18(5):309-15. Epub 2009 Oct 6. [https://doi.org/10.1016/j.breast.2009.09.006 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19811918/ PubMed]
 +
# Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK; Theratope® Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16(8):1092-100. Epub 2011 May 14. [https://doi.org/10.1634/theoncologist.2010-0307 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3228158/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21572124/ PubMed]
 +
==ECT, then auto HSCT {{#subobject:7a4gab|Regimen=1}}==
 +
ECT: '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''hiotepa
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:9d0a2n|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|0.55 - 0.59
+
|[https://doi.org/10.1016/S0140-6736(05)67784-7 Nitz et al. 2005 (WSG AM-01)]
−
|190 mg
+
|1995-2002
−
|150 mg
+
|style="background-color:#1a9851" |Phase 3 (E-esc)
−
|130 mg
+
|[[Breast_cancer#Dose-dense_Cyclophosphamide_.26_Epibicin_.28ddEC.29|ddEC]] x 4, then [[#Dose-dense_CMF_88|ddCMF]] x 3
−
|120 mg
+
| style="background-color:#91cf60" |Seems to have superior OS
 
|-
 
|-
−
|≥ 0.6
 
−
|375 mg/m<sup>2</sup>
 
−
|300 mg/m<sup>2</sup>
 
−
|260 mg/m<sup>2</sup>
 
−
|230 mg/m<sup>2</sup>
 
 
|}
 
|}
−
*PBSC on day 0
+
''No longer used, but of historical interest.''
−
'''50-Day Cycle'''
+
<div class="toccolours" style="background-color:#cbd5e8">
−
====Supportive Therapy, Tandem HSCT #2 (CEM)====
+
====Preceding treatment====
−
*[[Filgrastim (Neupogen)]] 5 μg/kg SubQ or IV once daily starting on day 0 and continuing until post-nadir ANC > 2000/μL for 3 consecutive days
+
*[[Surgery#Breast_cancer_surgery|Surgery]]
−
'''50-Day Cycle'''
+
</div>
−
====Radiotherapy, ====
+
<div class="toccolours" style="background-color:#b3e2cd">
−
*[[External beam radiotherapy]] by the following criteria no sooner than 42 days post-transplant:
+
====Chemotherapy====
−
**Primary tumor site and initially involved lymph nodes (CTV/PTV): 21.6  Gy in 12 daily fractions
+
*[[Epirubicin (Ellence)]]
−
**Metastatic disease present after Induction (mCTVx/mPTVx): 21.6 Gy in 12 daily fractions
+
*[[Cyclophosphamide (Cytoxan)]]
−
**Hepatomegaly leading to respiratory distress: 4.5 Gy delivered in 3 daily fractions
+
*[[Thiotepa (Thioplex)]]
−
===Post-Consolidation===
 
−
'''Cycles 1 through 5'''
 
−
'''Cycle 6'''
 
−
====Chemotherapy, Cycle 1 through 5====
 
−
*[[Dinutuximab (Unituxin)]] 17.5 mg/m<sup>2</sup> IV over 10 hours (may be extended up to 20 hours) on days 4 through 7
 
−
*[[Isotretinoin (Accutane)]] by the following BSA-based criteria:
 
−
**0.25 - 0.29 m<sup>2</sup>: 10 mg PO BID on days 11 through 24
 
−
**0.3 - 0.39 m<sup>2</sup>: 20 mg PO BID on days 11 through 24
 
−
**0.4 - 0.49 m<sup>2</sup>: 30 mg PO BID on days 11 through 24
 
−
**0.5 - 0.59 m<sup>2</sup>: 40 mg PO BID on days 11 through 24
 
−
**≥ 0.6 m<sup>2</sup>: 80 mg/m<sup>2</sup> (round to nearest 10 mg) PO BID on days 11 through 24
 
−
'''28-Day Cycle'''
 
−
====Immunotherapy, Cycle 1 through 5====
 
−
*[[Sargramostim (Leukine)]] 250 μg/m<sup>2</sup> SubQ once on Day 1 through 14 prior to [[Dinutuximab (Unituxin)]]
 
−
**Hold [[Sargramostim (Leukine)]] if the total white cell count is > 50,000/µL and resume once the total white cell count is < 20,000/µL and then resume at 50% dose for the remainder of that course
 
−
'''28-Day Cycles'''
 
−
====Chemotherapy, Cycle 6====
 
−
*[[Isotretinoin (Accutane)]] by the following BSA-based criteria:
 
−
**0.25 - 0.29 m<sup>2</sup>: 10 mg PO BID on days 15 through 28
 
−
**0.3 - 0.39 m<sup>2</sup>: 20 mg PO BID on days 15 through 28
 
−
**0.4 - 0.49 m<sup>2</sup>: 30 mg PO BID on days 15 through 28
 
−
**0.5 - 0.59 m<sup>2</sup>: 40 mg PO BID on days 15 through 28
 
−
**≥ 0.6 m<sup>2</sup>: 80 mg/m<sup>2</sup> (round to nearest 10 mg) PO BID on days 15 through 28
 
−
'''28-Day Cycle'''
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#'''COG ANBL17P1:'''Furman WL, Federico SM, McCarville MB, Shulkin BL, Davidoff AM, Krasin MJ, Sahr N, Sykes A, Wu J, Brennan RC, Bishop MW, Helmig S, Stewart E, Navid F, Triplett B, Santana VM, Bahrami A, Anthony G, Yu AL, Hank J, Gillies SD, Sondel PM, Leung WH, Pappo AS. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clin Cancer Res. 2019 Nov 1;28(21):6320-28. [https://doi.org/10.1158/1078-0432.ccr-19-1452 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825564/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31601569/ PubMed]
+
# '''WSG AM-01:''' Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M; West German Study Group. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005 Dec 3;366(9501):1935-44. Erratum in: Lancet. 2006 Mar 4;367(9512):730. [https://doi.org/10.1016/S0140-6736(05)67784-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16325695 PubMed]
−
#'''COG ANBL17P1:'''Furman WL, McCarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, Pan H, Wu J, Brennan R, Bishop MW, Helmig S, Stewart E, Navid F, Triplett B, Santana V, Santiago T, Hank JA, Gillies SD, Yu A, Sondel PM, Leung WH, Pappo A, Federico SM. Improved OUtcome in Children with Newly Diagnosed High-Risk Neuroblastoma Treated with Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. J Clin Oncol. 2022 Feb 1;40(4):335-344. [https://doi.org/10.1200/JCO.21.01375 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825564/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34871104/ PubMed]
+
==FAC & BCG {{#subobject:19f556|Regimen=1}}==
−
=Low-risk=
+
FAC & BCG: '''<u>F</u>'''luorouracil, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, BCG
−
=Intermediate-risk, all lines of therapy=
 
−
==COG A3961 regimen {{#subobject:fd2c99|Regimen=1}}==
 
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:c71517|Variant=1}}===
+
===Regimen {{#subobject:08e709|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
!style="width: 25%"|Study
 
!style="width: 25%"|Study
 
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993160/ Baker et al. 2010 (COG A3961)]
+
|[https://jamanetwork.com/journals/jama/article-abstract/366766 Buzdar et al. 1979]
 
| style="background-color:#91cf61" |Non-randomized
 
| style="background-color:#91cf61" |Non-randomized
 
|-
 
|-
 
|}
 
|}
−
''To be completed.''
+
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*See paper for details
+
*[[Fluorouracil (5-FU)]]
 +
*[[Doxorubicin (Adriamycin)]]
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
====Immunotherapy====
 +
*[[Bacillus Calmette-Guérin (BCG)]]
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''COG A3961:''' Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK; Children’s Oncology Group. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1313-23. [https://doi.org/10.1056/NEJMoa1001527 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993160/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20879880 PubMed]
+
# Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine: a follow-up report. JAMA. 1979 Oct 5;242(14):1509-13. [https://jamanetwork.com/journals/jama/article-abstract/366766 link to original article] [https://pubmed.ncbi.nlm.nih.gov/470088 PubMed]
−
=High-risk, induction=
+
==Fluorouracil & Methotrexate (MF) {{#subobject:e1def3|Regimen=1}}==
−
==COJEC {{#subobject:4gjzb6|Regimen=1}}==
+
MF: '''<u>M</u>'''ethotrexate & 5-'''<u>F</u>'''luorouracil
−
COJEC: '''<u>C</u>'''isplatin, '''<u>O</u>'''ncovin (Vicristine), '''<u>J</u>'''M8 (Carboplatin), '''<u>E</u>'''toposide, '''<u>C</u>'''yclophosphamide
 
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:188h51|Variant=1}}===
+
===Regimen {{#subobject:c6e0a3|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
Line 536: Line 779:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://doi.org/10.1016/s1470-2045(08)70069-x Pearson et al. 2008 (ENSG5)]
+
|[https://academic.oup.com/jnci/article-abstract/85/10/812/1024452 Shapiro et al. 1993]
−
|1990-1999
+
|1976-1985
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer#CMF|CMF]]
 +
| style="background-color:#ffffbf" |Did not meet endpoints of TTF/OS
 +
|-
 +
|[https://doi.org/10.1056/NEJM198902233200801 Fisher et al. 1989 (NSABP B-13)]
 +
|1981-1988
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
−
|[[#OPEC.2FOJEC_88|OPEC/OJEC]]
+
|[[Breast_cancer_-_null_regimens#Observation|Observation]]
−
| style="background-color:#91cf60" |Seems to have superior EFS36
+
| style="background-color:#1a9850" |Superior DFS<sup>1</sup>
 +
|-
 +
|[https://doi.org/10.1200/JCO.1996.14.7.1982 Fisher et al. 1996 (NSABP B-19)]
 +
|1988-1990
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer#CMF|CMF]]
 +
| style="background-color:#fee08b" |Might have inferior OS
 +
|-
 +
|}
 +
''<sup>1</sup>Reported efficacy for NSABP B-13 is based on the 1996 update.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
</div></div>
 +
===References===
 +
# '''NSABP B-13:''' Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, Wolmark N, Fisher ER, Margolese R, Sutherland C, Glass A, Foster R, Caplan R. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989 Feb 23;320(8):473-8. [https://doi.org/10.1056/NEJM198902233200801 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2644531 PubMed]
 +
## '''Update:''' Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul;14(7):1982-92. [https://doi.org/10.1200/JCO.1996.14.7.1982 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8683228 PubMed]
 +
## '''Pooled update:''' Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. [https://doi.org/10.1200/JCO.2006.06.9054 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16921044 PubMed]
 +
# Shapiro CL, Gelman RS, Hayes DF, Osteen R, Obando A, Canellos GP, Frei E 3rd, Henderson IC. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst. 1993 May 19;85(10):812-7. [https://academic.oup.com/jnci/article-abstract/85/10/812/1024452 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8487326 PubMed]
 +
# '''NSABP B-19:''' Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul;14(7):1982-92. [https://doi.org/10.1200/JCO.1996.14.7.1982 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8683228 PubMed]
 +
## '''Pooled update:''' Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. [https://doi.org/10.1200/JCO.2006.06.9054 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16921044 PubMed]
 +
==FNC {{#subobject:152c11|Regimen=1}}==
 +
FNC: '''<u>F</u>'''luorouracil, '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>C</u>'''yclophosphamide
 +
<br>CNF: '''<u>C</u>'''yclophosphamide, '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:950f9d|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1097/00000421-200108000-00001 Ron et al. 2001]
 +
|1988-1992
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[Breast_cancer#CMF|CMF]]
 +
| style="background-color:#91cf60" |Seems to have superior DFS
 +
|-
 +
|[https://doi.org/10.1097/01.coc.0000046121.51504.b9 Fountzilas et al. 2004 (HE 10/92)]
 +
|1992-1998
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_2|Tamoxifen]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of RFS
 +
|-
 +
|[https://doi.org/10.1200/JCO.2006.07.8576 Toledano et al. 2007 (ARCOSEIN)]
 +
|1996-2000
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#FNC_.26_RT_99|FNC & RT]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of DFS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Lumpectomy|Breast-conserving surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
 +
*[[Mitoxantrone (Novantrone)]] 12 mg/m<sup>2</sup> IV once on day 1
 +
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
 +
'''21-day cycle for 6 cycles'''
 +
</div>
 +
<div class="toccolours" style="background-color:#cbd5e7">
 +
====Subsequent treatment====
 +
*ARCOSEIN: [[Regimen_classes#Radiotherapy-based_regimen|RT]]
 +
</div></div>
 +
===References===
 +
# Ron IG, Wigler N, Borovik R, Brufman G, Rizel S, Shani A, Brenner J, Farbstein H, Dale A, Inbar MJ, Brenner HJ, Chaitchik S, Catane R. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast  cancer: a phase III randomized multicenter study. Am J Clin Oncol. 2001 Aug;24(4):323-7. [https://doi.org/10.1097/00000421-200108000-00001 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11474254 PubMed]
 +
# '''HE 10/92:''' Fountzilas G, Stathopoulos G, Kouvatseas G, Polychronis A, Klouvas G, Samantas E, Zamboglou N, Kyriakou K, Adamou A, Pectasidis D, Ekonomopoulos T, Kalofonos HP, Bafaloukos D, Georgoulias V, Razis E, Koukouras D, Zombolas V, Kosmidis P, Skarlos D, Pavlidis N; Hellenic Cooperative Oncology Group. Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. Am J Clin Oncol. 2004 Feb;27(1):57-67. [https://doi.org/10.1097/01.coc.0000046121.51504.b9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14758135 PubMed]
 +
# '''ARCOSEIN:''' Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, Calais G. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol. 2007 Feb 1;25(4):405-10. Erratum in: J Clin Oncol. 2007 Jun 1;25(16):2334. [https://doi.org/10.1200/JCO.2006.07.8576 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17264336 PubMed]
 +
==Levamisole monotherapy {{#subobject:b051c5|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:ec3553|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(76)91337-4 Rojas et al. 1976]
 +
|NR
 +
|style="background-color:#1a9851"|Randomized (E-esc)
 +
|[[Breast_cancer_-_null_regimens#Observation|Observation]]
 +
| style="background-color:#91cf60" |Seems to have superior OS
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(80)90173-7 Brincker et al. 1980]
 +
|NR
 +
|style="background-color:#1a9851"|Randomized (E-switch-ooc)
 +
|[[#Radiation_therapy_88|RT]]
 +
| style="background-color:#fc8d59" |Seems to have inferior RFS
 +
|-
 +
|}
 +
''Note: Rojas et al. 1976 included patients with inoperable breast cancer; definitive therapy was RT.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*Rojas et al. 1976: [[Regimen_classes#Radiotherapy-based_regimen|Radiotherapy]]
 +
*Brincker et al. 1980: [[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Immunotherapy====
 +
*[[Levamisole (Ergamisol)]]
 +
</div></div>
 +
===References===
 +
# Rojas AF, Feierstein JN, Mickiewicz E, Glait H, Olivari AJ. Levamisole in advanced human breast cancer. Lancet. 1976 Jan 31;1(7953):211-5. [https://doi.org/10.1016/S0140-6736(76)91337-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/55529 PubMed]
 +
# Brincker H, Mouridsen HT, Andersen KW, Andersen J, Castberg T, Fischermann K, Henriksen E, Hou-Jensen C, Johansen H, Rossing N, Rorth M; Danish Breast Cancer Cooperative Group. Increased breast-cancer recurrence rate after adjuvant therapy with levamisole: a preliminary report. Lancet. 1980 Oct 18;2(8199):824-7. [https://doi.org/10.1016/S0140-6736(80)90173-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6107500 PubMed]
 +
==Melphalan monotherapy {{#subobject:b062c5|Regimen=1}}==
 +
P: '''<u>P</u>'''henylalanine mustard (Melphalan)
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:ec3663|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1056/NEJM197501162920301 Fisher et al. 1975 (NSABP B-05)]
 +
|1972-1975
 +
|style="background-color:#1a9851"|Phase 3 (E-esc)
 +
|[[Breast_cancer_-_null_regimens#Placebo|Placebo]]
 +
| style="background-color:#d9ef8b" |Might have superior DFS<sup>1</sup>
 +
|-
 +
|[https://doi.org/10.1002/1097-0142%28197706%2939%3A6%3C2883%3A%3AAID-CNCR2820390676%3E3.0.CO%3B2-9 Fisher et al. 1977 (NSABP B-07)]
 +
|1975-1976
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#PF|PF]]
 +
| style="background-color:#fc8d59" |Seems to have inferior RFS
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19820801)50:3%3C423::AID-CNCR2820500307%3E3.0.CO;2-O Glucksberg et al. 1982 (SWOG S7436)]
 +
|1975-1978
 +
|style="background-color:#1a9851" |Randomized (C)
 +
|[[#CMFVP|CMFVP]]
 +
| style="background-color:#d73027" |Inferior OS
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(83)91385-5 Rubens et al. 1983]
 +
|1975-1979
 +
|style="background-color:#1a9851"|Phase 3 (E-esc)
 +
|[[Breast_cancer_-_null_regimens#Observation|Observation]]
 +
| style="background-color:#d9ef8b" |Might have superior RFS
 
|-
 
|-
 
|}
 
|}
 +
''<sup>1</sup>Reported efficacy for NSABP B-05 is based on the 1986 update.''<br>
 +
''Note: Fisher et al. 1977 is an update for NSABP B-05 and also the primary results for NSABP B-07.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Cisplatin (Platinol)]]
+
*[[Melphalan (Alkeran)]]
−
*[[Vincristine (Oncovin)]]
 
−
*[[Carboplatin (Paraplatin)]]
 
−
*[[Etoposide (Vepesid)]]
 
−
*[[Cyclophosphamide (Cytoxan)]]
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#'''ENSG5:''' Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008 Mar;9(3):247-56. [https://doi.org/10.1016/s1470-2045(08)70069-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/18308250/ PubMed] NCT00365755
+
# '''NSABP B-05:''' Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med. 1975 Jan 16;292(3):117-22. [https://doi.org/10.1056/NEJM197501162920301 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1105174 PubMed]
−
##'''Update:''' Moreno L, Vaidya SJ, Pinkerton CR, Lewis IJ, Imeson J, Machin D, Pearson AD; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG). Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience. Pediatr Blood Cancer. 2013 Jul;60(7):1135-40. Epub 2012 Dec 31. [https://doi.org/10.1002/pbc.24452 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23281263/ PubMed]
+
## '''Update:''' Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H, Volk H. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: an update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer. 1977 Jun;39(6 Suppl):2883-903. [https://doi.org/10.1002/1097-0142(197706)39:6%3C2883::AID-CNCR2820390676%3E3.0.CO;2-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/194679 PubMed]
−
==N5/N6 {{#subobject:4uyha6|Regimen=1}}==
+
## '''Update:''' Fisher B, Fisher ER, Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986 Jun;4(6):929-41. [https://doi.org/10.1200/JCO.1986.4.6.929 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3519883 PubMed]
 +
# '''NSABP B-07:''' Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H, Volk H. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: an update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer. 1977 Jun;39(6 Suppl):2883-903. [https://doi.org/10.1002/1097-0142%28197706%2939%3A6%3C2883%3A%3AAID-CNCR2820390676%3E3.0.CO%3B2-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/194679 PubMed]
 +
# '''SWOG S7436:''' Glucksberg H, Rivkin SE, Rasmussen S, Tranum B, Gad-el-Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J, Vaughn C. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer. 1982 Aug 1;50(3):423-34. [https://doi.org/10.1002/1097-0142(19820801)50:3%3C423::AID-CNCR2820500307%3E3.0.CO;2-O link to original article] [https://pubmed.ncbi.nlm.nih.gov/7046900 PubMed]
 +
## '''Update:''' Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 1;97(1):21-9. [https://doi.org/10.1002/cncr.10982 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12491501 PubMed]
 +
# Rubens RD, Hayward JL, Knight RK, Bulbrook RD, Fentiman IS, Chaudary M, Howell A, Bush H, Crowther D, Sellwood RA, George WD, Howat JM. Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet. 1983 Apr 16;1(8329):839-43. [https://doi.org/10.1016/S0140-6736(83)91385-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6132179 PubMed]
 +
==Oophorectomy==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:ayyh51|Variant=1}}===
+
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
Line 564: Line 965:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://doi.org/10.1016/j.annonc.2019.11.011 Berthold et al. 2020 (NB2004-HR)]
+
|[https://doi.org/10.1056/NEJM197708182970704 Ahmann et al. 1977]
−
|2004-2016
+
|NR
 +
| style="background-color:#1a9851" |Randomized (C)
 +
|[[#CFP_.26_Oophorectomy|CFP & Oophorectomy]]
 +
| style="background-color:#fc8d59" |Seems to have inferior PFS
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5052674/ Love et al. 2016 (OSU-0476)]
 +
|2004-2011
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
−
|[[#N8_99|N8]], then [[#N5.2FN6|N5/N6]]
+
|[[Endocrine_ablation_surgery#Bilateral_oophorectomy_99|Mid-luteal phase oophorectomy]]
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Endocrine_ablation_surgery#Bilateral_oophorectomy|Bilateral oophorectomy]]
 +
</div>
 +
<div class="toccolours" style="background-color:#cbd5e7">
 +
====Subsequent treatment====
 +
*OSU-0476: [[#Tamoxifen_monotherapy_88|Tamoxifen]]
 +
</div></div>
 +
===References===
 +
# Ahmann DL, O'Connell MJ, Hahn RG, Bisel HF, Lee RA, Edmonson JH. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med. 1977 Aug 18;297(7):356-60. [https://doi.org/10.1056/NEJM197708182970704 link to original article] [https://pubmed.ncbi.nlm.nih.gov/876327 PubMed]
 +
# '''OSU-0476:''' Love RR, Hossain SM, Hussain MM, Mostafa MG, Laudico AV, Siguan SS, Adebamowo C, Sun JZ, Fei F, Shao ZM, Liu Y, Akram Hussain SM, Zhang B, Cheng L, Panigaro S, Walta F, Chuan JH, Mirasol-Lumague MR, Yip CH, Navarro NS Jr, Huang CS, Lu YS, Ferdousy T, Salim R, Akhter C, Nahar S, Uy G, Young GS, Hade EM, Jarjoura D. Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. Eur J Cancer. 2016 Jun;60:107-16. Epub 2016 Apr 20. [https://doi.org/10.1016/j.ejca.2016.03.011 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5052674/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27107325/ PubMed] NCT00293540
 +
==Paclitaxel monotherapy, q3wk {{#subobject:1cb87f|Regimen=1}}==
 +
T: '''<u>T</u>'''axol (Paclitaxel)
 +
<br>P: '''<u>P</u>'''aclitaxel
 +
<br>pT: '''<u>p</u>'''acli'''<u>T</u>'''axel
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen variant #1, 175 mg/m<sup>2</sup> q3wk {{#subobject:c084f5|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1200/jco.2003.02.063 Henderson et al. 2003 (INT 0148/CALGB 9344)]
 +
|1994-1999
 +
| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
 +
|[[Breast_cancer_-_null_regimens#Observation|Observation]]
 +
| style="background-color:#1a9850" |Superior OS
 +
|-
 +
|}
 +
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*INT 0148/CALGB 9344: [[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#Cyclophosphamide_.26_Doxorubicin_.28AC.29_2|AC]] x 4 versus [[Breast_cancer#Cyclophosphamide_.26_Doxorubicin_.28AC.29_2|AC]]; high-dose x 4 versus [[Breast_cancer#Cyclophosphamide_.26_Doxorubicin_.28AC.29_2|AC]]; very-high-dose x 4
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 +
'''21-day cycle for 4 cycles'''
 +
</div></div>
 +
===References===
 +
# '''INT 0148/CALGB 9344:''' Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83. [https://doi.org/10.1200/jco.2003.02.063 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12637460 PubMed]
 +
==PAF {{#subobject:5750af|Regimen=1}}==
 +
PAF: '''<u>P</u>'''henylalanine mustard (Melphalan), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:763980|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.1989.7.5.572 Fisher et al. 1989 (NSABP B-11)]
 +
|1981-1984
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[#PF|PF]]
 +
| style="background-color:#91cf60" |Seems to have superior OS
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
−
====Chemotherapy, N5 cycles====
+
====Chemotherapy====
−
*[[Vindesine (Eldisine)]] as follows:
+
*[[Melphalan (Alkeran)]]
−
**Cycles 1, 3, 5: 3 mg/m<sup>2</sup> IV over 60 minutes once on day 1
+
*[[Doxorubicin (Adriamycin)]]
−
*[[Cisplatin (Platinol)]] as follows:
+
*[[Fluorouracil (5-FU)]]
−
**Cycles 1, 3, 5: 40 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m<sup>2</sup>)
 
−
*[[Etoposide (Vepesid)]] as follows:
 
−
**Cycles 1, 3, 5: 100 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 400 mg/m<sup>2</sup>)
 
−
====Chemotherapy, N6 cycles====
 
−
*[[Vincristine (Oncovin)]] as follows:
 
−
**Cycles 2, 4, 6: 1.5 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8
 
−
*[[Dacarbazine (DTIC)]] as follows:
 
−
**Cycles 2, 4, 6: 200 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 5
 
−
*[[Ifosfamide (Ifex)]] as follows:
 
−
**Cycles 2, 4, 6: 1500 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 7500 mg/m<sup>2</sup>)
 
−
*[[Doxorubicin (Adriamycin)]] as follows:
 
−
**Cycles 2, 4, 6: 30 mg/m<sup>2</sup> IV over 4 hours once per day on days 6 & 7
 
−
'''21-day cycle for 6 cycles'''
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#'''NB2004-HR:''' Berthold F, Faldum A, Ernst A, Boos J, Dilloo D, Eggert A, Fischer M, Frühwald M, Henze G, Klingebiel T, Kratz C, Kremens B, Krug B, Leuschner I, Schmidt M, Schmidt R, Schumacher-Kuckelkorn R, von Schweinitz D, Schilling FH, Theissen J, Volland R, Hero B, Simon T. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann Oncol. 2020 Mar;31(3):422-429. Epub 2020 Jan 24. [https://doi.org/10.1016/j.annonc.2019.11.011 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/32067684 PubMed] NCT03042429
+
# '''NSABP B-11:''' Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, Sass R, Fisher ER, Jochimsen P, Legault-Poisson S, Dimitrov N, Wolter J, Bornstein R, Elias EG, LiCalzi N, Paterson AHG, Sutherland CM. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989 May;7(5):572-82. [https://doi.org/10.1200/JCO.1989.7.5.572 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2651576 PubMed]
−
=High-risk, consolidation=
+
==PF {{#subobject:3a5d5f|Regimen=1}}==
−
==Busulfan & Melphalan, then auto HSCT {{#subobject:484436|Regimen=1}}==
+
PF: '''<u>P</u>'''henylalanine mustard (Melphalan) & '''<u>F</u>'''luorouracil
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:a61951|Variant=1}}===
+
===Regimen {{#subobject:06f47d|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
Line 603: Line 1,066:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://doi.org/10.1016/S1470-2045(17)30070-0 Ladenstein et al. 2017 (HR-NBL1 part 1)]
+
|[https://doi.org/10.1002/1097-0142%28197706%2939%3A6%3C2883%3A%3AAID-CNCR2820390676%3E3.0.CO%3B2-9 Fisher et al. 1977 (NSABP B-07)]
−
|2002-2010
+
|1975-1976
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
−
|[[#Carboplatin.2C_Etoposide.2C_Melphalan.2C_then_auto_HSCT_88|Carboplatin, Etoposide, Melphalan, then auto HSCT]]
+
|[[#Melphalan_monotherapy|P]]
−
| style="background-color:#1a9850" |Superior EFS36
+
| style="background-color:#91cf60" |Seems to have superior RFS
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19800815)46:4%2B%3C1009::AID-CNCR2820461326%3E3.0.CO;2-H Fisher et al. 1980 (NSABP B-08)]
 +
|1976-1977
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#PFM_99|PFM]]
 +
| style="background-color:#ffffbf" |Did not meet endpoint of OS
 +
|-
 +
|[https://doi.org/10.1056/NEJM198107023050101 Fisher et al. 1981 (NSABP B-09)]
 +
|1977-1980
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#PFT|PFT]]
 +
| style="background-color:#d73027" |Inferior RFS
 +
|-
 +
|[https://doi.org/10.1002/1097-0142%2819900715)66%3A2%3C220%3A%3AAID-CNCR2820660205%3E3.0.CO%3B2-6 Fisher et al. 1990 (NSABP B-10)]
 +
|1977-1981
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#PFCp_99|PFCp]]
 +
| style="background-color:#ffffbf" |Did not meet endpoints of DFS/OS
 +
|-
 +
|[https://doi.org/10.1200/JCO.1989.7.5.572 Fisher et al. 1989 (NSABP B-11)]
 +
|1981-1984
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#PAF|PAF]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 
|-
 
|-
 
|}
 
|}
−
''Note: the abstract does not specify exact days but this schedule is typical; IV dosing was used after a 2007 protocol amendment''
+
''Note: Fisher et al. 1980 is more of a meta-analysis than a primary publication, but is to our knowledge the first manuscript to report the findings from NSABP B-08, which was a negative trial.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Busulfan (Myleran)]] 0.8 to 1.2 mg/kg IV every 6 hours on days -6 to -3 (16 total doses)
+
*[[Melphalan (Alkeran)]]
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2
+
*[[Fluorouracil (5-FU)]]
−
'''Stem cells re-infused on day 0'''
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''HR-NBL1 part 1:''' Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN). Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):500-514. Epub 2017 Mar 2. [https://doi.org/10.1016/S1470-2045(17)30070-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/28259608 PubMed] NCT01704716
+
# '''NSABP B-07:''' Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H, Volk H. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: an update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer. 1977 Jun;39(6 Suppl):2883-903. [https://doi.org/10.1002/1097-0142%28197706%2939%3A6%3C2883%3A%3AAID-CNCR2820390676%3E3.0.CO%3B2-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/194679 PubMed]
−
==GM-CSF, IL-2, Isotretinoin, Dinutuximab {{#subobject:231faf|Regimen=1}}==
+
# '''NSABP B-08:''' Fisher B, Redmond C, Fisher ER. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology--an overview of findings. Cancer. 1980 Aug 15;46(4 Suppl):1009-25. [https://doi.org/10.1002/1097-0142(19800815)46:4%2B%3C1009::AID-CNCR2820461326%3E3.0.CO;2-H link to original article] [https://pubmed.ncbi.nlm.nih.gov/6994873 PubMed]
 +
# '''NSABP B-09:''' Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981 Jul 2;305(1):1-6. [https://doi.org/10.1056/NEJM198107023050101 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7015139 PubMed]
 +
## '''Update:''' Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol. 1986 Apr;4(4):459-71. [https://doi.org/10.1200/JCO.1986.4.4.459 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2856857 PubMed]
 +
## '''Update:''' Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, Dimitrov N, Legault-Poisson S, Schipper H, Prager D. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987 May;106(5):649-54. [https://doi.org/10.7326/0003-4819-106-5-649 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3551710 PubMed]
 +
# '''NSABP B-11:''' Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, Sass R, Fisher ER, Jochimsen P, Legault-Poisson S, Dimitrov N, Wolter J, Bornstein R, Elias EG, LiCalzi N, Paterson AHG, Sutherland CM. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989 May;7(5):572-82. [https://doi.org/10.1200/JCO.1989.7.5.572 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2651576 PubMed]
 +
# '''NSABP B-10:''' Fisher B, Brown A, Wolmark N, Fisher ER, Redmond C, Wickerham DL, Margolese R, Dimitrov N, Pilch Y, Glass A, Sutherland C, Foster R. Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer. 1990 Jul 15;66(2):220-7. [https://doi.org/10.1002/1097-0142%2819900715)66%3A2%3C220%3A%3AAID-CNCR2820660205%3E3.0.CO%3B2-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2196108 PubMed]
 +
==PFT {{#subobject:1cb87f|Regimen=1}}==
 +
PFT: '''<u>P</u>'''henylalanine mustard (Melphalan), 5-'''<u>F</u>'''luorouracil, '''<u>T</u>'''amoxifen
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:abc626|Variant=1}}===
+
===Regimen {{#subobject:c084f5|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
Line 629: Line 1,126:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086629/ Yu et al. 2010 (COG ANBL0032)]
+
|[https://doi.org/10.1056/NEJM198107023050101 Fisher et al. 1981 (NSABP B-09)]
−
|2001-2009
+
|1977-1980
−
|style="background-color:#1a9851"|Phase 3 (E-RT-esc)
+
| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
−
|[[#Isotretinoin_monotherapy|Isotretinoin]]
+
|[[#PF|PF]]
−
|style="background-color:#91cf60"|Seems to have superior OS
+
| style="background-color:#1a9850" |Superior RFS
 +
|-
 +
|rowspan=2|[https://doi.org/10.1200/JCO.1990.8.6.1005 Fisher et al. 1990 (NSABP B-16)]
 +
|rowspan=2|1985-1988
 +
|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|1. [[#ACT|ACT]]
 +
| style="background-color:#d3d3d3" |Not reported
 +
|-
 +
|2. [[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_2|Tamoxifen]]
 +
| style="background-color:#91cf60" |Seems to have superior DDFS
 
|-
 
|-
 
|}
 
|}
−
''Note: in distinction from most chemotherapy regimens, the first day of a cycle is day 0 and the last day of a 28-day cycle is day 27.''
+
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Breast_cancer_surgery|Surgery]]
 +
</div>
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
−
====Targeted therapy====
 
−
*[[Dinutuximab (Unituxin)]] as follows:
 
−
**Cycles 1, 3, 5: 25 mg/m<sup>2</sup> IV once per day on days 3 to 6
 
−
**Cycles 2 & 4: 25 mg/m<sup>2</sup> IV once per day on days 7 to 10
 
−
====Immunotherapy====
 
−
*[[Sargramostim (Leukine)]] as follows:
 
−
**Cycles 1, 3, 5: 250 mcg/m<sup>2</sup> SC once per day on days 0 to 13
 
−
*[[Aldesleukin (Proleukin)]] as follows:
 
−
**Cycles 2 & 4: 3,000,000 IU/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 0, then 4,500,000 IU/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 7 (total dose per cycle: 30,000,000 IU/m<sup>2</sup>)
 
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Isotretinoin (Accutane)]] 160 mg/m<sup>2</sup>/day PO on days 14 to 27
+
*[[Melphalan (Alkeran)]]
−
'''28-day cycle for 6 cycles'''
+
*[[Fluorouracil (5-FU)]]
 +
====Endocrine therapy====
 +
*[[Tamoxifen (Nolvadex)]]
 +
</div></div>
 +
===References===
 +
# '''NSABP B-09:''' Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981 Jul 2;305(1):1-6. [https://doi.org/10.1056/NEJM198107023050101 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7015139 PubMed]
 +
## '''Update:''' Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol. 1986 Apr;4(4):459-71. [https://doi.org/10.1200/JCO.1986.4.4.459 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2856857 PubMed]
 +
## '''Update:''' Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, Dimitrov N, Legault-Poisson S, Schipper H, Prager D. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987 May;106(5):649-54. [https://doi.org/10.7326/0003-4819-106-5-649 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3551710 PubMed]
 +
# '''NSABP B-16:''' Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Myers DB, Hoehn JL. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990 Jun;8(6):1005-18. [https://doi.org/10.1200/JCO.1990.8.6.1005 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2189950 PubMed]
 +
## '''Pooled update:''' Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. [https://doi.org/10.1200/JCO.2004.01.042 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15452182 PubMed]
 +
==PT {{#subobject:c08464|Regimen=1}}==
 +
PT: '''<u>P</u>'''rednisone & '''<u>T</u>'''amoxifen
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:2fc709|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|rowspan = 2|[https://doi.org/10.1016/S0140-6736(84)92445-0 Goldhirsch et al. 1984 (LBCS III)]
 +
|rowspan=2|1978-1981
 +
|rowspan = 2 style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|1. [[#CMFPT|CMFPT]]
 +
| style="background-color:#fc8d59" |Seems to have inferior DFS
 +
|-
 +
|2. [[Breast_cancer_-_null_regimens#Observation|Observation]]
 +
| style="background-color:#1a9850" |Superior DFS
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(84)92445-0 Goldhirsch et al. 1984 (LBCS IV)]
 +
|1978-1981
 +
|style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer_-_null_regimens#Observation|Observation]]
 +
| style="background-color:#91cf60" |Seems to have superior DFS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Mastectomy|Mastectomy]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]]
 +
*[[Tamoxifen (Nolvadex)]]
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''COG ANBL0032:''' Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34. [https://doi.org/10.1056/NEJMoa0911123 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086629/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20879881 PubMed] NCT00026312
+
# '''LBCS III/IV:''' Goldhirsch A; Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet. 1984 Jun 9;1(8389):1256-60. [https://doi.org/10.1016/S0140-6736(84)92445-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6144974 PubMed]
−
##'''Update:''' Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. Epub 2021 Jan 27. [https://doi.org/10.1158/1078-0432.ccr-20-3909 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8046731/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33504555/ PubMed]
+
==Thiotepa monotherapy {{#subobject:1cbc64|Regimen=1}}==
−
==Isotretinoin monotherapy {{#subobject:d9be60|Regimen=1}}==
 
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:54059a|Variant=1}}===
+
===Regimen {{#subobject:9fac12|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
Line 664: Line 1,207:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199910143411601 Matthay et al. 1999]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1387335/ Fisher et al. 1968 (NSABP B-01)]
−
|1991-1996
+
|1958-1961
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
| style="background-color:#1a9851" |Phase 3 (E-esc)
−
|[[#Observation_88|No further therapy]]
+
|[[#Placebo_88|Placebo]]
−
| style="background-color:#91cf60" |Seems to have superior EFS
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of RR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Thiotepa (Tepadina)]]
 +
</div></div>
 +
===References===
 +
# '''NSABP B-01:''' Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968 Sep;168(3):337-56. [https://doi.org/10.1097/00000658-196809000-00004 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1387335/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/4970947 PubMed]
 +
## '''Update:''' Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975 Apr;140(4):528-34. [https://pubmed.ncbi.nlm.nih.gov/805475 PubMed]
 +
==TMF {{#subobject:c08464|Regimen=1}}==
 +
TMF: '''<u>T</u>'''hiotepa, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:2fc709|Variant=1}}===
 +
{| class="wikitable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086629/ Yu et al. 2010 (COG ANBL0032)]
+
|[https://doi.org/10.1093/oxfordjournals.annonc.a058929 Semiglazov et al. 1994]
−
|2001-2009
+
|1985-1990
−
|style="background-color:#1a9851"|Phase 3 (C)
+
| style="background-color:#91cf61" |Non-randomized portion of RCT
−
|[[#GM-CSF.2C_IL-2.2C_Isotretinoin.2C_Dinutuximab|GM-CSF, IL-2, Isotretinoin, Dinutuximab]]
 
−
|style="background-color:#fc8d59"|Seems to have inferior OS
 
 
|-
 
|-
 
|}
 
|}
 
<div class="toccolours" style="background-color:#cbd5e8">
 
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
−
*Matthay et al. 1999: [[Regimen_classes#High-dose_chemotherapy_with_auto_HSCT|HDT with purged auto HSCT]] versus [[#Cisplatin.2C_Doxorubicin.2C_Etoposide_88|cisplatin, doxorubicin, etoposide]] consolidation
+
*[[#TMF|TMF]], then [[Regimen_classes#Radiotherapy-based_regimen|RT]] versus [[Regimen_classes#Radiotherapy-based_regimen|RT]], then [[Surgery#Mastectomy|Mastectomy]]
 
</div>
 
</div>
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Isotretinoin (Accutane)]] 80 mg/m<sup>2</sup> PO twice per day on days 1 to 14
+
*[[Thiotepa (Thioplex)]]
−
'''28-day cycle for 6 cycles'''
+
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
</div></div>
 +
===References===
 +
# Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, Orlov AA, Barash NY, Golubeva OM, Chepic OF. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 1994 Sep;5(7):591-5. [https://doi.org/10.1093/oxfordjournals.annonc.a058929 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7993833 PubMed]
 +
=Metastatic disease, all lines of therapy=
 +
==Aminoglutethimide monotherapy {{#subobject:821a2c|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:f62b32|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(78)92759-9 Smith et al. 1978]
 +
|1977-1978
 +
| style="background-color:#91cf61" |Non-randomized
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 +
|-
 +
|[https://doi.org/10.1056/NEJM198109033051003 Santen et al. 1981]
 +
|NR
 +
| style="background-color:#1a9851" |Randomized (E-switch-ic)
 +
|[[Endocrine_ablation_surgery#Bilateral_adrenalectomy_88|Bilateral adrenalectomy]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(84)90596-8 Stuart-Harris et al. 1984]
 +
|NR
 +
| style="background-color:#91cf61" |Phase 2
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 +
|-
 +
|[https://academic.oup.com/jnci/article-abstract/80/14/1147/908657 Canney et al. 1988]
 +
|NR
 +
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 +
|[[#Medroxyprogesterone_monotherapy|MPA]]
 +
|style="background-color:#ffffbf"|Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1007/BF01810736 Lundgren et al. 1989]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[#Megestrol_monotherapy|Megestrol]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1007/BF01961246 Garcia-Giralt et al. 1992]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[#Medroxyprogesterone_monotherapy|MPA]]
 +
| style="background-color:#91cf60" |Seems to have superior TTP
 +
|-
 +
|[https://pubmed.ncbi.nlm.nih.gov/8135469 Robustelli della Cuna et al. 1993]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Aminoglutethimide_monotherapy|Aminoglutethimide]]; higher-dose
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19940115)73:2%3C354::AID-CNCR2820730220%3E3.0.CO;2-J Gale et al. 1994]
 +
|1977-NR
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|1. [[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]<br>2. [[Endocrine_ablation_surgery#Bilateral_adrenalectomy_88|Bilateral adrenalectomy]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoints of DOR/TTF/OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Aminoglutethimide (Cytadren)]]
 +
====Supportive therapy====
 +
*[[Hydrocortisone (Cortef)]]
 +
</div></div>
 +
===References===
 +
# Smith IE, Fitzharris BM, McKinna JA, Fahmy DR, Nash AG, Neville AM, Gazet JC, Ford HT, Powles TJ. Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet. 1978 Sep 23;2(8091):646-9. [https://doi.org/10.1016/S0140-6736(78)92759-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/80576 PubMed]
 +
# Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med. 1981 Sep 3;305(10):545-51. [https://doi.org/10.1056/NEJM198109033051003 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7019703 PubMed]
 +
# Stuart-Harris R, Dowsett M, Bozek T, McKinna JA, Gazet JC, Jeffcoate SL, Kurkure A, Carr L, Smith IE. Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet. 1984 Sep 15;2(8403):604-7. [https://doi.org/10.1016/S0140-6736(84)90596-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6147642 PubMed]
 +
# Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst. 1988 Sep 21;80(14):1147-51. [https://academic.oup.com/jnci/article-abstract/80/14/1147/908657 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2970555 PubMed]
 +
# Lundgren S, Gundersen S, Klepp R, Lønning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat. 1989 Nov;14(2):201-6. [https://doi.org/10.1007/BF01810736 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2690972 PubMed]
 +
# Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Pommatau E, Pouillart P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M, Zylberait D. Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat. 1992;24(2):139-45. [https://doi.org/10.1007/BF01961246 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8443401 PubMed]
 +
# Robustelli della Cuna G, Pannuti F, Martoni A, Camaggi CM, Strocchi E, Da Prada GA, Tanneberger S; Italian Cooperative Group. Aminoglutethimide in advanced breast cancer: prospective, randomized comparison of two dose levels. Anticancer Res. 1993 Nov-Dec;13(6B):2367-71. [https://pubmed.ncbi.nlm.nih.gov/8135469 PubMed]
 +
# Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ; [[Study_Groups#ECOG|ECOG]]. Hormonal treatment for metastatic breast cancer: an Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 1994 Jan 15;73(2):354-61. [https://doi.org/10.1002/1097-0142(19940115)73:2%3C354::AID-CNCR2820730220%3E3.0.CO;2-J link to original article] [https://pubmed.ncbi.nlm.nih.gov/8293400 PubMed]
 +
==CAMF {{#subobject:4b99b8|Regimen=1}}==
 +
CAMF: '''<u>C</u>'''yclophosphamide,  '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil
 +
<br>AFCM: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>F</u>'''luorouracil, '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:7c9b85|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(197806)41:6%3C2078::AID-CNCR2820410602%3E3.0.CO;2-Q Tranum et al. 1978]
 +
|NR
 +
| style="background-color:#1a9851" |Randomized (E-esc)
 +
|1. [[#Doxorubin_.26_Fluorouracil_.28FA.29_88|AF]]<br>2. [[Breast_cancer#FAC_3|FAC]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(197908)44:2%3C392::AID-CNCR2820440204%3E3.0.CO;2-D Bezwoda et al. 1979]
 +
|1976-1977
 +
|style="background-color:#1a9851" |Randomized (E-switch-ic)
 +
|[[#CMFV|CMFV]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1200/JCO.1984.2.1.28 Lippman et al. 1984]
 +
|1977-1982
 +
| style="background-color:#1a9851" |Randomized (C)
 +
|[[#CAMFTP_99|CAMFTP]]
 +
| style="background-color:#ffffbf" |Did not meet endpoint of ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Doxorubicin (Adriamycin)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
</div></div>
 +
===References===
 +
# Tranum B, Hoogstraten B, Kennedy A, Vaughn CB, Samal B, Thigpen T, Rivkin S, Smith F, Palmer RL, Costanzi J, Tucker WG, Wilson H, Maloney TR; [[Study_Groups#SWOG|SWOG]]. Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study. Cancer. 1978 Jun;41(6):2078-83. [https://doi.org/10.1002/1097-0142(197806)41:6%3C2078::AID-CNCR2820410602%3E3.0.CO;2-Q link to original article] [https://pubmed.ncbi.nlm.nih.gov/657081 PubMed]
 +
# Bezwoda WR, de Moor NG, Derman D, Lange M, Saner R, Dando R. Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine. Cancer. 1979 Aug;44(2):392-7. [https://doi.org/10.1002/1097-0142(197908)44:2%3C392::AID-CNCR2820440204%3E3.0.CO;2-D link to original article] [https://pubmed.ncbi.nlm.nih.gov/383254 PubMed]
 +
# Lippman ME, Cassidy J, Wesley M, Young RC. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol. 1984 Jan;2(1):28-36. [https://doi.org/10.1200/JCO.1984.2.1.28 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6321686 PubMed]
 +
==CAF & MPA {{#subobject:6c7ff9|Regimen=1}}==
 +
CAF & MPA: '''<u>C</u>'''yclophosphamide,  '''<u>A</u>'''driamycin (Doxorubicin), '''<u>F</u>'''luorouracil, '''<u>M</u>'''edroxy'''<u>P</u>'''rogesterone '''<u>A</u>'''cetate
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:b2ce67|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1016/0959-8049(94)90123-6 Tominaga et al. 1994]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer#FAC_3|CAF]]
 +
| style="background-color:#91cf60" |Seems to have superior ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Doxorubicin (Adriamycin)]]
 +
*[[Fluorouracil (5-FU)]]
 +
====Endocrine therapy====
 +
*[[Medroxyprogesterone (MPA)]]
 +
</div></div>
 +
===References===
 +
# Tominaga T, Abe O, Ohshima A, Hayasaka H, Uchino J, Abe R, Enomoto K, Izuo M, Watanabe H, Takatani O, Yoshida M, Sakai K, Koyama H, Hattori T, Senoo T, Monden Y, Nomura Y. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer. 1994;30A(7):959-64. [https://doi.org/10.1016/0959-8049(94)90123-6 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/7946592 PubMed]
 +
==CAFVP {{#subobject:918bda|Regimen=1}}==
 +
CAFVP: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>F</u>'''luorouracil, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:e01caf|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3 Muss et al. 1978]
 +
|1975-1976
 +
|style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[#CMFVP_2|CMFVP]]
 +
| style="background-color:#d9ef8b" |Might have superior OS
 +
|-
 +
|rowspan=2|[https://doi.org/10.1200/JCO.1987.5.10.1523 Aisner et al. 1987]
 +
|rowspan=2|1976-1980
 +
|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|1. [[Breast_cancer#FAC_3|CAF]]
 +
| style="background-color:#d3d3d3" |Not reported
 +
|-
 +
|2. [[Breast_cancer#CMF_2|CMF]]
 +
| style="background-color:#1a9850" |Superior ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Doxorubicin (Adriamycin)]]
 +
*[[Fluorouracil (5-FU)]]
 +
*[[Vincristine (Oncovin)]]
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]]
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP; Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999 Oct 14;341(16):1165-73. [https://doi.org/10.1056/NEJM199910143411601 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/10519894 PubMed]
+
# Muss HB, White DR, Richards F 2nd, Cooper MR, Stuart JJ, Jackson DV, Rhyne L, Spurr CL. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial. Cancer. 1978 Nov;42(5):2141-8. [https://doi.org/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/363253 PubMed]
−
# '''COG ANBL0032:''' Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34. [https://doi.org/10.1056/NEJMoa0911123 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086629/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20879881 PubMed] NCT00026312
+
# Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A, Ginsberg S, Holland JF; [[Study_Groups#CALGB|CALGB]]. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol. 1987 Oct;5(10):1523-33. [https://doi.org/10.1200/JCO.1987.5.10.1523 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/3655855 PubMed]
−
##'''Update:''' Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. Epub 2021 Jan 27. [https://doi.org/10.1158/1078-0432.ccr-20-3909 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8046731/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33504555/ PubMed]
+
==CAV {{#subobject:90f8d0|Regimen=1}}==
−
==Isotretinoin & Dinutuximab {{#subobject:d0nx60|Regimen=1}}==
+
CAV: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''incristine
 +
<br>VAC: '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:59ab1a|Variant=1}}===
+
===Regimen {{#subobject:4da860|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
Line 700: Line 1,443:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://doi.org/10.1016/S1470-2045(18)30578-3 Ladenstein et al. 2018 (HR-NBL1 part 2)]
+
|[https://doi.org/10.1002/1097-0142(19821201)50:11%3C2269::aid-cncr2820501107%3E3.0.co;2-l Muss et al. 1982]
−
|2009-2013
+
|1979-1981
 +
|style="background-color:#1a9851"|Randomized (E-esc)
 +
|[[Breast_cancer#CMF_2|CMF]]
 +
| style="background-color:#91cf60" |Seems to have superior ORR
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19841201)54:11%3C2338::aid-cncr2820541105%3E3.0.co;2-4 Zekan et al. 1984]
 +
|1981-1982
 +
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[#High-dose_Cyclophosphamide_.26_Fluorouracil_99|CF]]
 +
|style="background-color:#ffffbf"|Did not meet primary endpoints
 +
|-
 +
|[https://doi.org/10.1016/0277-5379(86)90075-1 Gundersen et al. 1986]
 +
|1982-1983
 +
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[Breast_cancer#Doxorubicin_monotherapy_2|Doxorubicin]]
 +
|style="background-color:#ffffbf"|Did not meet endpoint of ORR
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977504/ Powles et al. 1991]
 +
|1985-1989
 +
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[Stub#3M|3M]]
 +
|style="background-color:#ffffbf"|Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1007/BF01806182 Green et al. 1996]
 +
|NR
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Interleukin-2.2C_Isotretinoin.2C_Dinutuximab_99|IL-2, Isotretinoin, Dinutuximab]]
+
|[[Stub#VNC|VNC]]
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS36
+
| style="background-color:#d9ef8b" |Might have superior ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Vincristine (Oncovin)]]
 +
*[[Doxorubicin (Adriamycin)]]
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
</div></div>
 +
===References===
 +
# Muss HB, Richards F 2nd, Jackson DV, Cooper MR, White DR, Stuart JJ, Ramseur W, Christian RM, Wells HB, Pope E, Spurr CL; Piedmont Oncology Association. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association. Cancer. 1982 Dec 1;50(11):2269-74. [https://doi.org/10.1002/1097-0142(19821201)50:11%3C2269::aid-cncr2820501107%3E3.0.co;2-l link to original article] [https://pubmed.ncbi.nlm.nih.gov/6754062 PubMed]
 +
# Zekan PJ, Muss HB, Capizzi RL, Cooper MR, Harding RW, Hopkins JO, Jackson DV, Ramseur WL, Richards F 2nd, Spurr CL, Stuart JJ, White DR, Pope E, Case D, Wells HB; Piedmont Oncology Association. High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast: a phase III study of the Piedmont Oncology Association (POA). Cancer. 1984 Dec 1;54(11):2338-43. [https://doi.org/10.1002/1097-0142(19841201)54:11%3C2338::aid-cncr2820541105%3E3.0.co;2-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6388802 PubMed]
 +
# Gundersen S, Kvinnsland S, Klepp O, Kvaløy S, Lund E, Høst H. Weekly adriamycin versus VAC in advanced breast cancer: a randomized trial. Eur J Cancer Clin Oncol. 1986 Dec;22(12):1431-4. [https://doi.org/10.1016/0277-5379(86)90075-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3595668 PubMed]
 +
# Powles TJ, Jones AL, Judson IR, Hardy JR, Ashley SE. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer. 1991 Aug;64(2):406-10. [https://doi.org/10.1038/bjc.1991.318 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977504/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/1892775 PubMed]
 +
# Green JA, Slater AJ, Campbell IR, Kelly V. Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine. Breast Cancer Res Treat. 1996;39(2):155-63. [https://doi.org/10.1007/BF01806182 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8872324 PubMed]
 +
==CFP {{#subobject:ba429d|Regimen=1}}==
 +
CFP: '''<u>C</u>'''yclophosphamide, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:26519a|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.1984.2.11.1260 Creagan et al. 1984]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#CAP_99|CAP]], then [[#CFP_2|CFP]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19870301)59:5%3C874::AID-CNCR2820590503%3E3.0.CO;2-O Rosner et al. 1987]
 +
|1981-1985
 +
| style="background-color:#1a9851" |Randomized (E-esc)
 +
|1. [[Breast_cancer#Cyclophosphamide_.26_Doxorubicin_.28AC.29_3|CA]]<br>2. [[#CMFVP_2|CMFVP]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19890515)63:10%3C1931::AID-CNCR2820631011%3E3.0.CO;2-F Marschke et al. 1989]
 +
|1982-1987
 +
| style="background-color:#1a9851" |Randomized (C)
 +
|[[#CMFP_2|CMFP]]
 +
| style="background-color:#fee08b" |Might have inferior ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Fluorouracil (5-FU)]]
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]]
 +
</div></div>
 +
===References===
 +
# Creagan ET, Green SJ, Ahmann DL, Ingle JN, Edmonson JH, Marschke RF Jr. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol. 1984 Nov;2(11):1260-5. [https://doi.org/10.1200/JCO.1984.2.11.1260 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6387059 PubMed]
 +
# Rosner D, Nemoto T, Lane WW. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. Cancer. 1987 Mar 1;59(5):874-83. [https://doi.org/10.1002/1097-0142(19870301)59:5%3C874::AID-CNCR2820590503%3E3.0.CO;2-O link to original article] [https://pubmed.ncbi.nlm.nih.gov/3815266 PubMed]
 +
# Marschke RF Jr, Ingle JN, Schaid DJ, Krook JE, Mailliard JA, Cullinan SA, Pfeifle DM, Votava HJ, Ebbert LP, Windschitl HE. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer. 1989 May 15;63(10):1931-7. [https://doi.org/10.1002/1097-0142(19890515)63:10%3C1931::AID-CNCR2820631011%3E3.0.CO;2-F link to original article] [https://pubmed.ncbi.nlm.nih.gov/2649221 PubMed]
 +
==Chlorambucil & Prednisolone {{#subobject:2cde9a|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:0044a9|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://jamanetwork.com/journals/jama/article-abstract/1163685 Freckman et al. 1964]
 +
|1955-1963
 +
| style="background-color:#91cf61" |Non-randomized
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 +
|-
 +
|rowspan=2|[https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/1097-0142%2819831101%2952%3A9%3C1570%3A%3AAID-CNCR2820520905%3E3.0.CO%3B2-W Løber et al. 1983]
 +
|rowspan=2|1978-1980
 +
|rowspan=2 style="background-color:#1a9851" |Phase 3 (C)
 +
|1. [[#Prednimustine_monotherapy_88|Prednimustine]]; continuous
 +
| style="background-color:#d73027" |Inferior TTP
 +
|-
 +
|2. [[#Prednimustine_monotherapy_88|Prednimustine]]; intermittent
 +
| style="background-color:#fee08b" |Might have inferior TTP
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Chlorambucil (Leukeran)]]
 +
====Endocrine therapy====
 +
*[[Prednisolone (Millipred)]]
 +
</div></div>
 +
===References===
 +
# Freckman HA, Fry HL, Mendez FL, Maurer ER. Chlorambucil-prednisolone therapy for disseminated breast carcinoma. JAMA. 1964 Jul 6;189:23-6. [https://jamanetwork.com/journals/jama/article-abstract/1163685 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14149018 PubMed]
 +
# Løber J, Mouridsen HT, Christiansen IE, Dombernowsky P, Mattsson W, Rørth M. A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer. Cancer. 1983 Nov 1;52(9):1570-6. [https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/1097-0142%2819831101%2952%3A9%3C1570%3A%3AAID-CNCR2820520905%3E3.0.CO%3B2-W link to original article] [https://pubmed.ncbi.nlm.nih.gov/6352005 PubMed]
 +
==CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:392c1c|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1038/sj.bmt.1705935 Biron et al. 2007 (Pegase 03)]
 +
|1995-2001
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer_-_null_regimens#Observation_2|No further treatment]]
 +
| style="background-color:#1a9850" |Superior DFS
 
|-
 
|-
 
|}
 
|}
−
''Note: this was a second randomization and second cohort of patients enrolled in HR-NBL1.''
 
 
<div class="toccolours" style="background-color:#cbd5e8">
 
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
−
*[[#Busulfan_.26_Melphalan.2C_then_auto_HSCT|Busulfan & Melphalan, then auto HSCT]] versus [[#Carboplatin.2C_Etoposide.2C_Melphalan.2C_then_auto_HSCT_88|Carboplatin, Etoposide, Melphalan, then auto HSCT]]
+
*[[Breast_cancer#FEC_3|FEC]] x 4
 
</div>
 
</div>
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Isotretinoin (Accutane)]]
+
*[[Cyclophosphamide (Cytoxan)]] 6000 mg/m<sup>2</sup>
−
====Targeted therapy====
+
*[[Thiotepa (Thioplex)]] 800 mg/m<sup>2</sup>
−
*[[Dinutuximab (Unituxin)]]
+
</div></div>
 +
===References===
 +
# '''Pegase 03:''' Biron P, Durand M, Roché H, Delozier T, Battista C, Fargeot P, Spaeth D, Bachelot T, Poiget E, Monnot F, Tanguy ML, Curé H. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008 Mar;41(6):555-62. Epub 2007 Nov 26. [https://doi.org/10.1038/sj.bmt.1705935 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18037940 PubMed] NCT00002870
 +
==CMFP {{#subobject:d1eccf|Regimen=1}}==
 +
CMFP: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:6c96a9|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1633086/ Canellos et al. 1974]
 +
|NR
 +
| style="background-color:#91cf61" |Non-randomized
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 +
|-
 +
|[https://doi.org/10.1007/BF01806026 Segaloff et al. 1985]
 +
|1971-1976
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#CMFVP_2|CMFVP]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19821001)50:7%3C1235::AID-CNCR2820500703%3E3.0.CO;2-L Tormey et al. 1982 (ECOG E2173)]
 +
|1973-1974
 +
| style="background-color:#1a9851" |Randomized (E-esc)
 +
|1. [[#Doxorubicin_.26_Vinblastine_.28AV.29_88|AV]]<br>2. [[Breast_cancer#CMF_2|CMF]]
 +
| style="background-color:#91cf60" |Seems to have superior OS
 +
|-
 +
|[https://doi.org/10.1200/JCO.1985.3.7.932 Cummings et al. 1985]
 +
|1978-1979
 +
| style="background-color:#1a9851" |Randomized (E-esc)
 +
|[[Breast_cancer#FAC_3|CAF]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19890515)63:10%3C1931::AID-CNCR2820631011%3E3.0.CO;2-F Marschke et al. 1989]
 +
|1982-1987
 +
| style="background-color:#1a9851" |Randomized (E-esc)
 +
|[[#CFP_2|CFP]]
 +
| style="background-color:#d9ef8b" |Might have superior ORR
 +
|-
 +
|[https://doi.org/10.1200/JCO.1999.17.8.2355 Bishop et al. 1999]
 +
|1993-NR
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]]
 +
</div></div>
 +
===References===
 +
# Canellos GP, Devita VT, Gold GL, Chabner BA, Schein PS, Young RC. Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J. 1974 Feb 9;1(5901):218-20. [https://doi.org/10.1136/bmj.1.5901.218 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1633086/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/4818162 PubMed]
 +
# '''ECOG E2173:''' Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, Perlia C, Rice MA. Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Cancer. 1982 Oct 1;50(7):1235-44. [https://doi.org/10.1002/1097-0142(19821001)50:7%3C1235::AID-CNCR2820500703%3E3.0.CO;2-L link to original article] [https://pubmed.ncbi.nlm.nih.gov/7049347 PubMed]
 +
# Segaloff A, Hankey BF, Carter AC, Escher GC, Ansfield FJ, Talley RW. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer. Breast Cancer Res Treat. 1985;5(3):311-9. [https://doi.org/10.1007/BF01806026 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3896353 PubMed]
 +
# Cummings FJ, Gelman R, Horton J. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol. 1985 Jul;3(7):932-40. [https://doi.org/10.1200/JCO.1985.3.7.932 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3894587 PubMed]
 +
# Marschke RF Jr, Ingle JN, Schaid DJ, Krook JE, Mailliard JA, Cullinan SA, Pfeifle DM, Votava HJ, Ebbert LP, Windschitl HE. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer. 1989 May 15;63(10):1931-7. [https://doi.org/10.1002/1097-0142(19890515)63:10%3C1931::AID-CNCR2820631011%3E3.0.CO;2-F link to original article] [https://pubmed.ncbi.nlm.nih.gov/2649221 PubMed]
 +
# Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999 Aug;17(8):2355-64. [https://doi.org/10.1200/JCO.1999.17.8.2355 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10561297 PubMed]
 +
==CMFV {{#subobject:e18ffa|Regimen=1}}==
 +
CMFV: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>V</u>'''inblastine
 +
<br>CVMF: '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''inblastine, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:405835|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1016/s0140-6736(75)90676-5 Edelstyn et al. 1975]
 +
|NR
 +
|style="background-color:#1a9851" |Randomized (E-esc)
 +
|[[#CMFV|CMFV]]; 1-day
 +
| style="background-color:#1a9850" |Superior ORR
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(197908)44:2%3C392::AID-CNCR2820440204%3E3.0.CO;2-D Bezwoda et al. 1979]
 +
|1976-1977
 +
|style="background-color:#1a9851" |Randomized (C)
 +
|[[#CAMF|CAMF]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
*[[Vincristine (Oncovin)]]
 +
</div></div>
 +
===References===
 +
# Edelstyn GA, Bates TD, Brinkley D, MacRae KD, Spittle MF, Wheeler T. Comparison of 5-day, 1-day, and 2-day cyclical combination chemotherapy in advanced breast cancer. Lancet. 1975 Aug 2;2(7927):209-11. [https://doi.org/10.1016/s0140-6736(75)90676-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/51964 PubMed]
 +
# Bezwoda WR, de Moor NG, Derman D, Lange M, Saner R, Dando R. Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine. Cancer. 1979 Aug;44(2):392-7. [https://doi.org/10.1002/1097-0142(197908)44:2%3C392::AID-CNCR2820440204%3E3.0.CO;2-D link to original article] [https://pubmed.ncbi.nlm.nih.gov/383254 PubMed]
 +
==CMFVP {{#subobject:9920da|Regimen=1}}==
 +
CMFVP: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone
 +
<br>COMFP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone
 +
<br>CFPMV: '''<u>C</u>'''yclophosphamide, '''<u>F</u>'''luorouracil, '''<u>P</u>'''rednisone, '''<u>M</u>'''ethotrexate, '''<u>V</u>'''incristine
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:e01cbf|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1007/BF01806026 Segaloff et al. 1985]
 +
|1971-1976
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[#CMFP_2|CMFP]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(197607)38:1%3C13::AID-CNCR2820380104%3E3.0.CO;2-5 Hoogstraten et al. 1976]
 +
|1972-1974
 +
|style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer#Doxorubicin_monotherapy_3|Doxorubicin]]
 +
| style="background-color:#91cf60" |Seems to have superior ORR
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(197708)40:2%3C625::AID-CNCR2820400206%3E3.0.CO;2-M Smalley et al. 1977]
 +
|1974-1975
 +
|style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer#FAC_3|CAF]]
 +
| style="background-color:#fee08b" |Might have inferior OS<sup>1</sup>
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3 Muss et al. 1978]
 +
|1975-1976
 +
|style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#CAFVP|CAFVP]]
 +
| style="background-color:#fee08b" |Might have inferior OS
 +
|-
 +
|[https://doi.org/10.1016/0014-2964(80)90037-7 Carmo-Pereira et al. 1980]
 +
|NR
 +
|style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[#Fluorouracil_monotherapy_88|5-FU]]
 +
| style="background-color:#1a9850" |Superior OS
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19870301)59:5%3C874::AID-CNCR2820590503%3E3.0.CO;2-O Rosner et al. 1987]
 +
|1981-1985
 +
| style="background-color:#1a9851" |Randomized (E-esc)
 +
|1. [[Breast_cancer#Cyclophosphamide_.26_Doxorubicin_.28AC.29_3|CA]]<br>2. [[#CFP_2|CFP]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 +
|-
 +
|}
 +
''<sup>1</sup>Reported efficacy for Smalley et al. 1977 is based on the 1983 update.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Methotrexate (MTX)]]
 +
*[[Fluorouracil (5-FU)]]
 +
*[[Vincristine (Oncovin)]]
 +
====Endocrine therapy====
 +
*[[Prednisone (Sterapred)]]
 +
</div></div>
 +
===References===
 +
# Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H; [[Study_Groups#SWOG|SWOG]]. Combination chemotherapy and adriamycin in patients with advanced breast cancer: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):13-20. [https://doi.org/10.1002/1097-0142(197607)38:1%3C13::AID-CNCR2820380104%3E3.0.CO;2-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/947510 PubMed]
 +
# Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S; Southeastern Cancer Study Group. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project. Cancer. 1977 Aug;40(2):625-32. [https://doi.org/10.1002/1097-0142(197708)40:2%3C625::AID-CNCR2820400206%3E3.0.CO;2-M link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/329975 PubMed]
 +
## '''Update:''' Smalley RV, Lefante J, Bartolucci A, Carpenter J, Vogel C, Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat. 1983;3(2):209-20. [https://doi.org/10.1007/BF01803563 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6688538 PubMed]
 +
# Muss HB, White DR, Richards F 2nd, Cooper MR, Stuart JJ, Jackson DV, Rhyne L, Spurr CL. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial. Cancer. 1978 Nov;42(5):2141-8. [https://doi.org/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/363253 PubMed]
 +
# Carmo-Pereira J, Costa FO, Henriques E. Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: a randomized study. Eur J Cancer. 1980 Dec;16(12):1621-5. [https://doi.org/10.1016/0014-2964(80)90037-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7014228 PubMed]
 +
# Segaloff A, Hankey BF, Carter AC, Escher GC, Ansfield FJ, Talley RW. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer. Breast Cancer Res Treat. 1985;5(3):311-9. [https://doi.org/10.1007/BF01806026 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3896353 PubMed]
 +
# Rosner D, Nemoto T, Lane WW. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. Cancer. 1987 Mar 1;59(5):874-83. [https://doi.org/10.1002/1097-0142(19870301)59:5%3C874::AID-CNCR2820590503%3E3.0.CO;2-O link to original article] [https://pubmed.ncbi.nlm.nih.gov/3815266 PubMed]
 +
==DES monotherapy {{#subobject:0a1860|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:128a40|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://pubmed.ncbi.nlm.nih.gov/14285946 Kennedy 1965]
 +
|NR in abstract
 +
| style="background-color:#1a9851" |Randomized (E-switch-ic)
 +
|[[#Testosterone_monotherapy_88|Testosterone]]
 +
| style="background-color:#d3d3d3" |Not available
 +
|-
 +
|[https://jamanetwork.com/journals/jama/article-abstract/353009 Carter et al. 1977]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[#DES_monotherapy|DES]]; other dosings
 +
| style="background-color:#d3d3d3" |See paper
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19810201)47:3%3C452::AID-CNCR2820470305%3E3.0.CO;2-Y Kiang et al. 1981]
 +
|1975-1982
 +
| style="background-color:#1a9851" |Randomized (C)
 +
|[[#Cyclophosphamide.2C_DES.2C_Fluorouracil_88|Cyclophosphamide, 5-FU, DES]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup>
 +
|-
 +
|[https://doi.org/10.1056/NEJM198101013040104 Ingle et al. 1981]
 +
|1977-1980
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|}
 +
''<sup>1</sup>Reported efficacy for Kiang et al. 1981 is based on the 1985 update.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Diethylstilbestrol (DES)]]
 +
</div></div>
 +
===References===
 +
# Kennedy BJ. Diethylstilbestrol versus testosterone propionate therapy in advanced breast cancer. Surg Gynecol Obstet. 1965 Jun;120:1246-50. [https://pubmed.ncbi.nlm.nih.gov/14285946 PubMed]
 +
# Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR; Cooperative Breast Cancer Group. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients: report of the Cooperative Breast Cancer Group. JAMA. 1977 May 9;237(19):2079-8. [https://jamanetwork.com/journals/jama/article-abstract/353009 link to original article] [https://pubmed.ncbi.nlm.nih.gov/576887 PubMed]
 +
# Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16-21. [https://doi.org/10.1056/NEJM198101013040104 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7001242 PubMed]
 +
# Kiang DT, Frenning DH, Gay J, Goldman AI, Kennedy BJ. Combination therapy of hormone and cytotoxic agents in advanced breast cancer. Cancer. 1981 Feb 1;47(3):452-6. [https://doi.org/10.1002/1097-0142(19810201)47:3%3C452::AID-CNCR2820470305%3E3.0.CO;2-Y link to original article] [https://pubmed.ncbi.nlm.nih.gov/7013960 PubMed]
 +
## '''Update:''' Kiang DT, Gay J, Goldman A, Kennedy BJ. A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med. 1985 Nov 14;313(20):1241-6. [https://doi.org/10.1056/NEJM198511143132001 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3903501 PubMed]
 +
==CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}==
 +
CTCb: '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''hiotepa, '''<u>C</u>'''ar'''<u>b</u>'''oplatin
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:3dea9c|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1056/NEJM200004133421501 Stadtmauer et al. 2000]
 +
|1990-1997
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer#CMF_2|CMF]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 +
|-
 +
|}
 +
''No longer used, but of historical interest.''
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
*[[Thiotepa (Thioplex)]]
 +
*[[Carboplatin (Paraplatin)]]
 +
</div></div>
 +
===References===
 +
# Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH; Philadelphia Bone Marrow Transplant Group. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med. 2000 Apr 13;342(15):1069-76. [https://doi.org/10.1056/NEJM200004133421501 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10760307 PubMed]
 +
==Cyclophosphamide monotherapy {{#subobject:78bzec|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:9dfaca|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025018/ Rubens et al. 1975]
 +
|1970-1974
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#CMFV|CMFV]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]]
 +
</div></div>
 +
===References===
 +
# Rubens RD, Knight RK, Hayward JL. Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer. 1975 Dec;32(6):730-6. [https://doi.org/10.1038/bjc.1988.273 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025018/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/766800 PubMed]
 +
==Estradiol monotherapy {{#subobject:edd4bd|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen variant #1, 6 mg/day {{#subobject:8e8202|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460383/ Ellis et al. 2009]
 +
|2004-2008
 +
| style="background-color:#1a9851" |Randomized Phase 2 (E-de-esc)
 +
|[[#Estradiol_monotherapy|Estradiol]]; 30 mg/day
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of CBR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Estradiol]] 6 mg PO once per day
 +
'''Continued indefinitely'''
 +
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen variant #2, 30 mg/day {{#subobject:8fahc02|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460383/ Ellis et al. 2009]
 +
|2004-2008
 +
| style="background-color:#1a9851" |Randomized Phase 2 (C)
 +
|[[#Estradiol_monotherapy|Estradiol]]; 6 mg/day
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of CBR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Estradiol]] 30 mg PO once per day
 +
'''Continued indefinitely'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''HR-NBL1 part 2:''' Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Interleukin 2 with anti-GD2 antibody ch14 18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Dec;19(12):1617-1629. Epub 2018 Nov 12. [https://doi.org/10.1016/S1470-2045(18)30578-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30442501 PubMed] NCT01704716
+
# Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009 Aug 19;302(7):774-80. [https://jamanetwork.com/journals/jama/fullarticle/184425 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460383/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/19690310 PubMed] NCT00324259
−
=Relapsed or refractory=
+
==Fluoxymesterone monotherapy {{#subobject:835187|Regimen=1}}==
−
==Cyclophosphamide monotherapy {{#subobject:ea894c|Regimen=1}}==
 
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:9134b2|Variant=1}}===
+
===Regimen {{#subobject:1914f4|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
!style="width: 25%"|Study
 
!style="width: 25%"|Study
 
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM196406182702503 Thurman et al. 1964]
+
|[https://doi.org/10.1056/NEJM195810022591404 Kennedy 1958]
 
| style="background-color:#91cf61" |Non-randomized
 
| style="background-color:#91cf61" |Non-randomized
 
|-
 
|-
 
|}
 
|}
−
''Of historic interest.''
+
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Fluoxymesterone (Halotestin)]]
 +
</div></div>
 +
===References===
 +
# Kennedy BJ. Fluoxymesterone therapy in advanced breast cancer. N Engl J Med. 1958 Oct 2;259(14):673-5. [https://doi.org/10.1056/NEJM195810022591404 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13590423 PubMed]
 +
==Formestane monotherapy {{#subobject:6c7bb9|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:8b5e67|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(84)92795-8 Coombes et al. 1984]
 +
|NR
 +
| style="background-color:#ffffbe" |Pilot
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 +
|-
 +
|[https://doi.org/10.1016/s0959-8049(97)00105-6 Thürlimann et al. 1997 (SAKK 20/90)]
 +
|1991-1995
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[#Megestrol_monotherapy|Megestrol]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTF
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Formestane (Lentaron)]]
 +
</div></div>
 +
===References===
 +
# Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984 Dec 1;2(8414):1237-9. [https://doi.org/10.1016/S0140-6736(84)92795-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6150277 PubMed]
 +
# '''SAKK 20/90:''' Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A; Swiss Group for Clinical Cancer Research. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer. 1997 Jun;33(7):1017-24. [https://doi.org/10.1016/s0959-8049(97)00105-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9376181 PubMed]
 +
==Medroxyprogesterone monotherapy {{#subobject:6c7bb9|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen variant #1, 500 mg/day {{#subobject:8b5e67|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://journals.sagepub.com/doi/abs/10.1177/030089167806400204 Cuna et al. 1978]
 +
|NR
 +
|style="background-color:#1a9851"|Phase 3 (E-de-esc)
 +
|[[#Medroxyprogesterone_monotherapy|MPA]]; 1000 mg/day
 +
|style="background-color:#ffffbf"|Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1016/0014-2964(79)90097-5 Pannuti et al. 1979 (UICC 75-09)]
 +
|NR
 +
|style="background-color:#1a9851"|Randomized (C)
 +
|[[#Medroxyprogesterone_monotherapy|MPA]]; 1500 mg/day
 +
|style="background-color:#ffffbf"|Did not meet primary endpoint of ORR
 +
|-
 +
|[https://academic.oup.com/jnci/article-abstract/80/14/1147/908657 Canney et al. 1988]
 +
|NR
 +
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[#Aminoglutethimide_monotherapy|Aminoglutethimide]]
 +
|style="background-color:#ffffbf"|Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1200/JCO.1997.15.9.3141 Byrne et al. 1997 (ANZ8613)]
 +
|1987-1993
 +
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[#Medroxyprogesterone_.26_Tamoxifen_99|MPA & Tamoxifen]]
 +
|style="background-color:#ffffbf"|Did not meet primary endpoint of TTP
 +
|-
 +
|}
 +
''Note: Canney et al. 1988 does not have dosing information in the abstract.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Medroxyprogesterone (MPA)]] 500 mg PO once per day
 +
'''Continued indefinitely'''
 +
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen variant #2, 900 mg/day {{#subobject:88ge67|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19860701)58:1%3C7::AID-CNCR2820580103%3E3.0.CO;2-%23 van Veelen et al. 1986]
 +
|1980-1984
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]
 +
|style="background-color:#ffffbf"|Did not meet primary endpoint of ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Medroxyprogesterone (MPA)]] 300 mg PO three times per day
 +
'''Continued indefinitely'''
 +
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen variant #3, 1000 mg/day (high-dose) {{#subobject:62af61|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.1984.2.5.414 Cavalli et al. 1984]
 +
|1979-1982
 +
|style="background-color:#1a9851"|Phase 3 (E-esc)
 +
|[[#Medroxyprogesterone_monotherapy|MPA]]; low-dose
 +
| style="background-color:#1a9850" |Superior ORR
 +
|-
 +
|[https://doi.org/10.1007/BF01961246 Garcia-Giralt et al. 1992]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Aminoglutethimide_monotherapy|Aminoglutethimide]]
 +
| style="background-color:#fc8d59" |Seems to have inferior TTP
 +
|-
 +
|[https://doi.org/10.1093/oxfordjournals.annonc.a058657 Castiglione-Gertsch et al. 1993]
 +
|1982-1985
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]
 +
| style="background-color:#d9ef8b" |Might have superior TTP
 +
|-
 +
|[https://doi.org/10.1200/JCO.1994.12.8.1630 Muss et al. 1994]
 +
|1985-1990
 +
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 +
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]
 +
| style="background-color:#d9ef8b" |Might have superior OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Medroxyprogesterone (MPA)]] 1000 mg PO or IM once per day or 500 mg PO twice per day
 +
'''Continued indefinitely'''
 +
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen variant #4, 1200 mg/day (high-dose) {{#subobject:628ga1|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19851201)56:11%3C2576::aid-cncr2820561107%3E3.0.co;2-i Izuo et al. 1985]
 +
|1981-1983
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[#Mepitiostate_monotherapy_77|Mepitiostane]]
 +
|style="background-color:#ffffbf"|Did not meet primary endpoint of ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Medroxyprogesterone (MPA)]] 400 mg PO three times per day
 +
'''Continued indefinitely'''
 +
</div></div>
 +
===References===
 +
# Cuna GR, Calciati A, Strada MR, Bumma C, Campio L. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori. 1978 Apr 30;64(2):143-9. [https://journals.sagepub.com/doi/abs/10.1177/030089167806400204 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/354147 PubMed]
 +
# '''UICC 75-09:''' Pannuti F, Martoni A, Di Marco AR, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnolo F, Palenzona D, Rocchetta G. Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer. 1979 Apr;15(4):593-601. [https://doi.org/10.1016/0014-2964(79)90097-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/86447 PubMed]
 +
# Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol. 1984 May;2(5):414-9. [https://doi.org/10.1200/JCO.1984.2.5.414 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6233398 PubMed]
 +
# Izuo M, Yoshida M, Tominaga T, Abe O, Enomoto K, Nomura Y, Kubo K, Takatani O. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer. Cancer. 1985 Dec 1;56(11):2576-9. [https://doi.org/10.1002/1097-0142(19851201)56:11%3C2576::aid-cncr2820561107%3E3.0.co;2-i link to original article] [https://pubmed.ncbi.nlm.nih.gov/2932213 PubMed]
 +
# van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DT. Oral high-dose medroxyprogesterone acetate versus tamoxifen: a randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer. 1986 Jul 1;58(1):7-13. [https://doi.org/10.1002/1097-0142(19860701)58:1%3C7::AID-CNCR2820580103%3E3.0.CO;2-%23 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/2939943 PubMed]
 +
# Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst. 1988 Sep 21;80(14):1147-51. [https://academic.oup.com/jnci/article-abstract/80/14/1147/908657 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2970555 PubMed]
 +
# Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Pommatau E, Pouillart P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M, Zylberait D. Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat. 1992;24(2):139-45. [https://doi.org/10.1007/BF01961246 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8443401 PubMed]
 +
# Castiglione-Gertsch M, Pampallona S, Varini M, Cavalli F, Brunner K, Senn HJ, Goldhirsch A, Metzger U. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?. Ann Oncol. 1993 Nov;4(9):735-40. [https://doi.org/10.1093/oxfordjournals.annonc.a058657 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8280653 PubMed]
 +
# Muss HB, Case LD, Atkins JN, Bearden JD 3rd, Cooper MR, Cruz JM, Jackson DV Jr, O'Rourke MA, Pavy MD, Powell BL, Richards F, Spurr CL, Eagle K, White DR; Piedmont Oncology Association. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 1994 Aug;12(8):1630-8. [https://doi.org/10.1200/JCO.1994.12.8.1630 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/8040675 PubMed]
 +
# '''ANZ8613:''' Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J; Australian-New Zealand Breast Cancer Trials Group. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. J Clin Oncol. 1997 Sep;15(9):3141-8. [https://doi.org/10.1200/JCO.1997.15.9.3141 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/9294477 PubMed]
 +
==Megestrol monotherapy {{#subobject:a806f8|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:27fd99|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.1988.6.7.1098 Muss et al. 1988]
 +
|1981-1984
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1007/BF01810736 Lundgren et al. 1989]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Aminoglutethimide_monotherapy|Aminoglutethimide]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1093/oxfordjournals.annonc.a058658 Gill et al. 1993]
 +
|1984-1989
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|1. [[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]<br>2. [[#Megestrol_.26_Tamoxifen_88|Megestrol & Tamoxifen]]
 +
| style="background-color:#ffffbf" |Did not meet endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1200/JCO.1996.14.7.2000 Buzdar et al. 1996]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer,_ER-positive#Anastrozole_monotherapy_4|Anastrozole]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup>
 +
|-
 +
|[https://doi.org/10.1200/JCO.1997.15.7.2494 Russell et al. 1997 (SWOG S8312)]
 +
|1984-1990
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Aminoglutethimide.2C_Hydrocortisone.2C_Megestrol_99|Aminoglutethimide, Hydrocortisone, Megestrol]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 +
|-
 +
|[https://doi.org/10.1200/jco.1990.8.11.1797 Muss et al. 1990]
 +
|1985-1988
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Megestrol_monotherapy|Megestrol]]; higher-dose
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|[https://doi.org/10.1016/0959-8049(96)00191-8 Stuart et al. 1996]
 +
|1985-1988
 +
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 +
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]
 +
| style="background-color:#ffffbf" |Did not meet endpoint of OS
 +
|-
 +
|[https://doi.org/10.1200/jco.1999.17.1.64 Abrams et al. 1999 (CALGB 8741)]
 +
|1987-1991
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Megestrol_monotherapy|Megestrol]]; higher-dose
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12%3C2503::AID-CNCR13%3E3.0.CO;2-W Buzdar et al. 1996 (Protocol 03)]
 +
|1989-1991
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Fadrozole_monotherapy_77|Fadrozole]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12%3C2503::AID-CNCR13%3E3.0.CO;2-W Buzdar et al. 1996 (Protocol 06)]
 +
|1989-1991
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Fadrozole_monotherapy_77|Fadrozole]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1016/s0959-8049(97)00105-6 Thürlimann et al. 1997 (SAKK 20/90)]
 +
|1991-1995
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Formestane_monotherapy|Formestane]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTF
 +
|-
 +
|[https://doi.org/10.1200/JCO.1999.17.1.52 Goss et al. 1999]
 +
|1991-1995
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[#Vorozole_monotherapy_77|Vorozole]]
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|[https://doi.org/10.1016/0959-8049(95)00014-3 Jonat et al. 1996]
 +
|1993-1994
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer,_ER-positive#Anastrozole_monotherapy_4|Anastrozole]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup>
 +
|-
 +
|rowspan=2|[https://doi.org/10.1200/JCO.1998.16.2.453 Dombernowsky et al. 1998 (AR/BC2)]
 +
|rowspan=2|1993-1994
 +
|rowspan=2 style="background-color:#1a9851"|Randomized (C)
 +
|[[Breast_cancer,_ER-positive#Letrozole_monotherapy_4|Letrozole]]; 0.5 mg/day
 +
| style="background-color:#d3d3d3" |Not reported
 +
|-
 +
|[[Breast_cancer,_ER-positive#Letrozole_monotherapy_4|Letrozole]]; 2.5 mg/day
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|[https://doi.org/10.1200/JCO.2000.18.7.1399 Kaufmann et al. 2000]
 +
|1995-1998
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer,_ER-positive#Exemestane_monotherapy_3|Exemestane]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|[https://doi.org/10.1200/JCO.2001.19.14.3357 Buzdar et al. 2001]
 +
|NR
 +
| style="background-color:#1a9851"|Phase 3 (C)
 +
|1. [[Breast_cancer#Letrozole_monotherapy_4|Letrozole]]; 0.5 mg/day<br>2. [[Breast_cancer#Letrozole_monotherapy_4|Letrozole]]; 2.5 mg/day
 +
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR
 +
|-
 +
|}
 +
''<sup>1</sup>Reported efficacy for Jonat et al. 1996 & Buzdar et al. 1996 is based on the 1998 pooled update.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Megestrol (Megace)]] 160 mg PO once per day or 40 mg PO four times per day
 +
'''Continued indefinitely'''
 +
</div></div>
 +
===References===
 +
# Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Powell BL, Richards F, White DR, Zekan PJ, Spurr CL, Pope E, Case D, Morgan TM; Piedmont Oncology Association. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1988 Jul;6(7):1098-106. [https://doi.org/10.1200/JCO.1988.6.7.1098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3292710 PubMed]
 +
# Lundgren S, Gundersen S, Klepp R, Lønning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat. 1989 Nov;14(2):201-6. [https://doi.org/10.1007/BF01810736 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2690972 PubMed]
 +
# Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, Richards F 2nd, Powell BL, Spurr CL, White D, Zekan P, Read S, Cates-Wilkie S, Bearden J, McCullough J, Callahan R, Karb K, Atkins J, Paschal B, Ramseur B, Lusk J, Stanley V; Piedmont Oncology Association. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1990 Nov;8(11):1797-805. [https://doi.org/10.1200/jco.1990.8.11.1797 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2230868 PubMed]
 +
# Gill PG, Gebski V, Snyder R, Burns I, Levi J, Byrne M, Coates A. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol. 1993 Nov;4(9):741-4. [https://doi.org/10.1093/oxfordjournals.annonc.a058658 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/8280654 PubMed]
 +
# Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996 Mar;32A(3):404-12. [https://doi.org/10.1016/0959-8049(95)00014-3 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/8814682 PubMed]
 +
## '''Pooled update:''' Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV; Arimidex Study Group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol. 1996 Jul;14(7):2000-11. [https://doi.org/10.1200/JCO.1996.14.7.2000 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8683230 PubMed]
 +
## '''Pooled update:''' Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D; Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 1998 Sep 15;83(6):1142-52. Erratum in: Cancer 1999 Feb 15;85(4):1010. [https://doi.org/10.1002/%28SICI)1097-0142%2819980915%2983%3A6%3C1142%3A%3AAID-CNCR13%3E3.0.CO%3B2-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9740079 PubMed]
 +
#'''Protocol 03:''' Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15;77(12):2503-13. [https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12%3C2503::AID-CNCR13%3E3.0.CO;2-W link to original article] [https://pubmed.ncbi.nlm.nih.gov/8640699 PubMed]
 +
#'''Protocol 06:''' Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15;77(12):2503-13. [https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12%3C2503::AID-CNCR13%3E3.0.CO;2-W link to original article] [https://pubmed.ncbi.nlm.nih.gov/8640699 PubMed]
 +
# Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV; Arimidex Study Group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol. 1996 Jul;14(7):2000-11. [https://doi.org/10.1200/JCO.1996.14.7.2000 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8683230 PubMed]
 +
## '''Update:''' Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A; Arimidex Study Group. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer. 1997 Feb 15;79(4):730-9. [https://doi.org/10.1002/%28SICI)1097-0142%2819970215%2979%3A4%3C730%3A%3AAID-CNCR10%3E3.0.CO%3B2-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/9024711 PubMed]
 +
## '''Pooled update:''' Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D; Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 1998 Sep 15;83(6):1142-52. Erratum in: Cancer 1999 Feb 15;85(4):1010. [https://doi.org/10.1002/%28SICI)1097-0142%2819980915%2983%3A6%3C1142%3A%3AAID-CNCR13%3E3.0.CO%3B2-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9740079 PubMed]
 +
# Stuart NS, Warwick J, Blackledge GR, Spooner D, Keen C, Taylor AR, Tyrell C, Webster DJ, Earl H. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer. 1996 Oct;32A(11):1888-92. [https://doi.org/10.1016/0959-8049(96)00191-8 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8943670 PubMed]
 +
# '''SAKK 20/90:''' Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A; Swiss Group for Clinical Cancer Research. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer. 1997 Jun;33(7):1017-24. [https://doi.org/10.1016/s0959-8049(97)00105-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9376181 PubMed]
 +
# '''SWOG S8312:''' Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol. 1997 Jul;15(7):2494-501. [https://doi.org/10.1200/JCO.1997.15.7.2494 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9215817 PubMed]
 +
# '''AR/BC2:''' Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998 Feb;16(2):453-61. [https://doi.org/10.1200/JCO.1998.16.2.453 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/9469328 PubMed]
 +
# Goss PE, Winer EP, Tannock IF, Schwartz LH; North American Vorozole Study Group. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol. 1999 Jan;17(1):52-63. [https://doi.org/10.1200/JCO.1999.17.1.52 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10458218 PubMed]
 +
# '''CALGB 8741:''' Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, Norton L. Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and Leukemia Group B phase III study 8741. J Clin Oncol. 1999 Jan;17(1):64-73. [https://doi.org/10.1200/jco.1999.17.1.64 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10458219 PubMed]
 +
# Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G; Exemestane Study Group. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000 Apr;18(7):1399-411. [https://doi.org/10.1200/JCO.2000.18.7.1399 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10735887 PubMed]
 +
# Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001 Jul 15;19(14):3357-66. [https://doi.org/10.1200/JCO.2001.19.14.3357 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/11454883 PubMed]
 +
==Melphalan monotherapy {{#subobject:b913c5|Regimen=1}}==
 +
P: '''<u>P</u>'''henylalanine mustard (Melphalan)
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:ab3663|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(197611)38:5%3C1882::AID-CNCR2820380503%3E3.0.CO;2-H Canellos et al. 1976]
 +
|NR
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Breast_cancer#CMF_2|CMF]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Cyclophosphamide (Cytoxan)]]
+
*[[Melphalan (Alkeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 5
 +
'''42-day cycles'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# Thurman WG, Fernbach DJ, Sullivan MP. Cyclophosphamide therapy in childhood neuroblastoma. N Engl J Med. 1964 Jun 18;270:1336-40. [https://doi.org/10.1056/NEJM196406182702503 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14140265 PubMed]
+
# Canellos GP, Pocock SJ, Taylor SG 3rd, Sears ME, Klaasen DJ, Band PR. Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer. 1976 Nov;38(5):1882-6. [https://doi.org/10.1002/1097-0142(197611)38:5%3C1882::AID-CNCR2820380503%3E3.0.CO;2-H link to original article] [https://pubmed.ncbi.nlm.nih.gov/991103 PubMed]
−
==Cyclophosphamide & Vincristine {{#subobject:f725b0|Regimen=1}}==
+
==Methotrexate & Thiotepa {{#subobject:c67a88|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:fecc86|Variant=1}}===
+
===Regimen {{#subobject:4c1582|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
!style="width: 25%"|Study
 
!style="width: 25%"|Study
 
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://jamanetwork.com/journals/jama/article-abstract/343795 Evans et al. 1969]
+
|[https://pubmed.ncbi.nlm.nih.gov/13950199 Greenspan et al. 1963]
 
| style="background-color:#91cf61" |Non-randomized
 
| style="background-color:#91cf61" |Non-randomized
 
|-
 
|-
 
|}
 
|}
−
''Of historic interest.''
+
''Note: this is possibly the first published trial of combination chemotherapy in breast cancer.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Methotrexate (MTX)]]
 +
*[[Thiotepa (Tepadina)]]
 +
</div></div>
 +
===References===
 +
# Greenspan EM, Fieber M, Lesnick G, Edelman S. Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA. J Mt Sinai Hosp N Y. 1963 May-Jun;30:246-67. [https://pubmed.ncbi.nlm.nih.gov/13950199 PubMed]
 +
==Mitoxantrone monotherapy {{#subobject:c67f55|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:4c8527|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1016/0140-6736(90)90277-C Harris et al. 1990]
 +
|NR
 +
| style="background-color:#91cf61" |Non-randomized portion of RCT
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 +
|-
 +
|[https://academic.oup.com/jnci/article-abstract/83/15/1077/882648 Cowan et al. 1991 (SWOG S8203)]
 +
|1983-1986
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|1. [[#Bisantrene_monotherapy_77|Bisantrene]]<br>2. [[Breast_cancer#Doxorubicin_monotherapy_3|Doxorubicin]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Cyclophosphamide (Cytoxan)]]
+
*[[Mitoxantrone (Novantrone)]] 14 mg/m<sup>2</sup> IV once on day 1
−
*[[Vincristine (Oncovin)]]
+
'''21-day cycles'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# Evans AE, Heyn RM, Newton WA Jr, Leikin SL. Vincristine sulfate and cyclophosphamide for children with metastatic neuroblastoma. JAMA. 1969 Feb 17;207(7):1325-7. [https://jamanetwork.com/journals/jama/article-abstract/343795 link to original article] [https://pubmed.ncbi.nlm.nih.gov/5818324 PubMed]
+
# Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RG. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 1990 Jan 27;335(8683):186-90. [https://doi.org/10.1016/0140-6736(90)90277-C link to original article] [https://pubmed.ncbi.nlm.nih.gov/1967666 PubMed]
−
==Irinotecan, Temozolomide, Dinutuximab {{#subobject:00704b|Regimen=1}}==
+
# '''SWOG S8203:''' Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 7;83(15):1077-84. [https://academic.oup.com/jnci/article-abstract/83/15/1077/882648 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/1875415 PubMed]
 +
==Mitoxantrone & Vinorelbine (MV) {{#subobject:eb48ba|Regimen=1}}==
 +
MV: '''<u>M</u>'''itoxantrone & '''<u>V</u>'''inorelbine
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:431f39|Variant=1}}===
+
===Regimen {{#subobject:hgaibc|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
Line 766: Line 2,299:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527694/ Mody et al. 2017 (COG ANBL1221)]
+
|[https://doi.org/10.1016/s0959-8049(01)00093-4 Namer et al. 2001]
−
|2013-2015
+
|NR in abstract
−
|style="background-color:#91cf61"|Randomized Phase 2, <20 pts (E-switch-ooc)
+
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
−
|[[#Irinotecan.2C_Temozolomide.2C_Temsirolimus_88|Irinotecan, Temozolomide, Temsirolimus]]
+
|1a. [[Breast_cancer#FAC_3|FAC]]<br>1b. [[Breast_cancer#FEC_3|FEC]]
−
|style="background-color:#1a9850"|Superior ORR
+
| style="background-color:#eeee01" |Equivalent ORR
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Mitoxantrone (Novantrone)]]
 +
*[[Vinorelbine (Navelbine)]]
 +
</div></div>
 +
===References===
 +
#Namer M, Soler-Michel P, Turpin F, Chinet-Charrot P, de Gislain C, Pouillart P, Delozier T, Luporsi E, Etienne PL, Schraub S, Eymard JC, Serin D, Ganem G, Calais G, Maillart P, Colin P, Trillet-Lenoir V, Prevost G, Tigaud D, Clavère P, Marti P, Romieu G, Wendling JL. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. Eur J Cancer. 2001 Jun;37(9):1132-40. [https://doi.org/10.1016/s0959-8049(01)00093-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11378344/ PubMed]
 +
==STAMP-I {{#subobject:c08ab4|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:7gy709|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.1988.6.9.1368 Peters et al. 1988]
 +
|NR
 +
| style="background-color:#91cf61" |Non-randomized
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 +
|-
 +
|[https://doi.org/10.1038/sj.bmt.1705367 Vredenburgh et al. 2006]
 +
|1992-1997
 +
|style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer_-_null_regimens#Observation_2|Observation]]
 +
| style="background-color:#1a9850" |Superior EFS
 
|-
 
|-
 
|}
 
|}
−
''Note: this dinutuximab dose is based on a mid-protocol revision.''
+
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*Duke AFM x 2 to 4
 +
</div>
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Irinotecan (Camptosar)]] 50 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 to 5
+
*[[Carmustine (BCNU)]] 600 mg/m<sup>2</sup> IV once on day -3
−
*[[Temozolomide (Temodar)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
*[[Cisplatin (Platinol)]] 55 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day -6 (total dose: 165 mg/m<sup>2</sup>)
−
====Targeted therapy====
+
*[[Cyclophosphamide (Cytoxan)]] 1875 mg/m<sup>2</sup> IV once per day on days -6 to -4
−
*[[Dinutuximab (Unituxin)]] 17.5 mg/m<sup>2</sup> IV over 10 hours once per day on days 2 to 5
+
'''Stem cells re-infused on days -1, 0, +1'''
−
**Infusion time could be extended to 20 hours "if patients experienced pain, fever, tachycardia, tachypnea, or hypotension unresponsive to supportive measures."
+
</div></div>
−
====Supportive therapy====
+
===References===
−
*[[Sargramostim (Leukine)]] 250 mcg/m<sup>2</sup> SC once per day on days 6 to 12
+
# Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1368-76. [https://doi.org/10.1200/JCO.1988.6.9.1368 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3047332 PubMed]
−
'''21-day cycle for up to 17 cycles'''
+
# Vredenburgh JJ, Madan B, Coniglio D, Ross M, Broadwater G, Niedzwiecki D, Edwards J, Marks L, Vandemark R, McDonald C, Affronti ML, Peters WP. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant. 2006 Jun;37(11):1009-15. [https://doi.org/10.1038/sj.bmt.1705367 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16633363 PubMed]
 +
==TAD (Tamoxifen) {{#subobject:1ac555|Regimen=1}}==
 +
TAD: '''<u>T</u>'''amoxifen, '''<u>A</u>'''minoglutethimide, '''<u>D</u>'''anazol
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:0b2c27|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://doi.org/10.1016/S0140-6736(84)91872-5 Powles et al. 1984]
 +
|1979-1983
 +
| style="background-color:#1a9851" |Phase 3 (E-esc)
 +
|[[Breast_cancer,_ER-positive#Tamoxifen_monotherapy_4|Tamoxifen]]
 +
| style="background-color:#91cf60" |Seems to have superior ORR
 +
|-
 +
|}
 +
''Note: this patient population was not selected by hormone receptor status.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Endocrine therapy====
 +
*[[Tamoxifen (Nolvadex)]]
 +
*[[Aminoglutethimide (Cytadren)]]
 +
*[[Danazol (Danocrine)]]
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''COG ANBL1221:''' Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 Jul;18(7):946-957. Epub 2017 May 23. [https://doi.org/10.1016/S1470-2045(17)30355-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527694/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28549783 PubMed] NCT01767194
+
# Powles TJ, Ashley S, Ford HT, Gazet JC, Nash AG, Neville AM, Coombes RC. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet. 1984 Jun 23;1(8391):1369-73. [https://doi.org/10.1016/S0140-6736(84)91872-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6145832 PubMed]
−
==Naxitamab monotherapy {{#subobject:ac2e27|Regimen=1}}==
+
==Thiotepa monotherapy {{#subobject:123f55|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:bf9b29|Variant=1}}===
+
===Regimen {{#subobject:4a8d27|Variant=1}}===
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
+
{| class="wikitable" style="width: 40%; text-align:center;"  
−
!style="width: 33%"|Study
+
!style="width: 25%"|Study
−
!style="width: 33%"|Years of enrollment
+
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|-
 +
|[https://doi.org/10.1056/NEJM195505262522101 Bateman 1955]
 +
| style="background-color:#91cf61" |Non-randomized
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6440722/ Kushner et al. 2018 (Study 12-230)]
+
|}
−
|2012-2016
+
<div class="toccolours" style="background-color:#b3e2cd">
−
| style="background-color:#ffffbe" |Phase 1 (RT)
+
====Chemotherapy====
 +
*[[Thiotepa (Thioplex)]]
 +
</div></div>
 +
===References===
 +
# Bateman JC. Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med. 1955 May 26;252(21):879-87. [https://doi.org/10.1056/NEJM195505262522101 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14370446 PubMed]
 +
==VAP {{#subobject:4b99b8|Regimen=1}}==
 +
VAP: '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin),  '''<u>P</u>'''rednisolone
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:7d4b85|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://www.clinicaltrials.gov/ct2/show/NCT03363373 Awaiting publication (Study 201)]
+
|[https://doi.org/10.1200/JCO.1987.5.7.1056 Leonard et al. 1987]
−
|2018-ongoing
+
|NR
−
| style="background-color:#91cf61" |Phase 2 (RT)
+
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[#Mitoxantrone.2C_Vincristine.2C_Prednisolone_99|VMP]]
 +
| style="background-color:#1a9850" |Superior ORR
 
|-
 
|-
 
|}
 
|}
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
−
====Targeted therapy====
+
====Chemotherapy====
−
*[[Naxitamab (Danyelza)]] 3 mg/kg (maximum of 150 mg/day) IV once per day on days 1, 3, 5
+
*[[Vincristine (Oncovin)]]
−
====Supportive therapy====
+
*[[Doxorubicin (Adriamycin)]]
−
*[[Sargramostim (Leukine)|GM-CSF]] 250 mcg/m<sup>2</sup>/day SC once per day on days -4 to 0, then 500 mcg/m<sup>2</sup>/day SC once per day on days 1 to 5
+
====Endocrine therapy====
−
'''28-day cycle for 4 cycles until complete response or partial response, followed by 5 additional cycles''' Subsequent cycles may be repeated every 8 weeks.
+
*[[Prednisolone (Millipred)]]
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''Study 12-230:''' Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial. JAMA Oncol. 2018 Dec 1;4(12):1729-1735. [https://doi.org/10.1001/jamaoncol.2018.4005 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6440722/ link to original article] [https://pubmed.ncbi.nlm.nih.gov/30326045/ PubMed] NCT01757626
+
# Leonard RC, Cornbleet MA, Kaye SB, Soukop M, White G, Hutcheon AW, Robinson S, Kerr ME, Smyth JF. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J Clin Oncol. 1987 Jul;5(7):1056-63. [https://doi.org/10.1200/JCO.1987.5.7.1056 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3298559 PubMed]
−
#'''Study 201:''' NCT03363373
+
[[Category:Breast cancer regimens]]
−
[[Category:Neuroblastoma regimens]]
+
[[Category:Historical regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
−
[[Category:Pediatric solid tumors]]
+
[[Category:Malignant breast neoplasm]]

Revision as of 00:21, 1 March 2023

Back to Top

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main breast cancer page for current regimens.

0 regimens on this page
0 variants on this page


Neoadjuvant therapy

CVAP

CVAP: Cyclophosphamide, Vincristine, Adriamycin (Doxorubicin), Prednisolone
VACP: Vincristine, Adriamycin (Doxorubicin), Cyclophosphamide, Prednisolone

Regimen

Study Evidence
Smith et al. 2002 Non-randomized portion of RCT
Thomas et al. 2004b Non-randomized portion of RCT

Chemotherapy

Endocrine therapy

Subsequent treatment

References

  1. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002 Mar 15;20(6):1456-66. link to original article PubMed
  2. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004 Jun 15;22(12):2294-302. link to original article PubMed

Adjuvant therapy, sequential protocols

FAC-MV

FAC-MV: Fluorouracil, Adriamycin (Doxorubicin), Cyclophosphamide, followed by Methotrexate & Vinblastine

Protocol

Study Years of enrollment Evidence Comparator Comparative Efficacy
Assikis et al. 2003 1986-1994 Phase 3 (E-switch-ooc) Tamoxifen Did not meet primary endpoint of OS

Preceding treatment

Chemotherapy, FAC portion

Chemotherapy, MV portion

Supportive therapy

21- to 28-day cycle for 4 cycles

References

  1. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 1;97(11):2716-23. link to original article contains dosing details in abstract PubMed

Adjuvant therapy

ACT

ACT: Adriamycin (Doxorubicin), Cyclophosphamide, Tamoxifen

Regimen variant #1, 40/500/20

Study Years of enrollment Evidence Comparator Comparative Efficacy
Shien et al. 2014 (JCOG9401) 1994-1999 Phase 3 (E-esc) Tamoxifen Seems to have superior RFS
Shien et al. 2014 (JCOG9404) 1994-1999 Phase 3 (E-de-esc) TUFT Did not meet primary endpoint of OS

Preceding treatment

Chemotherapy

Endocrine therapy

28-day cycle for 6 cycles, then continuous for a total of 2 years


Regimen variant #2, 60/600/20

Study Years of enrollment Evidence Comparator Comparative Efficacy
Fisher et al. 1990 (NSABP B-16) 1985-1988 Phase 3 (E-esc) 1. PFT Not reported
2. Tamoxifen Seems to have superior OS

Preceding treatment

Chemotherapy

Endocrine therapy

21-day cycle for 4 cycles, then continuous for a total of 5 years

References

  1. NSABP B-16: Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Myers DB, Hoehn JL. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990 Jun;8(6):1005-18. link to original article contains dosing details in manuscript PubMed
    1. Pooled update: Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. link to original article PubMed
  2. JCOG9401: Shien T, Iwata H, Aogi K, Fukutomi T, Inoue K, Kinoshita T, Takahashi M, Matsui A, Shibata T, Fukuda H. Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401). Int J Clin Oncol. 2014 Dec;19(6):982-8. Epub 2014 Jan 7. link to original article contains dosing details in manuscript PubMed
  3. JCOG9404: Shien T, Iwata H, Fukutomi T, Inoue K, Aogi K, Kinoshita T, Ando J, Takashima S, Nakamura K, Shibata T, Fukuda H. Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404. Cancer Chemother Pharmacol. 2014 Sep;74(3):603-9. Epub 2014 Jul 24. link to original article link to PMC article contains dosing details in manuscript PubMed

AVCF

AVCF: Adriamycin (Doxorubicin), Vincristine, Cyclophosphamide, Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Misset et al. 1996 (OncoFrance) 1978-1981 Phase 3 (E-RT-esc) CMF Superior OS

Preceding treatment

Chemotherapy

References

  1. OncoFrance: Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol. 1996 Apr;14(4):1136-45. link to original article PubMed

AVCMF

AVCMF: Adriamycin (Doxorubicin), Vinblastine, Cyclophosphamide, Methotrexate, Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Ploner et al. 2003 (ABCSG 3) 1984-NR Randomized (E-RT-esc) CMF Did not meet endpoints of DFS/OS

Preceding treatment

Chemotherapy

References

  1. ABCSG 3: Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; ABCSG. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie. 2003 Apr;26(2):115-9. link to original article PubMed

CAMFP

CAMFP: Cyclophosphamide, Adriamycin (Doxorubicin), Methotrexate, Fluorouracil, Prednisone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Recht et al. 1996 1984-1992 Phase 3 (E-switch-ic) See link See link

Note: this was a trial examining sequencing of chemotherapy and radiotherapy; see text for efficacy details.

Preceding treatment

Chemotherapy

Endocrine therapy

Supportive therapy

21-day cycle for 4 cycles

References

  1. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996 May 23;334(21):1356-61. link to original article contains dosing details in manuscript PubMed

CEF/CMF

CEF/CMF: Cyclophosphamide, Epirubicin, Fluorouracil alternating with Cyclophosphamide, Methotrexate, Fluorouracil

Protocol

Study Years of enrollment Evidence Comparator Comparative Efficacy
Bedognetti et al. 2011 1985-1992 Phase 3 (C) CEFT/CMFT Did not meet primary endpoint of OS

Preceding treatment

Chemotherapy, CEF portion

Chemotherapy, CMF portion

References

  1. Bedognetti D, Sertoli MR, Pronzato P, Del Mastro L, Venturini M, Taveggia P, Zanardi E, Siffredi G, Pastorino S, Queirolo P, Gardin G, Wang E, Monzeglio C, Boccardo F, Bruzzi P. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst. 2011 Oct 19;103(20):1529-39. Epub 2011 Sep 15. link to original article link to PMC article PubMed

CFP

CFP: Cyclophosphamide, Fluorouracil, Prednisone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Ahmann et al. 1978 NR Phase 3 (E-esc) Melphalan Seems to have superior OS
Caprini et al. 1980 1975-1979 Phase 3 (E-esc) 1. Melphalan Seems to have superior DFS
2. CFP & BCG Did not meet primary endpoint of DFS

Preceding treatment

Chemotherapy

Endocrine therapy

References

  1. Ahmann DL, Scanlon PW, Bisel HF, Edmonson JH, Frytak S, Payne WS, O'Fallon JR, Hahn RG, Ingle JN, O'Connell MJ, Rubin J. Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. Lancet. 1978 Apr 29;1(8070):893-6. link to original article PubMed
  2. Caprini JA, Oviedo MA, Cunningham MP, Cohen E, Trueheart RS, Khandekar JD, Scanlon EF. Adjuvant chemotherapy for stage II and III breast carcinoma. JAMA. 1980 Jul 18;244(3):243-6. link to original article PubMed

CFP & Oophorectomy

CFP & Oophorectomy: Cyclophosphamide, Fluorouracil, Prednisone & Bilateral Oophorectomy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Ahmann et al. 1977 NR Randomized (E-esc) Oophorectomy Seems to have superior PFS

Preceding treatment

Chemotherapy

Endocrine therapy

35-day cycles

References

  1. Ahmann DL, O'Connell MJ, Hahn RG, Bisel HF, Lee RA, Edmonson JH. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med. 1977 Aug 18;297(7):356-60. link to original article contains dosing details in manuscript PubMed

CMFL

CMFL: Cyclophosphamide, Methotrexate, Fluorouracil, Leucovorin (Folinic acid)

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Goldhirsch et al. 1989 (LCBS V) 1981-1985 Phase 3 (E-esc) No further treatment Seems to have superior DFS

Preceding treatment

Chemotherapy

8-day course

References

  1. LCBS V: Goldhirsch A, Gelber RD; Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 1989 Feb 23;320(8):491-6. link to original article PubMed

CMFP

CMFP: Cyclophosphamide, Methotrexate, Fluorouracil, Prednisone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Tormey et al. 1990 (ECOG E5177) 1978-1982 Phase 3 (E-esc) 1. CMF
2. CMFPT 		Did not meet primary endpoints of TTR/OS
Goldhirsch et al. 1988 (IBCSG V) 1981-1985 Phase 3 (C) CMFL x 1 Seems to have superior OS
Mansour et al. 1989 (INT-0011) 1981-1988 Phase 3 (E-esc) No further treatment Superior DFS

Preceding treatment

Chemotherapy

Endocrine therapy

28-day cycle for 6 to 12 cycles

References

  1. IBCSG V: Goldhirsch A; Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med. 1988 Sep 15;319(11):677-83. link to original article PubMed
  2. ECOG E1180: Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an intergroup study. N Engl J Med. 1989 Feb 23;320(8):485-90. link to original article PubMed
    1. Update: Mansour EG, Eudey L, Tormey DC, Shatila AH, Osborne CK, Gilchrist KW, Cooper MR, Falkson G. Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992;(11):97-104. PubMed
  3. ECOG E5177: Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. Cancer. 1990 Jan 15;65(2):200-6. link to original article PubMed

CMFPT

CMFPT: Cyclophosphamide, Methotrexate, Fluorouracil, Prednisone, Tamoxifen

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Goldhirsch et al. 1984 (LBCS III) 1978-1981 Phase 3 (E-esc) 1. Observation Superior DFS
2. PT Seems to have superior DFS
Tormey et al. 1990 (ECOG E5177) 1978-1982 Phase 3 (E-esc) 1. CMF
2. CMFP 		Did not meet primary endpoints of TTR/OS
Goldhirsch et al. 1988 (IBCSG V) 1981-1985 Phase 3 (C) CMFL x 1 Seems to have superior OS
Falkson et al. 1990 1982-NR Phase 3 (C) CMFPT x 4 Did not meet primary endpoint of DFS

Preceding treatment

Chemotherapy

Endocrine therapy

28-day cycle for 6 to 12 cycles

References

  1. LBCS III/IV: Goldhirsch A; Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet. 1984 Jun 9;1(8389):1256-60. link to original article PubMed
  2. IBCSG V: Goldhirsch A; Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med. 1988 Sep 15;319(11):677-83. link to original article PubMed
  3. ECOG E5177: Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. Cancer. 1990 Jan 15;65(2):200-6. link to original article PubMed
  4. Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC, Falkson G; ECOG. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol. 1990 Apr;8(4):599-607. Erratum in: J Clin Oncol 1990 Sep;8(9):1603. link to original article PubMed

CMFVP

CMFVP: Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, Prednisone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Glucksberg et al. 1982 (SWOG S7436) 1975-1978 Randomized (E-esc) Melphalan Superior OS
Tormey et al. 1983a 1975-1980 Phase 3 (E-esc) CMF Superior DFS
CMF-MER Not reported
Rivkin et al. 1993 (SWOG S7827ER-) 1979-1984 Phase 3 (C) CMFVP x 2 y Did not meet primary endpoints of DFS/OS
Rivkin et al. 1996 (SWOG S7821) 1979-1989 Randomized (C) CMFVP & Oophorectomy Did not meet primary endpoints of DFS/OS
Perloff et al. 1996 (CALGB 8082) 1980-1984 Non-randomized portion of RCT
Budd et al. 1995 (SWOG S8313) 1984-1990 Phase 3 (C) FAC-M Might have superior DFS

Preceding treatment

Chemotherapy

Endocrine therapy

References

  1. SWOG S7436: Glucksberg H, Rivkin SE, Rasmussen S, Tranum B, Gad-el-Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J, Vaughn C. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer. 1982 Aug 1;50(3):423-34. link to original article PubMed
    1. Update: Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 1;97(1):21-9. link to original article PubMed
  2. Tormey DC, Weinberg VE, Holland JF, Weiss RB, Glidewell OJ, Perloff M, Falkson G, Falkson HC, Henry PH, Leone LA, Rafla S, Ginsberg SJ, Silver RT, Blom J, Carey RW, Schein PS, Lesnick GJ. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. J Clin Oncol. 1983 Feb;1(2):138-45. link to original article PubMed
  3. SWOG S7827: Rivkin SE, Green S, Metch B, Jewell WR, Costanzi JJ, Altman SJ, Minton JP, O'Bryan RM, Osborne CK. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 1993 Sep;11(9):1710-6. link to original article PubMed
  4. SWOG S8313: Budd GT, Green S, O'Bryan RM, Martino S, Abeloff MD, Rinehart JJ, Hahn R, Harris J, Tormey D, O'Sullivan J, Osborne CK. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. J Clin Oncol. 1995 Apr;13(4):831-9. link to original article PubMed
  5. SWOG S7821: Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Osborne CK. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996 Jan;14(1):46-51. link to original article PubMed
  6. CALGB 8082: Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May;14(5):1589-98. link to original article PubMed

CPB

CPB: Cyclophosphamide, Platinol (Cisplatin), BCNU (Carmustine)

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Peters et al. 2005 (CALGB 9082) 1991-1998 Phase 3 (E-de-esc) HD-CPB with auto HSCT Did not meet primary endpoint of EFS

Note: this trial is of important historic significance. Although neither arm was standard of care, the results established the non-value of high-dose therapy with autologous HSCT in the adjuvant treatment of breast cancer.

Preceding treatment

Chemotherapy

Subsequent treatment

References

  1. CALGB 9082: Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 1;23(10):2191-200. Epub 2005 Mar 14. link to original article PubMed

CTCb, then auto HSCT

CTCb: Cyclophosphamide, Thiotepa, Carboplatin
STAMP-V

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Eder et al. 1990 1987-1988 Phase 1/2
Rodenhuis et al. 1998 1991-1995 Randomized Phase 2 (E-esc) Standard adjuvant therapy Did not meet primary endpoint of PFS
Rodenhuis et al. 2003 (Dutch National Study) 1993-1999 Phase 3 (E-esc) FEC x 5 Did not meet primary endpoint of OS1
Bergh et al. 2000 (SBG 9401) 1994-1998 Phase 3 (C) See link See link

1Reported efficacy for the Dutch National Study is based on the 2020 update.

Preceding treatment

Chemotherapy

Stem cells re-infused on day 0

References

  1. Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E 3rd, Antman K. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol. 1990 Jul;8(7):1239-45. link to original article PubMed
  2. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998 Aug 15;352(9127):515-21. link to original article PubMed
  3. SBG 9401: Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N; Scandinavian Breast Group. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet. 2000 Oct 21;356(9239):1384-91. Erratum in: Lancet 2000 Dec 23-30;356(9248):2196. link to original article PubMed
  4. Dutch National Study: Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003 Jul 3;349(1):7-16. link to original article PubMed NCT03087409
    1. Update: Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, van Tinteren H, Peterse JL, van de Vijver MJ, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumours. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol. 2006 Apr;17(4):588-96. Epub 2006 Jan 30. link to original article PubMed
    2. Update: Steenbruggen TG, Steggink LC, Seynaeve CM, van der Hoeven JJM, Hooning MJ, Jager A, Konings IR, Kroep JR, Smit WM, Tjan-Heijnen VCG, van der Wall E, Bins AD, Linn SC, Schaapveld M, Jacobse JN, van Leeuwen FE, Schröder CP, van Tinteren H, de Vries EGE, Sonke GS, Gietema JA. High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Apr 1;6(4):528-534. link to original article link to PMC article PubMed

Cyclophosphamide monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Brinker et al. 1983 (DBCG 77B) 1977-1983 Phase 3 (C) 1. CMF Did not meet primary endpoint of RFS
2. Observation Seems to have superior OS1
3. Levamisole Not reported
Killander et al. 2009 1978-1983 Phase 3 (E-switch-ooc) 1. RT
2. Cyclophosphamide & RT 		Not reported
Miles et al. 2011 1998-2003 Phase 3 (C) STn-KLH vaccine Did not meet primary endpoints of TTP/OS

1Reported efficacy for DBCG 77B is based on the 2010 update.

Chemotherapy

References

  1. DBCG 77B: Brincker H, Mouridsen HT, Andersen KW. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat. 1983;3(1):91-5. link to original article contains dosing details in manuscript PubMed
    1. Update: Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Andersson M, Kamby C, Knoop AS; Danish Breast Cancer Cooperative Group. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Cancer. 2010 May 1;116(9):2081-9. link to original article PubMed
  2. Killander F, Anderson H, Rydén S, Möller T, Hafström LO, Malmström P. Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer - a randomized trial from the South Sweden Breast Cancer Group. Breast. 2009 Oct;18(5):309-15. Epub 2009 Oct 6. link to original article PubMed
  3. Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK; Theratope® Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16(8):1092-100. Epub 2011 May 14. link to original article link to PMC article PubMed

ECT, then auto HSCT

ECT: Epirubicin, Cyclophosphamide, Thiotepa

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Nitz et al. 2005 (WSG AM-01) 1995-2002 Phase 3 (E-esc) ddEC x 4, then ddCMF x 3 Seems to have superior OS

No longer used, but of historical interest.

Preceding treatment

Chemotherapy

References

  1. WSG AM-01: Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M; West German Study Group. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005 Dec 3;366(9501):1935-44. Erratum in: Lancet. 2006 Mar 4;367(9512):730. link to original article PubMed

FAC & BCG

FAC & BCG: Fluorouracil, Adriamycin (Doxorubicin), Cyclophosphamide, BCG

Regimen

Study Evidence
Buzdar et al. 1979 Non-randomized

Preceding treatment

Chemotherapy

Immunotherapy

References

  1. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine: a follow-up report. JAMA. 1979 Oct 5;242(14):1509-13. link to original article PubMed

Fluorouracil & Methotrexate (MF)

MF: Methotrexate & 5-Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Shapiro et al. 1993 1976-1985 Phase 3 (C) CMF Did not meet endpoints of TTF/OS
Fisher et al. 1989 (NSABP B-13) 1981-1988 Phase 3 (E-esc) Observation Superior DFS1
Fisher et al. 1996 (NSABP B-19) 1988-1990 Phase 3 (C) CMF Might have inferior OS

1Reported efficacy for NSABP B-13 is based on the 1996 update.

Preceding treatment

Chemotherapy

References

  1. NSABP B-13: Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, Wolmark N, Fisher ER, Margolese R, Sutherland C, Glass A, Foster R, Caplan R. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989 Feb 23;320(8):473-8. link to original article PubMed
    1. Update: Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul;14(7):1982-92. link to original article PubMed
    2. Pooled update: Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. link to original article PubMed
  2. Shapiro CL, Gelman RS, Hayes DF, Osteen R, Obando A, Canellos GP, Frei E 3rd, Henderson IC. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst. 1993 May 19;85(10):812-7. link to original article PubMed
  3. NSABP B-19: Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul;14(7):1982-92. link to original article PubMed
    1. Pooled update: Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. link to original article PubMed

FNC

FNC: Fluorouracil, Novantrone (Mitoxantrone), Cyclophosphamide
CNF: Cyclophosphamide, Novantrone (Mitoxantrone), Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Ron et al. 2001 1988-1992 Phase 3 (E-switch-ic) CMF Seems to have superior DFS
Fountzilas et al. 2004 (HE 10/92) 1992-1998 Phase 3 (C) Tamoxifen Did not meet primary endpoint of RFS
Toledano et al. 2007 (ARCOSEIN) 1996-2000 Phase 3 (C) FNC & RT Did not meet primary endpoint of DFS

Preceding treatment

Chemotherapy

21-day cycle for 6 cycles

Subsequent treatment

  • ARCOSEIN: RT

References

  1. Ron IG, Wigler N, Borovik R, Brufman G, Rizel S, Shani A, Brenner J, Farbstein H, Dale A, Inbar MJ, Brenner HJ, Chaitchik S, Catane R. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study. Am J Clin Oncol. 2001 Aug;24(4):323-7. link to original article PubMed
  2. HE 10/92: Fountzilas G, Stathopoulos G, Kouvatseas G, Polychronis A, Klouvas G, Samantas E, Zamboglou N, Kyriakou K, Adamou A, Pectasidis D, Ekonomopoulos T, Kalofonos HP, Bafaloukos D, Georgoulias V, Razis E, Koukouras D, Zombolas V, Kosmidis P, Skarlos D, Pavlidis N; Hellenic Cooperative Oncology Group. Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. Am J Clin Oncol. 2004 Feb;27(1):57-67. link to original article PubMed
  3. ARCOSEIN: Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, Calais G. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol. 2007 Feb 1;25(4):405-10. Erratum in: J Clin Oncol. 2007 Jun 1;25(16):2334. link to original article contains dosing details in manuscript PubMed

Levamisole monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Rojas et al. 1976 NR Randomized (E-esc) Observation Seems to have superior OS
Brincker et al. 1980 NR Randomized (E-switch-ooc) RT Seems to have inferior RFS

Note: Rojas et al. 1976 included patients with inoperable breast cancer; definitive therapy was RT.

Preceding treatment

Immunotherapy

References

  1. Rojas AF, Feierstein JN, Mickiewicz E, Glait H, Olivari AJ. Levamisole in advanced human breast cancer. Lancet. 1976 Jan 31;1(7953):211-5. link to original article PubMed
  2. Brincker H, Mouridsen HT, Andersen KW, Andersen J, Castberg T, Fischermann K, Henriksen E, Hou-Jensen C, Johansen H, Rossing N, Rorth M; Danish Breast Cancer Cooperative Group. Increased breast-cancer recurrence rate after adjuvant therapy with levamisole: a preliminary report. Lancet. 1980 Oct 18;2(8199):824-7. link to original article PubMed

Melphalan monotherapy

P: Phenylalanine mustard (Melphalan)

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Fisher et al. 1975 (NSABP B-05) 1972-1975 Phase 3 (E-esc) Placebo Might have superior DFS1
Fisher et al. 1977 (NSABP B-07) 1975-1976 Phase 3 (C) PF Seems to have inferior RFS
Glucksberg et al. 1982 (SWOG S7436) 1975-1978 Randomized (C) CMFVP Inferior OS
Rubens et al. 1983 1975-1979 Phase 3 (E-esc) Observation Might have superior RFS

1Reported efficacy for NSABP B-05 is based on the 1986 update.
Note: Fisher et al. 1977 is an update for NSABP B-05 and also the primary results for NSABP B-07.

Preceding treatment

Chemotherapy

References

  1. NSABP B-05: Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med. 1975 Jan 16;292(3):117-22. link to original article PubMed
    1. Update: Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H, Volk H. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: an update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer. 1977 Jun;39(6 Suppl):2883-903. link to original article PubMed
    2. Update: Fisher B, Fisher ER, Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986 Jun;4(6):929-41. link to original article PubMed
  2. NSABP B-07: Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H, Volk H. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: an update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer. 1977 Jun;39(6 Suppl):2883-903. link to original article PubMed
  3. SWOG S7436: Glucksberg H, Rivkin SE, Rasmussen S, Tranum B, Gad-el-Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J, Vaughn C. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer. 1982 Aug 1;50(3):423-34. link to original article PubMed
    1. Update: Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 1;97(1):21-9. link to original article PubMed
  4. Rubens RD, Hayward JL, Knight RK, Bulbrook RD, Fentiman IS, Chaudary M, Howell A, Bush H, Crowther D, Sellwood RA, George WD, Howat JM. Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet. 1983 Apr 16;1(8329):839-43. link to original article PubMed

Oophorectomy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Ahmann et al. 1977 NR Randomized (C) CFP & Oophorectomy Seems to have inferior PFS
Love et al. 2016 (OSU-0476) 2004-2011 Phase 3 (C) Mid-luteal phase oophorectomy Did not meet primary endpoint of OS

Preceding treatment

Endocrine therapy

Subsequent treatment

References

  1. Ahmann DL, O'Connell MJ, Hahn RG, Bisel HF, Lee RA, Edmonson JH. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med. 1977 Aug 18;297(7):356-60. link to original article PubMed
  2. OSU-0476: Love RR, Hossain SM, Hussain MM, Mostafa MG, Laudico AV, Siguan SS, Adebamowo C, Sun JZ, Fei F, Shao ZM, Liu Y, Akram Hussain SM, Zhang B, Cheng L, Panigaro S, Walta F, Chuan JH, Mirasol-Lumague MR, Yip CH, Navarro NS Jr, Huang CS, Lu YS, Ferdousy T, Salim R, Akhter C, Nahar S, Uy G, Young GS, Hade EM, Jarjoura D. Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. Eur J Cancer. 2016 Jun;60:107-16. Epub 2016 Apr 20. link to original article link to PMC article PubMed NCT00293540

Paclitaxel monotherapy, q3wk

T: Taxol (Paclitaxel)
P: Paclitaxel
pT: pacliTaxel

Regimen variant #1, 175 mg/m2 q3wk

Study Years of enrollment Evidence Comparator Comparative Efficacy
Henderson et al. 2003 (INT 0148/CALGB 9344) 1994-1999 Phase 3 (E-RT-esc) Observation Superior OS

Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.

Preceding treatment

  • INT 0148/CALGB 9344: Surgery, then AC x 4 versus AC; high-dose x 4 versus AC; very-high-dose x 4

Chemotherapy

21-day cycle for 4 cycles

References

  1. INT 0148/CALGB 9344: Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83. link to original article contains dosing details in manuscript PubMed

PAF

PAF: Phenylalanine mustard (Melphalan), Adriamycin (Doxorubicin), Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Fisher et al. 1989 (NSABP B-11) 1981-1984 Phase 3 (E-esc) PF Seems to have superior OS

Preceding treatment

Chemotherapy

References

  1. NSABP B-11: Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, Sass R, Fisher ER, Jochimsen P, Legault-Poisson S, Dimitrov N, Wolter J, Bornstein R, Elias EG, LiCalzi N, Paterson AHG, Sutherland CM. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989 May;7(5):572-82. link to original article PubMed

PF

PF: Phenylalanine mustard (Melphalan) & Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Fisher et al. 1977 (NSABP B-07) 1975-1976 Phase 3 (E-esc) P Seems to have superior RFS
Fisher et al. 1980 (NSABP B-08) 1976-1977 Phase 3 (C) PFM Did not meet endpoint of OS
Fisher et al. 1981 (NSABP B-09) 1977-1980 Phase 3 (C) PFT Inferior RFS
Fisher et al. 1990 (NSABP B-10) 1977-1981 Phase 3 (C) PFCp Did not meet endpoints of DFS/OS
Fisher et al. 1989 (NSABP B-11) 1981-1984 Phase 3 (C) PAF Seems to have inferior OS

Note: Fisher et al. 1980 is more of a meta-analysis than a primary publication, but is to our knowledge the first manuscript to report the findings from NSABP B-08, which was a negative trial.

Preceding treatment

Chemotherapy

References

  1. NSABP B-07: Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H, Volk H. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: an update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer. 1977 Jun;39(6 Suppl):2883-903. link to original article PubMed
  2. NSABP B-08: Fisher B, Redmond C, Fisher ER. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology--an overview of findings. Cancer. 1980 Aug 15;46(4 Suppl):1009-25. link to original article PubMed
  3. NSABP B-09: Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981 Jul 2;305(1):1-6. link to original article PubMed
    1. Update: Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol. 1986 Apr;4(4):459-71. link to original article PubMed
    2. Update: Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, Dimitrov N, Legault-Poisson S, Schipper H, Prager D. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987 May;106(5):649-54. link to original article PubMed
  4. NSABP B-11: Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, Sass R, Fisher ER, Jochimsen P, Legault-Poisson S, Dimitrov N, Wolter J, Bornstein R, Elias EG, LiCalzi N, Paterson AHG, Sutherland CM. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989 May;7(5):572-82. link to original article PubMed
  5. NSABP B-10: Fisher B, Brown A, Wolmark N, Fisher ER, Redmond C, Wickerham DL, Margolese R, Dimitrov N, Pilch Y, Glass A, Sutherland C, Foster R. Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer. 1990 Jul 15;66(2):220-7. link to original article PubMed

PFT

PFT: Phenylalanine mustard (Melphalan), 5-Fluorouracil, Tamoxifen

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Fisher et al. 1981 (NSABP B-09) 1977-1980 Phase 3 (E-RT-esc) PF Superior RFS
Fisher et al. 1990 (NSABP B-16) 1985-1988 Phase 3 (E-esc) 1. ACT Not reported
2. Tamoxifen Seems to have superior DDFS

Preceding treatment

Chemotherapy

Endocrine therapy

References

  1. NSABP B-09: Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981 Jul 2;305(1):1-6. link to original article PubMed
    1. Update: Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol. 1986 Apr;4(4):459-71. link to original article PubMed
    2. Update: Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, Dimitrov N, Legault-Poisson S, Schipper H, Prager D. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987 May;106(5):649-54. link to original article PubMed
  2. NSABP B-16: Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Myers DB, Hoehn JL. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990 Jun;8(6):1005-18. link to original article PubMed
    1. Pooled update: Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. link to original article PubMed

PT

PT: Prednisone & Tamoxifen

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Goldhirsch et al. 1984 (LBCS III) 1978-1981 Phase 3 (E-esc) 1. CMFPT Seems to have inferior DFS
2. Observation Superior DFS
Goldhirsch et al. 1984 (LBCS IV) 1978-1981 Phase 3 (E-esc) Observation Seems to have superior DFS

Preceding treatment

Endocrine therapy

References

  1. LBCS III/IV: Goldhirsch A; Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet. 1984 Jun 9;1(8389):1256-60. link to original article PubMed

Thiotepa monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Fisher et al. 1968 (NSABP B-01) 1958-1961 Phase 3 (E-esc) Placebo Did not meet primary endpoint of RR

Chemotherapy

References

  1. NSABP B-01: Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968 Sep;168(3):337-56. link to original article link to PMC article PubMed
    1. Update: Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975 Apr;140(4):528-34. PubMed

TMF

TMF: Thiotepa, Methotrexate, Fluorouracil

Regimen

Study Years of enrollment Evidence
Semiglazov et al. 1994 1985-1990 Non-randomized portion of RCT

Preceding treatment

Chemotherapy

References

  1. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, Orlov AA, Barash NY, Golubeva OM, Chepic OF. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 1994 Sep;5(7):591-5. link to original article PubMed

Metastatic disease, all lines of therapy

Aminoglutethimide monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Smith et al. 1978 1977-1978 Non-randomized
Santen et al. 1981 NR Randomized (E-switch-ic) Bilateral adrenalectomy Did not meet primary endpoint of ORR
Stuart-Harris et al. 1984 NR Phase 2
Canney et al. 1988 NR Phase 3 (E-switch-ic) MPA Did not meet primary endpoint of ORR
Lundgren et al. 1989 NR Phase 3 (E-switch-ic) Megestrol Did not meet primary endpoint of ORR
Garcia-Giralt et al. 1992 NR Phase 3 (E-switch-ic) MPA Seems to have superior TTP
Robustelli della Cuna et al. 1993 NR Phase 3 (C) Aminoglutethimide; higher-dose Did not meet primary endpoint of ORR
Gale et al. 1994 1977-NR Phase 3 (E-switch-ic) 1. Tamoxifen
2. Bilateral adrenalectomy 		Did not meet primary endpoints of DOR/TTF/OS

Endocrine therapy

Supportive therapy

References

  1. Smith IE, Fitzharris BM, McKinna JA, Fahmy DR, Nash AG, Neville AM, Gazet JC, Ford HT, Powles TJ. Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet. 1978 Sep 23;2(8091):646-9. link to original article PubMed
  2. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med. 1981 Sep 3;305(10):545-51. link to original article PubMed
  3. Stuart-Harris R, Dowsett M, Bozek T, McKinna JA, Gazet JC, Jeffcoate SL, Kurkure A, Carr L, Smith IE. Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet. 1984 Sep 15;2(8403):604-7. link to original article PubMed
  4. Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst. 1988 Sep 21;80(14):1147-51. link to original article PubMed
  5. Lundgren S, Gundersen S, Klepp R, Lønning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat. 1989 Nov;14(2):201-6. link to original article PubMed
  6. Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Pommatau E, Pouillart P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M, Zylberait D. Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat. 1992;24(2):139-45. link to original article PubMed
  7. Robustelli della Cuna G, Pannuti F, Martoni A, Camaggi CM, Strocchi E, Da Prada GA, Tanneberger S; Italian Cooperative Group. Aminoglutethimide in advanced breast cancer: prospective, randomized comparison of two dose levels. Anticancer Res. 1993 Nov-Dec;13(6B):2367-71. PubMed
  8. Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ; ECOG. Hormonal treatment for metastatic breast cancer: an Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 1994 Jan 15;73(2):354-61. link to original article PubMed

CAMF

CAMF: Cyclophosphamide, Adriamycin (Doxorubicin), Methotrexate, Fluorouracil
AFCM: Adriamycin (Doxorubicin), Fluorouracil, Cyclophosphamide, Methotrexate

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Tranum et al. 1978 NR Randomized (E-esc) 1. AF
2. FAC 		Did not meet primary endpoint of ORR
Bezwoda et al. 1979 1976-1977 Randomized (E-switch-ic) CMFV Did not meet primary endpoint of ORR
Lippman et al. 1984 1977-1982 Randomized (C) CAMFTP Did not meet endpoint of ORR

Chemotherapy

References

  1. Tranum B, Hoogstraten B, Kennedy A, Vaughn CB, Samal B, Thigpen T, Rivkin S, Smith F, Palmer RL, Costanzi J, Tucker WG, Wilson H, Maloney TR; SWOG. Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study. Cancer. 1978 Jun;41(6):2078-83. link to original article PubMed
  2. Bezwoda WR, de Moor NG, Derman D, Lange M, Saner R, Dando R. Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine. Cancer. 1979 Aug;44(2):392-7. link to original article PubMed
  3. Lippman ME, Cassidy J, Wesley M, Young RC. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol. 1984 Jan;2(1):28-36. link to original article PubMed

CAF & MPA

CAF & MPA: Cyclophosphamide, Adriamycin (Doxorubicin), Fluorouracil, MedroxyProgesterone Acetate

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Tominaga et al. 1994 NR Phase 3 (E-esc) CAF Seems to have superior ORR

Chemotherapy

Endocrine therapy

References

  1. Tominaga T, Abe O, Ohshima A, Hayasaka H, Uchino J, Abe R, Enomoto K, Izuo M, Watanabe H, Takatani O, Yoshida M, Sakai K, Koyama H, Hattori T, Senoo T, Monden Y, Nomura Y. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer. 1994;30A(7):959-64. link to original article contains dosing details in abstract PubMed

CAFVP

CAFVP: Cyclophosphamide, Adriamycin (Doxorubicin), Fluorouracil, Vincristine, Prednisone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Muss et al. 1978 1975-1976 Phase 3 (E-switch-ic) CMFVP Might have superior OS
Aisner et al. 1987 1976-1980 Phase 3 (E-esc) 1. CAF Not reported
2. CMF Superior ORR

Chemotherapy

Endocrine therapy

References

  1. Muss HB, White DR, Richards F 2nd, Cooper MR, Stuart JJ, Jackson DV, Rhyne L, Spurr CL. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial. Cancer. 1978 Nov;42(5):2141-8. link to original article PubMed
  2. Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A, Ginsberg S, Holland JF; CALGB. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol. 1987 Oct;5(10):1523-33. link to original article contains dosing details in abstract PubMed

CAV

CAV: Cyclophosphamide, Adriamycin (Doxorubicin), Vincristine
VAC: Vincristine, Adriamycin (Doxorubicin), Cyclophosphamide

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Muss et al. 1982 1979-1981 Randomized (E-esc) CMF Seems to have superior ORR
Zekan et al. 1984 1981-1982 Phase 3 (C) CF Did not meet primary endpoints
Gundersen et al. 1986 1982-1983 Phase 3 (C) Doxorubicin Did not meet endpoint of ORR
Powles et al. 1991 1985-1989 Phase 3 (C) 3M Did not meet primary endpoint of ORR
Green et al. 1996 NR Phase 3 (C) VNC Might have superior ORR

Chemotherapy

References

  1. Muss HB, Richards F 2nd, Jackson DV, Cooper MR, White DR, Stuart JJ, Ramseur W, Christian RM, Wells HB, Pope E, Spurr CL; Piedmont Oncology Association. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association. Cancer. 1982 Dec 1;50(11):2269-74. link to original article PubMed
  2. Zekan PJ, Muss HB, Capizzi RL, Cooper MR, Harding RW, Hopkins JO, Jackson DV, Ramseur WL, Richards F 2nd, Spurr CL, Stuart JJ, White DR, Pope E, Case D, Wells HB; Piedmont Oncology Association. High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast: a phase III study of the Piedmont Oncology Association (POA). Cancer. 1984 Dec 1;54(11):2338-43. link to original article PubMed
  3. Gundersen S, Kvinnsland S, Klepp O, Kvaløy S, Lund E, Høst H. Weekly adriamycin versus VAC in advanced breast cancer: a randomized trial. Eur J Cancer Clin Oncol. 1986 Dec;22(12):1431-4. link to original article PubMed
  4. Powles TJ, Jones AL, Judson IR, Hardy JR, Ashley SE. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer. 1991 Aug;64(2):406-10. link to original article link to PMC article PubMed
  5. Green JA, Slater AJ, Campbell IR, Kelly V. Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine. Breast Cancer Res Treat. 1996;39(2):155-63. link to original article PubMed

CFP

CFP: Cyclophosphamide, Fluorouracil, Prednisone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Creagan et al. 1984 NR Phase 3 (C) CAP, then CFP Did not meet primary endpoint of ORR
Rosner et al. 1987 1981-1985 Randomized (E-esc) 1. CA
2. CMFVP 		Did not meet primary endpoint of OS
Marschke et al. 1989 1982-1987 Randomized (C) CMFP Might have inferior ORR

Chemotherapy

Endocrine therapy

References

  1. Creagan ET, Green SJ, Ahmann DL, Ingle JN, Edmonson JH, Marschke RF Jr. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol. 1984 Nov;2(11):1260-5. link to original article PubMed
  2. Rosner D, Nemoto T, Lane WW. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. Cancer. 1987 Mar 1;59(5):874-83. link to original article PubMed
  3. Marschke RF Jr, Ingle JN, Schaid DJ, Krook JE, Mailliard JA, Cullinan SA, Pfeifle DM, Votava HJ, Ebbert LP, Windschitl HE. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer. 1989 May 15;63(10):1931-7. link to original article PubMed

Chlorambucil & Prednisolone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Freckman et al. 1964 1955-1963 Non-randomized
Løber et al. 1983 1978-1980 Phase 3 (C) 1. Prednimustine; continuous Inferior TTP
2. Prednimustine; intermittent Might have inferior TTP

Chemotherapy

Endocrine therapy

References

  1. Freckman HA, Fry HL, Mendez FL, Maurer ER. Chlorambucil-prednisolone therapy for disseminated breast carcinoma. JAMA. 1964 Jul 6;189:23-6. link to original article PubMed
  2. Løber J, Mouridsen HT, Christiansen IE, Dombernowsky P, Mattsson W, Rørth M. A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer. Cancer. 1983 Nov 1;52(9):1570-6. link to original article PubMed

CHUT, then auto HSCT

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Biron et al. 2007 (Pegase 03) 1995-2001 Phase 3 (E-esc) No further treatment Superior DFS

Preceding treatment

Chemotherapy

References

  1. Pegase 03: Biron P, Durand M, Roché H, Delozier T, Battista C, Fargeot P, Spaeth D, Bachelot T, Poiget E, Monnot F, Tanguy ML, Curé H. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008 Mar;41(6):555-62. Epub 2007 Nov 26. link to original article PubMed NCT00002870

CMFP

CMFP: Cyclophosphamide, Methotrexate, Fluorouracil, Prednisone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Canellos et al. 1974 NR Non-randomized
Segaloff et al. 1985 1971-1976 Phase 3 (C) CMFVP Did not meet primary endpoint of OS
Tormey et al. 1982 (ECOG E2173) 1973-1974 Randomized (E-esc) 1. AV
2. CMF 		Seems to have superior OS
Cummings et al. 1985 1978-1979 Randomized (E-esc) CAF Did not meet primary endpoint of ORR
Marschke et al. 1989 1982-1987 Randomized (E-esc) CFP Might have superior ORR
Bishop et al. 1999 1993-NR Phase 3 (C) Paclitaxel Seems to have inferior OS

Chemotherapy

Endocrine therapy

References

  1. Canellos GP, Devita VT, Gold GL, Chabner BA, Schein PS, Young RC. Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J. 1974 Feb 9;1(5901):218-20. link to original article link to PMC article PubMed
  2. ECOG E2173: Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, Perlia C, Rice MA. Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Cancer. 1982 Oct 1;50(7):1235-44. link to original article PubMed
  3. Segaloff A, Hankey BF, Carter AC, Escher GC, Ansfield FJ, Talley RW. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer. Breast Cancer Res Treat. 1985;5(3):311-9. link to original article PubMed
  4. Cummings FJ, Gelman R, Horton J. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol. 1985 Jul;3(7):932-40. link to original article PubMed
  5. Marschke RF Jr, Ingle JN, Schaid DJ, Krook JE, Mailliard JA, Cullinan SA, Pfeifle DM, Votava HJ, Ebbert LP, Windschitl HE. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer. 1989 May 15;63(10):1931-7. link to original article PubMed
  6. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999 Aug;17(8):2355-64. link to original article contains dosing details in abstract PubMed

CMFV

CMFV: Cyclophosphamide, Methotrexate, Fluorouracil, Vinblastine
CVMF: Cyclophosphamide, Vinblastine, Methotrexate, Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Edelstyn et al. 1975 NR Randomized (E-esc) CMFV; 1-day Superior ORR
Bezwoda et al. 1979 1976-1977 Randomized (C) CAMF Did not meet primary endpoint of ORR

Chemotherapy

References

  1. Edelstyn GA, Bates TD, Brinkley D, MacRae KD, Spittle MF, Wheeler T. Comparison of 5-day, 1-day, and 2-day cyclical combination chemotherapy in advanced breast cancer. Lancet. 1975 Aug 2;2(7927):209-11. link to original article PubMed
  2. Bezwoda WR, de Moor NG, Derman D, Lange M, Saner R, Dando R. Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine. Cancer. 1979 Aug;44(2):392-7. link to original article PubMed

CMFVP

CMFVP: Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, Prednisone
COMFP: Cyclophosphamide, Oncovin (Vincristine), Methotrexate, Fluorouracil, Prednisone
CFPMV: Cyclophosphamide, Fluorouracil, Prednisone, Methotrexate, Vincristine

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Segaloff et al. 1985 1971-1976 Phase 3 (E-esc) CMFP Did not meet primary endpoint of OS
Hoogstraten et al. 1976 1972-1974 Phase 3 (E-esc) Doxorubicin Seems to have superior ORR
Smalley et al. 1977 1974-1975 Phase 3 (C) CAF Might have inferior OS1
Muss et al. 1978 1975-1976 Phase 3 (C) CAFVP Might have inferior OS
Carmo-Pereira et al. 1980 NR Phase 3 (E-esc) 5-FU Superior OS
Rosner et al. 1987 1981-1985 Randomized (E-esc) 1. CA
2. CFP 		Did not meet primary endpoint of OS

1Reported efficacy for Smalley et al. 1977 is based on the 1983 update.

Chemotherapy

Endocrine therapy

References

  1. Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H; SWOG. Combination chemotherapy and adriamycin in patients with advanced breast cancer: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):13-20. link to original article PubMed
  2. Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S; Southeastern Cancer Study Group. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project. Cancer. 1977 Aug;40(2):625-32. link to original article contains dosing details in manuscript PubMed
    1. Update: Smalley RV, Lefante J, Bartolucci A, Carpenter J, Vogel C, Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat. 1983;3(2):209-20. link to original article PubMed
  3. Muss HB, White DR, Richards F 2nd, Cooper MR, Stuart JJ, Jackson DV, Rhyne L, Spurr CL. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial. Cancer. 1978 Nov;42(5):2141-8. link to original article PubMed
  4. Carmo-Pereira J, Costa FO, Henriques E. Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: a randomized study. Eur J Cancer. 1980 Dec;16(12):1621-5. link to original article PubMed
  5. Segaloff A, Hankey BF, Carter AC, Escher GC, Ansfield FJ, Talley RW. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer. Breast Cancer Res Treat. 1985;5(3):311-9. link to original article PubMed
  6. Rosner D, Nemoto T, Lane WW. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. Cancer. 1987 Mar 1;59(5):874-83. link to original article PubMed

DES monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Kennedy 1965 NR in abstract Randomized (E-switch-ic) Testosterone Not available
Carter et al. 1977 NR Phase 3 (E-switch-ic) DES; other dosings See paper
Kiang et al. 1981 1975-1982 Randomized (C) Cyclophosphamide, 5-FU, DES Seems to have inferior OS1
Ingle et al. 1981 1977-1980 Phase 3 (C) Tamoxifen Did not meet primary endpoint of ORR

1Reported efficacy for Kiang et al. 1981 is based on the 1985 update.

Endocrine therapy

References

  1. Kennedy BJ. Diethylstilbestrol versus testosterone propionate therapy in advanced breast cancer. Surg Gynecol Obstet. 1965 Jun;120:1246-50. PubMed
  2. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR; Cooperative Breast Cancer Group. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients: report of the Cooperative Breast Cancer Group. JAMA. 1977 May 9;237(19):2079-8. link to original article PubMed
  3. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16-21. link to original article PubMed
  4. Kiang DT, Frenning DH, Gay J, Goldman AI, Kennedy BJ. Combination therapy of hormone and cytotoxic agents in advanced breast cancer. Cancer. 1981 Feb 1;47(3):452-6. link to original article PubMed
    1. Update: Kiang DT, Gay J, Goldman A, Kennedy BJ. A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med. 1985 Nov 14;313(20):1241-6. link to original article PubMed

CTCb, then auto HSCT

CTCb: Cyclophosphamide, Thiotepa, Carboplatin

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Stadtmauer et al. 2000 1990-1997 Phase 3 (E-esc) CMF Did not meet primary endpoint of OS

No longer used, but of historical interest.

Chemotherapy

References

  1. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH; Philadelphia Bone Marrow Transplant Group. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med. 2000 Apr 13;342(15):1069-76. link to original article PubMed

Cyclophosphamide monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Rubens et al. 1975 1970-1974 Phase 3 (C) CMFV Did not meet primary endpoint of ORR

Chemotherapy

References

  1. Rubens RD, Knight RK, Hayward JL. Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer. 1975 Dec;32(6):730-6. link to original article link to PMC article PubMed

Estradiol monotherapy

Regimen variant #1, 6 mg/day

Study Years of enrollment Evidence Comparator Comparative Efficacy
Ellis et al. 2009 2004-2008 Randomized Phase 2 (E-de-esc) Estradiol; 30 mg/day Did not meet primary endpoint of CBR

Endocrine therapy

Continued indefinitely


Regimen variant #2, 30 mg/day

Study Years of enrollment Evidence Comparator Comparative Efficacy
Ellis et al. 2009 2004-2008 Randomized Phase 2 (C) Estradiol; 6 mg/day Did not meet primary endpoint of CBR

Endocrine therapy

Continued indefinitely

References

  1. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009 Aug 19;302(7):774-80. link to original article link to PMC article contains dosing details in abstract PubMed NCT00324259

Fluoxymesterone monotherapy

Regimen

Study Evidence
Kennedy 1958 Non-randomized

Endocrine therapy

References

  1. Kennedy BJ. Fluoxymesterone therapy in advanced breast cancer. N Engl J Med. 1958 Oct 2;259(14):673-5. link to original article PubMed

Formestane monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Coombes et al. 1984 NR Pilot
Thürlimann et al. 1997 (SAKK 20/90) 1991-1995 Phase 3 (E-switch-ic) Megestrol Did not meet primary endpoint of TTF

Endocrine therapy

References

  1. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984 Dec 1;2(8414):1237-9. link to original article PubMed
  2. SAKK 20/90: Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A; Swiss Group for Clinical Cancer Research. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer. 1997 Jun;33(7):1017-24. link to original article PubMed

Medroxyprogesterone monotherapy

Regimen variant #1, 500 mg/day

Study Years of enrollment Evidence Comparator Comparative Efficacy
Cuna et al. 1978 NR Phase 3 (E-de-esc) MPA; 1000 mg/day Did not meet primary endpoint of ORR
Pannuti et al. 1979 (UICC 75-09) NR Randomized (C) MPA; 1500 mg/day Did not meet primary endpoint of ORR
Canney et al. 1988 NR Phase 3 (C) Aminoglutethimide Did not meet primary endpoint of ORR
Byrne et al. 1997 (ANZ8613) 1987-1993 Phase 3 (C) MPA & Tamoxifen Did not meet primary endpoint of TTP

Note: Canney et al. 1988 does not have dosing information in the abstract.

Endocrine therapy

Continued indefinitely


Regimen variant #2, 900 mg/day

Study Years of enrollment Evidence Comparator Comparative Efficacy
van Veelen et al. 1986 1980-1984 Phase 3 (E-switch-ic) Tamoxifen Did not meet primary endpoint of ORR

Endocrine therapy

Continued indefinitely


Regimen variant #3, 1000 mg/day (high-dose)

Study Years of enrollment Evidence Comparator Comparative Efficacy
Cavalli et al. 1984 1979-1982 Phase 3 (E-esc) MPA; low-dose Superior ORR
Garcia-Giralt et al. 1992 NR Phase 3 (C) Aminoglutethimide Seems to have inferior TTP
Castiglione-Gertsch et al. 1993 1982-1985 Phase 3 (E-switch-ic) Tamoxifen Might have superior TTP
Muss et al. 1994 1985-1990 Phase 3 (E-switch-ic) Tamoxifen Might have superior OS

Endocrine therapy

Continued indefinitely


Regimen variant #4, 1200 mg/day (high-dose)

Study Years of enrollment Evidence Comparator Comparative Efficacy
Izuo et al. 1985 1981-1983 Phase 3 (E-switch-ic) Mepitiostane Did not meet primary endpoint of ORR

Endocrine therapy

Continued indefinitely

References

  1. Cuna GR, Calciati A, Strada MR, Bumma C, Campio L. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori. 1978 Apr 30;64(2):143-9. link to original article contains dosing details in abstract PubMed
  2. UICC 75-09: Pannuti F, Martoni A, Di Marco AR, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnolo F, Palenzona D, Rocchetta G. Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer. 1979 Apr;15(4):593-601. link to original article contains dosing details in abstract PubMed
  3. Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol. 1984 May;2(5):414-9. link to original article PubMed
  4. Izuo M, Yoshida M, Tominaga T, Abe O, Enomoto K, Nomura Y, Kubo K, Takatani O. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer. Cancer. 1985 Dec 1;56(11):2576-9. link to original article PubMed
  5. van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DT. Oral high-dose medroxyprogesterone acetate versus tamoxifen: a randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer. 1986 Jul 1;58(1):7-13. link to original article contains dosing details in abstract PubMed
  6. Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst. 1988 Sep 21;80(14):1147-51. link to original article PubMed
  7. Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Pommatau E, Pouillart P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M, Zylberait D. Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat. 1992;24(2):139-45. link to original article PubMed
  8. Castiglione-Gertsch M, Pampallona S, Varini M, Cavalli F, Brunner K, Senn HJ, Goldhirsch A, Metzger U. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?. Ann Oncol. 1993 Nov;4(9):735-40. link to original article PubMed
  9. Muss HB, Case LD, Atkins JN, Bearden JD 3rd, Cooper MR, Cruz JM, Jackson DV Jr, O'Rourke MA, Pavy MD, Powell BL, Richards F, Spurr CL, Eagle K, White DR; Piedmont Oncology Association. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 1994 Aug;12(8):1630-8. link to original article contains dosing details in abstract PubMed
  10. ANZ8613: Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J; Australian-New Zealand Breast Cancer Trials Group. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. J Clin Oncol. 1997 Sep;15(9):3141-8. link to original article contains dosing details in abstract PubMed

Megestrol monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Muss et al. 1988 1981-1984 Phase 3 (E-switch-ic) Tamoxifen Did not meet primary endpoint of ORR
Lundgren et al. 1989 NR Phase 3 (C) Aminoglutethimide Did not meet primary endpoint of ORR
Gill et al. 1993 1984-1989 Phase 3 (E-switch-ic) 1. Tamoxifen
2. Megestrol & Tamoxifen 		Did not meet endpoint of ORR
Buzdar et al. 1996 NR Phase 3 (C) Anastrozole Seems to have inferior OS1
Russell et al. 1997 (SWOG S8312) 1984-1990 Phase 3 (C) Aminoglutethimide, Hydrocortisone, Megestrol Did not meet primary endpoint of OS
Muss et al. 1990 1985-1988 Phase 3 (C) Megestrol; higher-dose Seems to have inferior OS
Stuart et al. 1996 1985-1988 Phase 3 (E-switch-ic) Tamoxifen Did not meet endpoint of OS
Abrams et al. 1999 (CALGB 8741) 1987-1991 Phase 3 (C) Megestrol; higher-dose Did not meet primary endpoint of ORR
Buzdar et al. 1996 (Protocol 03) 1989-1991 Phase 3 (C) Fadrozole Did not meet primary endpoint of ORR
Buzdar et al. 1996 (Protocol 06) 1989-1991 Phase 3 (C) Fadrozole Did not meet primary endpoint of ORR
Thürlimann et al. 1997 (SAKK 20/90) 1991-1995 Phase 3 (C) Formestane Did not meet primary endpoint of TTF
Goss et al. 1999 1991-1995 Phase 3 (C) Vorozole Did not meet primary endpoint of ORR
Jonat et al. 1996 1993-1994 Phase 3 (C) Anastrozole Seems to have inferior OS1
Dombernowsky et al. 1998 (AR/BC2) 1993-1994 Randomized (C) Letrozole; 0.5 mg/day Not reported
Letrozole; 2.5 mg/day Seems to have inferior OS
Kaufmann et al. 2000 1995-1998 Phase 3 (C) Exemestane Seems to have inferior OS
Buzdar et al. 2001 NR Phase 3 (C) 1. Letrozole; 0.5 mg/day
2. Letrozole; 2.5 mg/day 		Did not meet primary endpoint of ORR

1Reported efficacy for Jonat et al. 1996 & Buzdar et al. 1996 is based on the 1998 pooled update.

Endocrine therapy

Continued indefinitely

References

  1. Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Powell BL, Richards F, White DR, Zekan PJ, Spurr CL, Pope E, Case D, Morgan TM; Piedmont Oncology Association. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1988 Jul;6(7):1098-106. link to original article PubMed
  2. Lundgren S, Gundersen S, Klepp R, Lønning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat. 1989 Nov;14(2):201-6. link to original article PubMed
  3. Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, Richards F 2nd, Powell BL, Spurr CL, White D, Zekan P, Read S, Cates-Wilkie S, Bearden J, McCullough J, Callahan R, Karb K, Atkins J, Paschal B, Ramseur B, Lusk J, Stanley V; Piedmont Oncology Association. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1990 Nov;8(11):1797-805. link to original article PubMed
  4. Gill PG, Gebski V, Snyder R, Burns I, Levi J, Byrne M, Coates A. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol. 1993 Nov;4(9):741-4. link to original article contains dosing details in abstract PubMed
  5. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996 Mar;32A(3):404-12. link to original article contains dosing details in abstract PubMed
    1. Pooled update: Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV; Arimidex Study Group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol. 1996 Jul;14(7):2000-11. link to original article PubMed
    2. Pooled update: Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D; Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 1998 Sep 15;83(6):1142-52. Erratum in: Cancer 1999 Feb 15;85(4):1010. link to original article PubMed
  6. Protocol 03: Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15;77(12):2503-13. link to original article PubMed
  7. Protocol 06: Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15;77(12):2503-13. link to original article PubMed
  8. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV; Arimidex Study Group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol. 1996 Jul;14(7):2000-11. link to original article PubMed
    1. Update: Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A; Arimidex Study Group. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer. 1997 Feb 15;79(4):730-9. link to original article contains dosing details in abstract PubMed
    2. Pooled update: Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D; Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 1998 Sep 15;83(6):1142-52. Erratum in: Cancer 1999 Feb 15;85(4):1010. link to original article PubMed
  9. Stuart NS, Warwick J, Blackledge GR, Spooner D, Keen C, Taylor AR, Tyrell C, Webster DJ, Earl H. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer. 1996 Oct;32A(11):1888-92. link to original article contains dosing details in manuscript PubMed
  10. SAKK 20/90: Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A; Swiss Group for Clinical Cancer Research. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer. 1997 Jun;33(7):1017-24. link to original article PubMed
  11. SWOG S8312: Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol. 1997 Jul;15(7):2494-501. link to original article PubMed
  12. AR/BC2: Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998 Feb;16(2):453-61. link to original article contains dosing details in abstract PubMed
  13. Goss PE, Winer EP, Tannock IF, Schwartz LH; North American Vorozole Study Group. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol. 1999 Jan;17(1):52-63. link to original article PubMed
  14. CALGB 8741: Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, Norton L. Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and Leukemia Group B phase III study 8741. J Clin Oncol. 1999 Jan;17(1):64-73. link to original article contains dosing details in abstract PubMed
  15. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G; Exemestane Study Group. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000 Apr;18(7):1399-411. link to original article contains dosing details in abstract PubMed
  16. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001 Jul 15;19(14):3357-66. link to original article contains dosing details in abstract PubMed

Melphalan monotherapy

P: Phenylalanine mustard (Melphalan)

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Canellos et al. 1976 NR Phase 3 (C) CMF Seems to have inferior OS

Chemotherapy

42-day cycles

References

  1. Canellos GP, Pocock SJ, Taylor SG 3rd, Sears ME, Klaasen DJ, Band PR. Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer. 1976 Nov;38(5):1882-6. link to original article PubMed

Methotrexate & Thiotepa

Regimen

Study Evidence
Greenspan et al. 1963 Non-randomized

Note: this is possibly the first published trial of combination chemotherapy in breast cancer.

Chemotherapy

References

  1. Greenspan EM, Fieber M, Lesnick G, Edelman S. Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA. J Mt Sinai Hosp N Y. 1963 May-Jun;30:246-67. PubMed

Mitoxantrone monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Harris et al. 1990 NR Non-randomized portion of RCT
Cowan et al. 1991 (SWOG S8203) 1983-1986 Phase 3 (C) 1. Bisantrene
2. Doxorubicin 		Seems to have inferior OS

Chemotherapy

21-day cycles

References

  1. Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RG. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 1990 Jan 27;335(8683):186-90. link to original article PubMed
  2. SWOG S8203: Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 7;83(15):1077-84. link to original article contains dosing details in abstract PubMed

Mitoxantrone & Vinorelbine (MV)

MV: Mitoxantrone & Vinorelbine

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Namer et al. 2001 NR in abstract Phase 3 (E-switch-ic) 1a. FAC
1b. FEC 		Equivalent ORR

Chemotherapy

References

  1. Namer M, Soler-Michel P, Turpin F, Chinet-Charrot P, de Gislain C, Pouillart P, Delozier T, Luporsi E, Etienne PL, Schraub S, Eymard JC, Serin D, Ganem G, Calais G, Maillart P, Colin P, Trillet-Lenoir V, Prevost G, Tigaud D, Clavère P, Marti P, Romieu G, Wendling JL. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. Eur J Cancer. 2001 Jun;37(9):1132-40. link to original article PubMed

STAMP-I

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Peters et al. 1988 NR Non-randomized
Vredenburgh et al. 2006 1992-1997 Phase 3 (E-esc) Observation Superior EFS

Preceding treatment

  • Duke AFM x 2 to 4

Chemotherapy

Stem cells re-infused on days -1, 0, +1

References

  1. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1368-76. link to original article PubMed
  2. Vredenburgh JJ, Madan B, Coniglio D, Ross M, Broadwater G, Niedzwiecki D, Edwards J, Marks L, Vandemark R, McDonald C, Affronti ML, Peters WP. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant. 2006 Jun;37(11):1009-15. link to original article PubMed

TAD (Tamoxifen)

TAD: Tamoxifen, Aminoglutethimide, Danazol

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Powles et al. 1984 1979-1983 Phase 3 (E-esc) Tamoxifen Seems to have superior ORR

Note: this patient population was not selected by hormone receptor status.

Endocrine therapy

References

  1. Powles TJ, Ashley S, Ford HT, Gazet JC, Nash AG, Neville AM, Coombes RC. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet. 1984 Jun 23;1(8391):1369-73. link to original article PubMed

Thiotepa monotherapy

Regimen

Study Evidence
Bateman 1955 Non-randomized

Chemotherapy

References

  1. Bateman JC. Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med. 1955 May 26;252(21):879-87. link to original article PubMed

VAP

VAP: Vincristine, Adriamycin (Doxorubicin), Prednisolone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Leonard et al. 1987 NR Phase 3 (C) VMP Superior ORR

Chemotherapy

Endocrine therapy

References

  1. Leonard RC, Cornbleet MA, Kaye SB, Soukop M, White G, Hutcheon AW, Robinson S, Kerr ME, Smyth JF. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J Clin Oncol. 1987 Jul;5(7):1056-63. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Staging_page&oldid=66695"